Characterisation of tools for studying renal mineral ion homeostasis and drug-induced nephrotoxicity by Wadey, Rebecca
  
1 
 
 
 
 
Characterisation of Tools for Studying Renal Mineral Ion 
Homeostasis and Drug-Induced Nephrotoxicity 
 
Rebecca Martina Wadey (0954796) 
PhD Thesis 2014 
 
 
  
  
2 
 
DECLARATION 
This work has not been submitted in substance for any other degree or award at this or any other 
university or place of learning, nor is it being submitted concurrently in candidature for any 
degree or other award. 
 
STATEMENT 1 
This thesis is being submitted in partial fulfilment of the requirements for the degree of PhD. 
 
STATEMENT 2 
This thesis is the result of my own independent work/investigation, except where otherwise 
stated.  Other sources are acknowledged by explicit references.  The views expressed are my own. 
 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-
library-loan, and for the title and summary to be made available to outside organisations. 
 
Signed:       (candidate)  
Date:      06.02.2015 
  
1 
 
Summary  
The complex interplay between regulatory factors of kidney mineral ion homeostasis are 
difficult to investigate in vivo.  In addition, preclinical drug safety testing is limited by lack 
of translational tools for screening novel drugs for nephrotoxicity.  At Cardiff University, 
my PhD project aimed to characterise tools to address these needs.  At AstraZeneca, the 
use of tissue biomarkers as tools for assessing kidney injury in retrospective studies where 
urine biomarker samples are not available, was evaluated. 
To enable studies of mineral ion homeostasis, an in vitro human primary renal cell model 
was characterised.  Cells expressed phenotypic marker proteins (E-, N-Cadherin) as well 
as proteins involved in mineral ion homeostasis (FGFR1-4, Klotho, NaPi IIa, NCX1, PMCA1).  
They also exhibited morphological features and functional characteristics of renal cells in 
vivo.  Data were presented as an oral abstract communication at the American Society of 
Nephology Meeting, 2013. 
To enable studies of drug-induced nephrotoxicity, in vitro primary mouse and human 
renal cell models were characterised.  A concentration-dependent increase in apoptosis 
was observed in mouse cells following 24-hour treatment with medium containing 
cisplatin, cyclosporin A and BEA.  Following 24-hour treatment, the same nephrotoxins 
increased expression of the kidney injury biomarkers kidney injury molecule-1 (KIM-1) 
and osteopontin.  Human cells responded to 24-hour treatment with medium containing 
cisplatin with expression of KIM-1, osteopontin and clusterin.  Parallel use of such rodent 
and human models would revolutionise preclinical translational drug safety assessment. 
Cisplatin-treated rats were used to evaluate the use of tissue biomarkers as tools in 
studies where urine biomarker samples are not available, such as retrospective studies in 
drug safety testing.  Of the biomarkers investigated, KIM-1 and osteopontin showed 
greatest correlation with their corresponding urinary biomarkers.  As such, they offer 
greatest utility as tissue biomarkers in retrospective studies.  Data were published in 
Toxicologic Pathology (Wadey et al. 2013).  
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CHAPTER 1 
Characterisation of Primary Human Renal Cells as a Novel Tool 
for Studying Mineral Ion Homeostasis by the Kidney 
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1.1 Abstract 
Mineral ion homeostasis involves the complex interplay between Ca and Pi regulating 
transporting mechanisms and their regulating hormones (i.e., PTH, FGF23, Klotho and 
1,25(OH)2D3). However, complex interactions between FGF23, PTH, 1,25(OH)2D3, Pi and 
extracellular free ionized calcium (Ca2+) that regulate mineral ion homeostasis by the 
kidney are difficult to investigate in humans under normal physiological conditions, let 
alone under states of disordered mineral ion metabolism such as chronic kidney disease-
mineral and bone disorder (CKD-MBD).  As such, much of the data regarding mineral ion 
metabolism presented in the literature is gathered from observations in rodents, but a 
complete understanding of the cause-effect relationship is currently lacking.  In this study, 
we performed a cross-species comparison of the expression patterns of FGFr1-4 and 
Klotho (key proteins involved in mineral ion metabolism) in human, rat and mouse 
kidneys.  Differences in the expression patterns of FGFr1-4 were identified suggesting that 
rodent models may not be appropriate for studying mineral ion metabolism by the human 
kidney as differences in protein expression may indicate differences in mineral ion 
handling.  As such, an in vitro co-culture of primary human proximal and distal tubule cells 
as a novel tool for studying mineral ion metabolism specifically by the human kidney was 
characterised.  FGFr1-4 and Klotho, as well as other proteins involved in mineral ion 
metabolism by the kidney including NaPi IIa, NCX1 and PMCA1, are expressed in culture.  
The cell model responds as expected to known physiological stimuli (FGF23-induced ERK 
phosphorylation) and we show that changes in protein expression and cellular localization 
occur when cells are cultured in Pi-free medium (NaPi IIa and PMCA1 upregulation) or in 
the presence of Pi-containing medium supplemented with FGF23 (NCX1 translocation to 
the cell membrane).  This chapter demonstrates the suitability of the primary kidney cell 
model, thereby enabling future studies of mineral ion metabolism by the human kidney 
under experimental conditions that mimic both physiological and pathophysiological 
scenarios. 
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1.2 Introduction 
Inorganic Phosphorus 
Inorganic phosphorus (Pi) is essential for normal physiological function.  As well as being 
required for bone and tooth mineralisation, phospholipid bilayer membranes and 
nucleotides that form DNA and RNA, it is used as a cell signalling molecule and an energy 
source for metabolic processes (Jüppner 2011; Takeda et al. 2004).  As such, the ability to 
detect and react to changes in the extracellular concentration of Pi is critical.  In healthy 
individuals, Pi levels are maintained within the physiological range of 0.81 to 1.45mM (2.5 
to 4.5 mg/dl) (S. Moe 2008) with reserves sequestered in bone and any excess is excreted 
by the kidney (Kirchner et al. 2008).  The homeostatic mechanism controlling Pi levels is, 
however, complex.  It involves several different factors including fibroblast growth factor-
23 (FGF23), parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3; the 
active form of Vitamin D), Ca2+, and Pi itself. 
Pi Homeostasis and FGF23 
Fibroblast growth factors (FGFs) are a family of structurally related glycoproteins that 
control many different biological activities (Beenken and Mohammadi 2009).  Fibroblast 
growth factor-23 is a 30kDa member of the FGF family that acts within the homeostatic 
‘bone-parathyroid-kidney’ axis to eliminate excess Pi from the body in the urine; it is a 
phosphaturic factor.  Following an acute Pi loading event, such as after the consumption 
of a Pi-rich meal, FGF23 is secreted into the circulation by osteocytes (Bonewald and 
Wacker 2013).  It is currently unclear how a change in serum Pi is sensed (Bergwitz and 
Jüppner 2011; Witteveen et al. 2012; Wolf 2010).  Nevertheless, once FGF23 has been 
secreted into the circulation, it behaves like a hormone and exerts its homeostatic effect 
in its target organ, the kidney.  FGF23 signals for the down-regulation of the proximal 
tubule brush border membrane sodium-dependent phosphate co-transporters, NaPi IIa 
and NaPi IIc (Gattineni et al. 2009).  Downregulation of these phosphate-conserving 
proteins by FGF23 has been elegantly illustrated both in vitro using isolated, 
microperfused mouse proximal tubule segments (Baum et al. 2005) and in vivo using mice 
treated with recombinant FGF23 (Shimada et al. 2002).  FGF23 also acts in the proximal 
tubule to suppress 1α-hydrolase (CYP27B1) activity and stimulate 24-hydroxylase 
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(CYP24A1) activity (Shimada et al. 2004b).  Changing the dynamics of these enzymes 
negatively modulates the formation of 1,25(OH)2D3 and, as such, prevents dietary Pi 
absorption in the gut via NaPi IIb (Miyamoto et al. 2005).  FGF23 therefore has two means 
of reducing serum Pi levels; firstly, by increasing its urinary excretion, and secondly, by 
reducing any further intestinal absorption.  Figure 1.1 shows the regulation of 
hyperphosphatemia by FGF23. 
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Figure 1.1.  Regulation of Hyperphosphatemia by Fibroblast Growth Factor-23.  
Hyperphospatemia induces the secretion of the hormone fibroblast growth factor-23 (FGF23) 
from osteocytes (Bonewald and Wacker 2013).  FGF23 circulates in the blood to act on its target 
organ, the kidney.  Together with its cofactor, Klotho, FGF23 signals for the downregulation of the 
sodium-phosphate co-transporter types IIa and IIc (NaPi IIa, NaPi IIc) present on proximal tubule 
cell brush border membranes (Gattineni et al. 2009).  Downregulation of NaPi transporters 
prevents the reabsorbtion of Pi filtered at the glomerulus thereby increasing urinary Pi excretion 
(phosphaturia).  In addition, FGF23 negatively modulates 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
production in the proximal tubule by supressing and simulating the anabolic and catabolic 
activities of 1α-hydrolase and 25-hydroxylase respectively (Shimada et al. 2004b).  Reduced 
circulating levels of 1,25(OH)2D3 results in the downregulation of the sodium-phosphate co-
transporter type IIb (NaPi IIb) in the gut which thereby prevents further Pi absorption into the 
blood (Miyamoto et al. 2005).  In summary, FGF23 restores normophosphatemia during a state 
of hyperphosphatemia in two ways; firstly, by increasing urinary Pi excretion, and secondly, by 
reducing Pi absorption from the diet in the gut.  
Hyperphosphatemia 
FGF23 secretion from 
osteocytes 
Decreased NaPi IIa and 
NaPi IIc in the proximal 
tubule 
Decreased 1,25(OH)2D3 
production in proximal 
tubule cell cytoplasm 
Increased Pi excretion in 
the urine 
Decreased Pi absorption 
in the gut 
Normophosphatemia 
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Structure and Localisation of Fibroblast Growth Factor Receptors in the Kidney 
There are five fibroblast growth factor receptors (FGFr), four of which are highly 
conserved single-pass transmembrane receptors with extracellular immunoglobulin-like, 
ligand-binding domains, and an intracellular tyrosine kinase-linked domain (A. Brooks et 
al. 2012; Eswarakumar et al. 2005; Mohammadi et al. 2005; Powers et al. 2000).  Based 
on current data gathered by immunohistochemistry, in situ hybridisation and polymerase 
chain reaction (PCR), FGFr1, FGFr2, FGFr3 and FGFr4 are expressed by kidney tubule 
epithelium.  However, published data are discordant in terms of the localisation of each 
receptor along the nephron. 
Previous studies have reported expression of FGFr1 in the proximal tubule in mouse 
(Andrukhova et al. 2012; Gattineni et al. 2009), and in the distal tubule in mouse 
(Andrukhova et al. 2012; Liu et al. 2008), rat (Cancilla et al. 2001) and human (Floege et 
al. 1999).  FGFr1 has also been reported to be expressed in the kidney in humans with no 
specific location (Hughes 1997). 
FGFr2 expression has been reported previously in both the proximal and distal tubules 
(Andrukhova et al. 2012) as well as the macula densa in mouse (Liu et al. 2008).  In rats, 
it has been reported in the distal tubule (Cancilla et al. 2001), and in humans, it has been 
reported to be express in the kidney with no specific location (Hughes 1997). 
Previous studies have localised FGFr3 in mouse kidney to the proximal (Andrukhova et al. 
2012; Gattineni et al. 2009; Liu et al. 2008) and distal tubules (Andrukhova et al. 2012; Liu 
et al. 2008).  In rat kidney, FGFr3 has been shown to be expressed in proximal tubule and 
distal tubule (Cancilla et al. 2001).  In humans, expression of FGFr3 has been reported as 
minimal with no specific location (Hughes 1997). 
Previous studies have localised FGFr4 in mouse kidney to the proximal (Andrukhova et al. 
2012; Gattineni et al. 2009) and distal tubules (Andrukhova et al. 2012; Liu et al. 2008).  
Literature searches reveal little information regarding the expression pattern FGFr4 in rat 
(Horlick et al. 1992) and human (Fuhrmann et al. 1999; Hughes 1997) kidneys other than 
that they are expressed.  A summary of FGFr1-4 expression patterns presented in current 
literature in human, rat and mouse kidneys is presented in Table 1.1.  
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Protein Species Method Localisation 
FGFr1 
Human 
Rat 
Mouse 
IHC/ISH 
IHC 
IHC/ISH/PCR 
DTb, Kidneyd 
Gc, Thin Lc, DTc, CDc 
PTe, PTf, DTa, DTf 
FGFr2 
Human 
Rat 
Mouse 
IHC 
IHC 
IHC/PCR 
Kidneyd 
PTc, DTc 
PTf, DTf, MDa 
FGFr3 
Human 
Rat 
Mouse 
IHC 
IHC 
IHC/ISH/PCR 
Kidneyd 
PTc, DTc 
PTa, PTe, PTf, DTa, DTf 
FGFr4 
Human 
Rat 
Mouse 
IHC/PCR 
NB 
IHC/ISH/PCR 
Kidneyd, Kidneyg, Kidneyi 
Kidneyh 
PTe, PTf, DTa, DTf 
 
Table 1.1. Summary of the Localisation of Fibroblast Growth Factor Receptors (FGFr) 1-
4 in Adult Human, Rat and Mouse Kidney Presented in Current Literature.  Details 
regarding the localisation of FGFr1-4 human, rat and mouse kidney are detailed.  The 
methods used to localise each receptor to a nephron segment in each study are also 
detailed.  IHC = immunohistochemistry; ISH = in situ hybridisation; PCR = polymerase 
chain reaction; NB = Northern blot; CD = collecting duct; DT = distal tubule; G = 
glomerulus; MD = macula densa; PT = proximal tubule; Thin L = Thin Limb. (a(Liu et al. 
2008); b(Floege et al. 1999); c(Cancilla et al. 2001); d(Hughes 1997); e(Gattineni et al. 2009); 
f(Andrukhova et al. 2012) g(Fuhrmann et al. 1999), h(Horlick et al. 1992), i(Mutsaers et al. 
2014)).  
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Lack of consistency between species could be due to true species differences, but it may 
also be a consequence of differences in methodology, or in antibody/probes used or 
metabolic/pathophysiological status.  Each immunohistochemistry study, for example, 
used different methods of tissue fixation (Methyl Carnoy’s solution (Floege et al. 1999), 
10% neutral buffered-formalin (Floege et al. 1999; Hughes 1997), paraformaldehyde (Liu 
et al. 2008) and Bouin’s fixative (Cancilla et al. 2001)) as well as different methods of heat-
mediated or enzymatic antigen retrieval (no antigen retrieval (Floege et al. 1999), 0.01% 
protease XXIV at 37°C for 5-15 minutes (Hughes 1997), target retrieval solution at 95°C 
for 30 minutes (Liu et al. 2008) and 0.2% trypsin solution at room temperature for 30 
minutes (Cancilla et al. 2001)).  In addition to all these methodological differences, 
different antibodies were used across each of the studies, and as such, it is very difficult 
to draw any reliable conclusions when the results between each study are so different.  
Given the importance of FGF23 in maintaining serum Pi homeostasis, and the fact that 
animal models are often used to study it, it is surprising that to date there has been no 
cross-species comparison of FGFr localisation along the nephron using the same 
antibodies.  Indeed, better understanding of FGFr localisation may help in elucidating 
which FGFr (or combination of FGFrs) FGF23 signals through. 
Which FGFr is the receptor for FGF23? 
The exact identity of the FGF23-specific FGFr is currently not known.  Owing to the fact 
that the phosphaturic effects of FGF23 occur in the proximal tubule (Gattineni et al. 2009; 
Miyamoto et al. 2005), it may seem logical to hypothesize that the FGF23-specific FGFr 
also resides in the proximal tubule.  However, data for and against this hypothesis are 
abundant. 
Firstly, FGFr activation by FGF23 requires the presence of the cofactor, Klotho, a 130kDa 
type 1 single-pass transmembrane protein (Kurosu et al. 2006).  Klotho was originally 
identified as an ‘age suppressor’ when mice with a defect in Klotho gene expression were 
shown to exhibit multiple ageing-like phenotypes including osteoporosis, arteriosclerosis, 
skin atrophy and infertility, and die prematurely at 2 months of age (Kuro-o et al. 1997).  
Deletion of Klotho specifically from the nephron results in an aging-like phenotype similar 
to that of systemic Klotho deletion (Lindberg et al. 2014).  Klotho is essential for FGF23 
signalling as it converts FGFr into a receptor specific for FGF23 (Urakawa et al. 2006).  
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Highlighting its requirement in this role are the facts that Klotho-/- mice have a similar 
phenotype to Fgf23-/- mice (Nakatani et al. 2009) and that monoclonal antibodies raised 
against Klotho inhibit FGF23 signalling in a dose-dependent manner (Urakawa et al. 2006).  
Current opinion is that expression of Klotho (both mRNA and protein) is confined to the 
distal tubule (Farrow et al. 2009; Kato et al. 2000; S. Li et al. 2004).  More recent data 
show Klotho mRNA and protein expression in the proximal tubule (Andrukhova et al. 
2012; Hu et al. 2010).  However, the subcellular localisation of Klotho in the proximal 
tubule between these two studies does not match; Andrukhova et al. (2012) report 
basolateral expression, whilst Hu et al. (2010) report apical, basolateral and cytoplasmic 
expression.  In addition, whilst both groups identified much less Klotho mRNA in the 
proximal tubule compared to the distal tubule, Andrukhova et al. reported equal levels of 
protein expression with Hu et al. reporting much weaker protein expression in the 
proximal tubule compared to the distal tubule.  As such, more localisation studies are 
needed to validate the presence or absence of Klotho in the proximal tubule. 
If Klotho is not expressed in the proximal tubule, then ‘how do signalling events linking 
Klotho-dependent FGF23 signalling in the distal tubule produce a physiological effect in 
the proximal tubule?’ In order to answer that question, a distal-proximal paracrine 
signalling mechanism (Farrow et al. 2009) possibly involving peritubular capillaries (Hu et 
al. 2012), has been proposed.  According to this model, Klotho is produced in the distal 
tubule and translocates to the proximal tubule.  This view is supported by the fact that in 
addition to the 130kDa transmembrane-bound form, Klotho also exists as a 70kDa soluble 
protein, which is a product of alternative gene splicing or shedding of the extracellular 
domain of the transmembrane-bound form (Hu et al. 2012). 
However, regardless of whether or not Klotho is expressed in the proximal tubule or 
translocates there following production in the distal tubule, there is important evidence 
supporting the fact that the FGF23-specific FGFr resides in the distal tubule; FGF23 
induces signalling events in the distal tubule before changes in the proximal tubule are 
seen.  Mice treated with recombinant FGF23 display ERK phosphorylation in distal tubules 
after 10 minutes followed by downregulation of NaPi IIa protein (but not mRNA) in 
proximal tubules after 30-60 minutes (Farrow et al. 2010).  In vitro studies have also 
shown the ability of FGF23 to activate ERK (Yamazaki et al. 2010) and as ERK is part of the 
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RAF/MEK/ERK pathway, it is also interesting to note that mice treated with inhibitors of 
MEK, have a similar phenotype to FGF23-/- or Klotho-/- mice (Diaz et al. 2012).   
All that said, in terms of functional studies, FGFr1 appears to be the predominant receptor 
for the phosphaturic actions of FGF23 in mice with FGFr4 playing a lesser role (Gattineni 
et al. 2009).  Indeed, a pull-down binding assay has shown that FGF23 binds specifically 
to splice variant FGFr1(IIIc) in the presence of Klotho (Urakawa et al. 2006).  In addition, 
deletion of FGFr3 or FGFr4 was not shown to correct hypophosphatemia in Hyp mice (a 
mouse model of X-linked hypophosphatemia) and as such neither were considered to 
mediate the phosphaturic effects of FGF23 by these authors (Liu et al. 2008). 
Studies of FGF23 under Pathophysiological Conditions Reveal Physiological Role 
Much of the current understanding of FGF23 and Pi physiology has come from studying it 
under pathophysiological states.  FGF23 was originally identified as a key player in 
phosphate metabolism when a mutated form was shown to be responsible for autosomal 
dominant hypophosphatemic rickets (ADHR) (White et al. 2000).  ADHR is an inherited, 
gain-of-function disease whereby missense mutations in the fgf23 gene prevent it from 
degradation by protease cleavage resulting in prolonged biological activity (Shimada et 
al. 2002; White et al. 2001).  Since then, FGF23 has been shown to be central to a number 
of other diseases of phosphate metabolism. 
X-linked hypophosphatemia (XLH) is an inherited phosphate-wasting disease.  It is caused 
by an inactivating mutation in phosphate-regulating endopeptidase (PHEX) which, by an 
as yet unknown mechanism, results in increased FGF23 levels (Strom and Jüppner 2008).  
Tumour-induced osteomalacia (TIO) is an acquired disease of small and often benign 
FGF23-secreting mesenchymal tumours (Shimada et al. 2001).  In similarity with ADHR 
and XLH patients, TIO patients have persistently high levels of FGF23 resulting in renal 
phosphate wasting, hypophosphatemia and impaired bone mineralisation (Chong et al. 
2011; Shimada et al. 2001).  FGF23 levels can however be restored towards normal and 
the disease treated by removal of the tumours (Fukumoto 2012). 
The effects of raised FGF23 can be modelled in mice by constitutively overexpressing the 
Fgf23 gene.  Mice with raised FGF23 are phenotypically similar to patients with ADHR, 
XLH and TIO with regards to their renal phosphate-wasting, hypophosphatemia and 
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impaired bone mineralisation (Larsson et al. 2004; Shimada et al. 2004c).  
Pharmacological inhibition of FGFr (Wöhrle et al. 2013) and inhibition of FGF23 using 
FGF23 antibodies (Aono et al. 2009) restores normophosphatemia in these mice.  These 
findings indicate that there is the potential for therapeutic treatment of such diseases in 
humans. 
On the other hand, insufficient levels of circulating FGF23 can also produce problems.  In 
humans, familial tumoral calcinosis (FTC) is an autosomal recessive disorder characterised 
by hyperphosphatemia and ectopic soft tissue calcifications (Benet-Pagès et al. 2005).  It 
can be caused by mutations in FGF23 itself, the FGF23-glycosylating enzyme GALANT3 or 
the FGF23 cofactor Klotho (Lammoglia and Mericq 2009).  In a similar manner to 
hypophosphatemic diseases, hyperphosphatemic diseases such as FTC can be modelled 
and studied in mice.  Fgf23 knockout mice develop hyperphosphatemia as a result of 
increased renal phosphate reabsorption via NaPi IIa, have elevated 1,25(OH)2D3 levels, 
and show excessive mineralisation of soft tissues such as the heart and kidney (Shimada 
et al. 2004a; Sitara et al. 2004; Sitara 2007). 
FGF23 within the Bone-Parathyroid-Kidney Axis of Pi Homeostasis 
FGF23 plays a key role in maintaining Pi balance, but it is just one part of the much wider 
‘bone-parathyroid-kidney’ axis of Pi homeostasis in which Pi is also under the control of 
parathyroid hormone (PTH), 1,25(OH)2D3 and Ca2+, as well as Pi itself (Bergwitz and 
Jüppner 2010). 
In addition to raising FGF23 levels via an unknown mechanism (Wolf 2010), an increase 
in Pi increases PTH by stabilising PTH mRNA (Moallem et al. 1998) and stimulating PTH 
secretion (Almaden et al. 1996; Estepa et al. 1999).  The primary role of PTH is to increase 
Ca2+ levels by increasing bone resorption, kidney reabsorption and gut absorption when 
extracellular free ionised calcium (Ca2+o) levels fall below their normal physiological range 
of 1.1 - 1.3mM  (4.4 - 5.4 mg/dL) (Peacock 2010).  However, PTH also acts to both increase 
and decrease Pi levels simultaneously.  It acts to increase Pi levels by stimulating the 
production of 1,25(OH)2D3 (Kinoshita et al. 2005) thereby increasing NaPi IIb mediated Pi 
absorption in the gut (Marks et al. 2006), and acts to decrease Pi levels via kidney 
parathyroid hormone receptor 1 (PTHR1)-mediated NaPi IIa downregulation (Kempson et 
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al. 1995; Matsumoto et al. 2010) and lysosomal degradation (Keusch et al. 1998).  PTH 
also stimulates the production of FGF23 both directly (Lavi-Moshayoff et al. 2010), and 
indirectly by increasing 1,25(OH)2D3 (Kinoshita et al. 2005) which itself increases FGF23 
levels (Liu et al. 2006).  Whilst PTH increases FGF23 and 1,25(OH)2D3 levels, they both 
exert negative feedback on PTH by inhibiting gene transcription and secretion (Ben-Dov 
et al. 2007; Demay et al. 1992).  FGF23 decreases 1,25(OH)2D3 (Clarke 2011; Shimada et 
al. 2004b). 
As depicted below, Pi homeostasis is a balance of complex interacting reciprocal control 
mechanisms acting between FGF23, PTH, 1,25(OH)2D3 and Pi itself.  Figure 1.2 summarises 
the ‘bone-kidney-parathyroid’ axis of serum Pi homeostasis discussed above. 
 
Figure 1.2.  The ‘Bone-Parathyroid-Kidney’ Axis of Serum Pi Homeostasis.  The ‘bone-parathyroid-kidney’ 
axis is a complex inter-relationship between Pi, FGF23, 1,25(OH)2D3 and PTH that controls Pi homeostasis in 
vivo.  Arrows inicate a positive influence (one factor increases the expression of another) and flat heads 
indicate a negative influence (one factor decreases the expression of another) between factors.  An increase 
in serum Pi (hyperphosphatemia), increases serum FGF23 and serum PTH levels (Bergwitz and Jüppner 
2010).  PTH levels increase as a result of PTH mRNA stabilisation (Moallem et al. 1998) and stimulation of 
PTH secretion (Almaden et al. 1996; Estepa et al. 1999).  PTH acts to both increase and decrease Pi levels 
simultaneously.  It acts to increase Pi levels by stimulating the production of 1,25(OH)2D3 (Kinoshita et al. 
2005) thereby increasing NaPi IIb mediated Pi absorption in the gut (Marks et al. 2006), and acts to decrease 
Pi levels via kidney parathyroid hormone receptor 1 (PTHR1)-mediated NaPi IIa downregulation (Kempson 
et al. 1995; Matsumoto et al. 2010) and lysosomal degradation (Keusch et al. 1998), the result of which is 
phosphaturia. PTH also stimulates the production of FGF23 both directly (Lavi-Moshayoff et al. 2010), and 
indirectly by increasing 1,25(OH)2D3 (Kinoshita et al. 2005) which itself increases FGF23 levels (Liu et al. 
2006).  Whilst PTH increases FGF23 and 1,25(OH)2D3 levels, they both exert negative feedback on PTH by 
inhibiting gene transcription and secretion (Ben-Dov et al. 2007; Demay et al. 1992).  FGF23 decreases 
serum 1,25(OH)2D3 (Clarke 2011; Shimada et al. 2004b) leading to reduced Pi absorption in the gut via NaPi 
IIb. 
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Chronic Kidney Disease-Mineral Bone Disorder, FGF23 and Klotho 
In 2006, the Kidney Disease Improving Global Outcomes Foundation (KDIGO) coined the 
term ‘Chronic Kidney Disease-Mineral Bone Disorder’ (CKD-MBD) (S. Moe et al. 2006) in 
light of the fact that disordered mineral metabolism is a key feature of chronic kidney 
disease.  CKD is a disease whereby glomerular filtration rate (GFR) declines over time and 
the kidneys lose their ability to excrete Pi (Kuro-o 2010).  Pi retention is a target for 
therapeutic intervention because it is associated with an extremely increased risk of 
cardiovascular disease and mortality (Isakova et al. 2011; Quarles 2012).  Controversies 
regarding the onset of the disease exist, particularly at the early stages when GFR has 
decreased, but Pi levels are normal. 
Results from both the Chronic Renal Insufficiency Cohort (CRIC) longitudinal study 
(Isakova et al. 2011) and the Chronic Kidney Disease in Children observational study 
(Portale et al. 2014) show that increased FGF23 is the earliest detectable event following 
CKD onset.  In early CKD, therefore, the rise in FGF23 followed by decrease in 1,25(OH)2D3 
and increase in PTH (Wolf 2010) maintain Pi levels within a normal physiological range 
(Gutierrez et al. 2005; Oliveira et al. 2010).  However, over time, as renal function 
continues to deteriorate, these defence mechanisms are overwhelmed and 
hyperphosphatemia ensues (Shanahan et al. 2011). 
A recent cross-sectional study (Pavik et al. 2013) confirmed a previous report (Koh et al. 
2001) that levels of Klotho, the FGF23 receptor cofactor, decrease in early CKD.  CKD may 
therefore be a state of renal resistance to FGF23, whereby Klotho deficiency causes FGF23 
levels increase as a compensatory mechanism (Hu et al. 2011; Sakan et al. 2014; Six et al. 
2014).  As such, increased FGF23 and decreased Klotho have both been proposed as early 
biomarkers of disordered Pi metabolism/CKD onset (Fliser et al. 2007; Isakova et al. 2009; 
Wahl and Wolf 2012). 
The full significance of FGF23 elevation in CKD remains to be fully elucidated (O. Moe and 
Kuro-O 2014).  It appears that FGF23 may not just be a mere marker of disordered Pi 
metabolism but may also directly contribute to CKD pathophysiology.  In CKD, FGF23 
strongly and independently associates with cardiovascular events and all-cause mortality 
(Kendrick et al. 2011).  Endothelial dysfunction and vascular stiffening (Mirza et al. 2009a), 
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atherosclerosis (Mirza et al. 2009b), vascular calcification (Desjardins et al. 2012) and left 
ventricular hypertrophy (Faul et al. 2011), are all associated with pathologically high levels 
of FGF23.  As Klotho is not expressed in the heart (Faul et al. 2011), the effects of FGF23 
outside the kidney and parathyroid gland are thought to be independent of Klotho.  
Indeed, there is evidence showing that FGF23 can bind, albeit with very low affinity, to 
FGFr in the absence of Klotho (Urakawa et al. 2006) and that Klotho-independent FGF23 
signalling in the heart occurs via PLCγ rather than ERK (the classical Klotho-dependent 
FGF23 signalling pathway) to induce cardiomyocyte hypertrophy (Faul et al. 2011).   It 
seems possible that the 1000-fold greater than normal FGF23 levels seen in CKD patients 
(Larsson et al. 2003), could have Klotho-independent effects. 
FGFrs, Cancer and Ectopic Mineralisation 
As previously mentioned, FGF23 is just one member of the FGF family (Beenken and 
Mohammadi 2009).  Whilst FGF23 is involved in Pi homeostasis, other members play a 
role in regulating key cellular events such as cell proliferation, survival, differentiation and 
migration.  Therefore, dysregulation of FGF/FGFr signalling is associated with many 
different developmental disorders and cancerous tumours (A. Brooks et al. 2012; Daniele 
et al. 2012; Dieci et al. 2013).  As a consequence of this, FGF/FGFr signalling has become 
a target for therapeutic intervention in cancer, with in vitro and in vivo data highlighting 
the efficacy of inhibiting this pathway to preventing tumour growth (Dienstmann et al. 
2014).  However, because FGFs perform such a wide range of biological roles, broad FGFr 
inhibition has many unwanted side effects.  One of the biggest complications 
pharmaceutical companies face in developing anti-cancer FGFr inhibitors has been 
hyperphosphatemia-mediated ectopic tissue mineralisation due to blockade of FGF23 
phosphate homeostasis (Diaz et al. 2012; Turner and Grose 2010).   Results from Phase I 
studies using AZD4547, a potent and selective inhibitor of FGFr1-3 (Gavine et al. 2012) 
and NVP-BGJ398, a pan FGFr inhibitor (Guagnano et al. 2011) both highlighted 
hyperphosphatemia as a common adverse event, with ectopic calcifications only 
minimised in the BJG398 trial with the aid of phosphate-binders (Dienstmann et al. 2014).  
Rather than balancing efficacy with unwanted side effects by using lower doses or using 
Pi lowering drugs as adjuncts, efforts to identify subtype selective FGFr inhibitors are 
ongoing. 
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1.3 Project Overview 
The discovery of FGF23 as a key player in autosomal dominant hypophosphatemic rickets 
(White et al. 2000) drastically changed our understanding of Pi homeostasis.  Presented 
previously is a summary detailing what is already known about FGF23 physiology and 
pathophysiology, and some of the major issues still facing the field have been highlighted.  
One of the biggest questions is ‘which FGFr is the FGF23-specific FGFr?’  Knowing the 
answer could revolutionise the treatment of both CKD-MBD and cancer.  It is surprising, 
therefore, that to date, no cross-species comparison of FGFr localisation in the kidney has 
been carried out, especially given the fact that rodent species are used to model both 
CKD-MBD and cancer.  If, based on current FGFr localisation studies, there are indeed 
differences in the expression patterns of FGFr along the nephron, then it begs the 
question, how good are rodent species as models for studying FGF23-mediated Pi 
homeostasis in humans?  Differences in expression patterns and expression levels could 
indicate differences in Pi regulation between species.  To negate species differences, it 
would be much better to adopt a human-specific in vivo model.  However, due to the 
complex nature of the bone-parathyroid-kidney axis, studying it in humans in vivo is very 
difficult.  The availability of an in vitro human kidney model through which the individual 
influence of FGF23, PTH, 1,25(OH)2D3, Ca2+ and Pi itself has on Pi homeostasis would be 
greatly advantageous.  Currently available human cell lines such as Human Embryonic 
Kidney (HEK)293 cells (Urakawa et al. 2006) and renal proximal tubule cells (RPTC) 
(Shalhoub et al. 2011) have been used for studying the actions of FGF23 in vitro.  However, 
the phosphaturic action of FGF23 is thought to be a ‘cross-talk’ between proximal and 
distal tubule cells and a single cell type in culture does not enable such interactions.  Co-
cultures of primary human proximal and distal tubule cells have, however, been 
established by C. Brown et al. as a model for studying xenobiotic handling in the kidney 
(C. Brown et al. 2008).  Another use of these cells is as a model for studying mineral ion 
homeostasis by the human kidney under defined conditions. 
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1.4 Aims 
The aims of this study were: 
1. To localise FGFr1, FGFr2, FGFr3 and FGFr4 in human, rat and mouse kidney tissue.  
The specific aims include: 
a. To perform sequence alignments for epitopes targeted by antibodies raised 
against FGFr1, FGFr2, FGFr3 and FGFr4 in each species to determine their 
species selectivity. 
b. To use immunohistochemistry to compare and contrast FGFr1, FGFr2, FGFr3 
and FGFr4 expression patterns between species, and compare these findings 
against published literature. 
 
2. To check the specificity of antibodies raised against Klotho, sodium-phosphate co-
transporter IIa (NaPi IIa), sodium-calcium exchanger 1 (NCX1) and plasma 
membrane calcium ATPase 1 (PMCA1) (other proteins also involved in mineral ion 
homeostasis by the kidney) by immunohistochemistry in human kidney. 
 
3. To characterise an in vitro human primary co-culture of proximal and distal tubule 
cells as a novel model for studying mineral ion homeostasis by the human kidney.  
The specific aims include: 
a. Assess viability over time (using proliferation and apoptosis assays). 
b. Assess the maintenance of renal phenotype over time (using presence of E-
Cadherin and N-Cadherin as markers of distal and proximal tubule cell 
phenotypes respectively). 
c. Assess cell morphology (including cobblestone appearance and proximal 
tubule cell brush border membranes). 
d. Assess the ability of in vitro renal cells to mimic in vivo renal cell responses to 
known physiological stimuli (including NaPi IIa upregulation in response to no 
Pi, FGF23-induced ERK1/2 phosphorylation and MEK inhibitor-induced 
mineralisation). 
e. Assess the expression of key proteins in culture (FGFr1-4, Klotho, NaPi IIa, 
NCX1 and PMCA1), and identify if FGF23 or Pi modulate their expression. 
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1.5 Materials and Methods 
Antibody Epitope Sequence Alignments 
Protein sequences for human, rat and mouse FGFr1, FGFr2, FGFr3 and FGFr4 were 
obtained from the UniProt database.  Using Basic Local Alignment Search Tool (BLAST) 
the protein sequences for each protein from each species were aligned.  The epitope 
(antigenic region) detected by each antibody for each of the proteins used in this study 
were selected and a comparison of similarities and differences in terms of sequence 
homology were made.  The accession number used were: FGFr1 = Human (P11362), Rat 
(Q04589), Mouse (P16092); FGFr2 = Human (P21802), Rat (Q63238), Mouse (P21809); 
FGFr3 = Human (P22607), Rat (Q9JHX9), Mouse (Q61851); FGFr4 = Human (P22455), Rat 
(Q498D6), Mouse (Q03142).  A list of the antibodies used in this study can be found in 
Table 1.2. 
Obtaining Human, Rat and Mouse Kidney Tissue 
Adult human kidney tissue for immunohistochemistry and cell culture was obtained from 
ethically-consented human kidneys surgically resected at The University Hospital Wales 
due to renal cell carcinoma (RCC) (Research Ethics Committee approval reference 
number: 07/WSE04/53) in collaboration with the Wales Cancer Bank.  Macroscopically 
normal kidney cortex tissue was taken from a region separate to the carcinoma.  Use of 
human kidney tissue was compliant the Human Tissue Act.  Additional adult human 
kidney tissue for immunohistochemistry was sourced from Dr David Griffiths at The 
University Hospital Wales who had previously collected and prepared a human tissue 
microarray (TMA) of kidney cortex samples (both normal and diseased) (Searchfield et al. 
2011).  Adult human kidney cortex tissue for immunohistochemistry performed at 
AstraZeneca was obtained from the AstraZeneca Global Tissue Bank.  Use of the tissue 
was compliant with the Human Tissue Act (HTA) as well as Global AstraZeneca Policy.  Rat 
and mouse kidney tissue for immunohistochemistry was obtained from an adult male Han 
Wister rat (Harlan, UK) and an adult male C57Bl/6 mouse (Harlan, UK). 
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Immunohistochemistry 
Cardiff: 4µm-thick formalin-fixed, paraffin-embedded sections of human kidney cortex 
were cut and air-dried onto strongly adhesive slides (Raymond A Lamb Limited, HistoBond 
E27.5HB), deparaffinised in xylene (Sigma, 534056) (2 x 5 minutes) and rehydrated using 
100% (2 x 5 minutes) and 95% (1 x 5 minutes), 70% (1 x 5 minutes) ethanol (Sigma, 
458600) and running tap water (1 x 5 minutes).  Following pre-treatment (if required as 
per Table 1.2), tissue sections were incubated with 3% (v/v) H2O2 (Fisher Scientific, 
H/1750/15) in 1 x phosphate-buffered saline 0.05% (v/v) Tween-20 (Sigma, P5927) (PBST) 
(10 minutes) to quench endogenous peroxidase activity.  Sections were washed with PBST 
(3 x 5 minutes).  Non-specific binding of antibodies to tissue sections was prevented using 
serum-free protein block (Dako; X0909) (20 minutes).  Individually diluted in antibody 
diluent (Dako, S2022), primary antibodies raised against FGFr1, FGFr2, FGFr3, FGFr4, 
Klotho, NaPi IIa, NCX1, PMCA1, E-Cadherin and N-Cadherin (as per Table 1.2) were applied 
to tissue sections for 1 hour.  Sections were washed with PBST (3 x 5 minutes).  
Immunoreactivity was detected and visualised using an anti-rabbit HRP polymer (Dako, 
K4065) (20 minutes) and liquid stable 3, 3’ diaminobenzidine (DAB) (Dako; K3468) (1 
minute) before sections were counterstained in haematoxylin (Sigma, HHS16) (1 minute).  
Sections were dehydrated using running water (1 x 5 minutes), 70% (1 x 5 minutes), 95% 
(1 x 5 minutes) and 100% (2 x 5 minutes) ethanol (Sigma, 458600), and then cleared in 
xylene (Sigma, 534056) (2 x 5 minutes).  Slides were allowed to air dry before coverslips 
were mounted on slides using histomount (TAAB Labs, UK).  Images were captured using 
a Mirax scanner (Zeiss, Germany) and Pannoramic Viewer software (3DHISTECH Kft, 
Hungary).  For immunohistochemistry performed on human kidney cortex tissue 
microarray (TMA) samples, one section was used per antibody from which one image of 
the entire sample/field of view was captured.  From this image, all proximal and distal 
tubules present were assessed for expression of the protein of interest.  For 
immunohistochemistry performed on larger samples of human kidney cortex, one section 
was used per antibody.  From these sections, images of 10 random fields of view were 
captured from which all proximal and distal tubules present were assessed for expression 
of the protein of interest. 
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AstraZeneca: 4µm-thick formalin-fixed, paraffin-embedded sections of human kidney 
cortex, or mouse and rat kidneys embedded in the transverse plane were cut and air-
dried onto strongly adhesive slides (Leica Biosystems, Wetzlar, Germany). Sections were 
deparaffinised in xylene (Sigma, 33817) (2 x 5 minutes), and rehydrated using 100% (2 x 
5 minutes) and 95% (1 x 5 minutes) ethanol (Sigma, 458600) followed by running tap 
water (1 x 5 minutes). Following pre-treatment (if required as per Table 1.2), all 
immunostaining was carried out at room temperature using a Labvision autostainer 
(Labvision, Fremont, USA). Sections were incubated with 3% H2O2 (Fisher Scientific, 
H/1750/15) 1 x Tris-buffered saline 0.05% Tween-20 (USB Corporation, 20605) (TBST) (10 
minutes) to quench endogenous peroxidase activity.  Sections were briefly rinsed with 
TBST before non-specific antibody binding was minimised using background blocker with 
casein (MP-966-P500; Menarini Diagnostics, Florence, Italy) (20 minutes). Individually 
diluted in 1X TBST, primary antibodies raised against FGFr1, FGFr2, FGFr3 and FGFr4 (as 
per Table 1.2) were applied to tissue sections for 1 hour. Sections were briefly rinsed with 
TBST before primary antibodies were conjugated with HRP using X-Cell Plus Universal 
Polymer HRP Kit (MP-XCP-U100, Menarini Diagnostics, Florence, Italy) (20 minutes).  
Sections were rinsed twice with TBST. Immunoreactivity was visualised using liquid stable 
3, 3’ diaminobenzidine (DAB) (MP-860-K25, Menarini Diagnostics, Florence, Italy) (10 
minutes).  Sections were rinsed twice with TBST and then counterstained using Carazzi’s 
haematoxylin (Clin Tech Ltd, 642300) (1 minute).  Sections were dehydrated using running 
tap water (1 x 5 minutes), 95% (1 x 5 minutes) and 100% (2 x 5 minutes) ethanol (Sigma, 
458600), and then cleared in xylene (Sigma, 33817) (2 X 5 minutes). Sections were allowed 
to air dry before coverslips were mounted on the slides using histomount (TAAB Labs, 
Aldermaston, UK). Slides were scanned using a ScanScope scanner and images captured 
using ImageScope software (Aperio Technologies Incorporated, USA).  For 
immunohistochemistry performed on human kidney cortex samples, one section was 
used per antibody.  Form these sections, images of 10 random fields of view were 
captured from which all proximal and distal tubules present were assessed for expression 
of the proteins of interest.  For immunohistochemistry performed on rat and mouse 
kidneys, one section per antibody was tested.  In each case, 10 random fields of view of 
the kidney cortex were captured from which all proximal and distal tubules present were 
assessed for expression of the proteins of interest.
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Table 1.2.  Summary of antibodies used in the protein localisation study, and the human renal cell characterisation study.  Details regarding 
the proteins investigated, the antibody suppliers and catalogue numbers, the antigen retrieval methods performed, antibody dilutions and 
antibody dilutions are provided.  For the protein localisation study, work was done both at Cardiff University and AstraZeneca.  The species 
in which the antibodies were tested are human (H), rat (R) and mouse (M). At AstraZeneca, citrate antigen retrieval (Citrate; Sigma, C1909) 
was performed at pH6 for 2 minutes at 110°C using a RHS-2 Rapid Histoprocessor (Milestone, Sorisole, Italy).  Ethylenediaminetetraacetic 
acid (EDTA; Sigma, ED255) antigen retrieval was performed at pH8 for 2 minutes at 110°C using a RHS-2 Rapid Histoprocessor.  FFPE = 
formalin-fixed, paraffin-embedded human kidney.  Frozen = fresh frozen human kidney.
Protein Supplier IHC/IF Antigen Retrieval and Antibody Dilution ICC Dilution 
FGFr1 Abcam (ab71928) Cardiff = 1:250 (H).  AstraZeneca = Citrate 1:1000 (H, R & M) 1:200 (H) 
FGFr2 Abcam (ab10648) Cardiff = 1:500 (H).  AstraZeneca = 1:1000 (H), 1:1500 (R), 1:2000 (M) 1:200 (H) 
FGFr3 Abcam (ab10651) Cardiff = 1:500 (H).  AstraZeneca = 1:2000 (H, R & M) 1:100 (H) 
FGFr4 Abcam (ab41948) Cardiff = 1:250 (H).  AstraZeneca = EDTA 1:500 (H, R &M) 1:100 (H) 
Klotho Abcam (ab75023) Cardiff = 1:200 (H) 1:200 (H) 
NaPi IIa Jürg Biber (Switzerland) Cardiff = 1:500 (H) 1:200 (H) 
NCX1 Abcam (ab2869) Cardiff = 1:200 (H) 1:200 (H) 
PMCA1 Abcam (ab3528) Cardiff = 1:150 (H) 1:200 (H) 
N-Cadherin Abcam (ab12221) Cardiff = 1:100 (FFPE) (H), 1:250 (Frozen) (H) 1:100 (H) 
E-Cadherin Abcam (ab1416) Cardiff = 1:200 (FFPE) (H), 1:400 (Frozen) (H) 1:100 (H) 
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Human Renal Cell Isolation and Culture 
Within 1 hour of removal from a patient, samples of macroscopically normal cortical 
tissue were dissected by a pathologist or biomedical scientist from the Wales Cancer Bank 
at the University Hospital Wales and transported to the host laboratory in isolation 
medium (RMPI 1640 medium with L-glutamine (VWR; 733-1708) containing 5% (v/v) FBS 
(GE Healthcare, UK), 2% (v/v) Pen/Strep (Invitrogen; 15140-122)) at 4°C.  Under sterile 
conditions in a laminar flow hood (BIOQUELL, ABS1200CLS2-MK2), roughly 1cm3 pieces of 
freshly dissected cortical tissue were washed in phosphate-buffered saline pH 7.4 (PBS; 
Invitrogen, 10010-015) at 4°C.  All metallic tools used were sterilised by autoclaving prior 
to use.  Using metal tweezers and a disposable scalpel (Swann-Morton; 0501), cortical 
tissue was minced into a paste in 200µl 1X PBS pH 7.4 (Invitrogen; 10010-015) at 4°C.  The 
resultant tissue paste was roughly divided into quarters.  Using a sterile pipette tip with 
the top cut off, each quarter was placed in one of four 50ml polypropylene, conical 
bottom, tubes (Corning®, 430829) containing 37.5ml isolation medium (RMPI 1640 
medium with L-glutamine (VWR; 733-1708) supplemented with 5% FBS (GE Healthcare, 
UK), 2% Pen/Strep (Invitrogen; 15140-122) and 0.67mg/ml collagenase type-IV 
(Worthington, LS004188)).  (See method of collagenase type-IV preparation below).  The 
four tubes were left at 4°C until the next day.  Gentle agitation of the suspension inside 
the tubes to prevent settling of the tissue was achieved during this time using a cyclic 
rotator (VWR; 444-0502).  Upon warming to 37°C for 15 minutes in a water bath the next 
day, tissue suspensions were vigorously agitated at 200 rotations/minute (rpm) in a 
shaking incubator (Jencons-PLS, Orbital incubator and shaker, 5150) for 2 hours at 37°C 
to enzymatically and mechanically dissociate the cells into a single cell suspension.  To 
remove any remaining undigested tissue, the cell suspensions were filtered through a 
40μm pore nylon strainer (BD Biosciences, UK; 352340) in to fresh 50ml tubes.  To remove 
the collagenase and end the enzymatic digestion, cells were centrifuged twice at 150g for 
7 minutes and each time re-suspended in fresh RMPI 1640 isolation medium (minus 
collagenase).  The first time cells were re-suspended in 50ml RMPI 1640 isolation 
medium, and the second time, in 5ml RMPI 1640 isolation medium (minus collagenase).  
Cell suspensions were then loaded on top of discontinuous Percoll (GE Healthcare, 
GZ17089102) gradients made up of 1.04 and 1.07g/ml Percoll in isolation medium and 1X 
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PBS, respectively (See Percoll Gradient method below).  Cells were then centrifuged at 
1200g for 25 minutes in a swing out rotor (Eppendorf; Germany; 5720).  A mixed 
population of proximal and distal tubule cells was aspirated from the intersection of the 
gradients and centrifuged twice at 150g for 7 minutes to remove excess Percoll.  The first 
time, cells were re-suspended in 50ml RMPI 1640 isolation medium (minus collagenase), 
and the second time, cells were re-suspended in 5ml renal epithelial growth medium 
(REGM; Lonza, CC3191) containing the REGM SingleQuot kit supplements and growth 
factors, fetal calf serum (FCS), amphotericin B, epinephrine, human epidermal growth 
factor, hydrocortisone, insulin, transferrin and triiodothyronine (Lonza; CC4127).  Rather 
than adding the gentamycin aliquot of the REGM SingleQuot kit supplements, 1% 
Penicillin (100units/ml)/Streptomycin (100µg/ml) (Invitrogen; 15140-122), was added to 
the culture medium.  Gentamycin is a regularly used antibiotic in cell culture.  However, 
it is also a nephrotoxin and it was thought that it may induce cell injury.  As such a 
combination of Penicillin/Streptomycin was used.  Once a bottle of Renal Epithelial 
Growth Medium containing the desired supplements was prepared, it was stored in 
darkness at 4°C, and used for up to one month. 
For immunocytochemical assays, 100,000 cells were plated per 13mm Ø collagen type-IV 
(Sigma, C5533)-coated borosilicate glass coverslips (VWR, 631-0149) that were 
individually placed inside the wells of a 24-well tissue culture-treated plate 
(ThermoScientific, NunclonTM, 142475), or 0.4µm pore size polyethylene terephthalate 
(PET) transwells  (VWR, 353180).  300,000 cells were plated in 35mm tissue culture-
treated polypropylene plates (Falcon®, 353001).  Cells were cultured in a humidified, 5% 
CO2 incubator at 37°C (SANYO, MCO-18AIC).  After warming to 37°C in a water bath, the 
cell culture medium was replaced on day 4, day 7, day 9 and day 14. 
The cell culture protocol is based on that published by C. Brown et al., 2008. 
For studies of protein regulation by Pi or FGF23, REGM was designated as Pi-containing 
medium as it inherently possessed Na2HP04•7H2O and NaH2P04•H20 at concentrations of 
135mg/l and 62.50mg/l respectively, and Pi-free Dulbecco’s Modified Eagle Medium 
(DMEM) (Invitrogen; 11971-025), with added REGM SingleQuot kit supplements and 
growth factors, was designated as Pi-free medium.  Recombinant FGF23 (R&D systems, 
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2604-FG/CF) and recombinant Klotho (R&D systems, 1819-KL) plus heparin (Sigma, 
H3149) were added at working concentrations of 1μg/ml, 0.1μg/ml and 10μg/ml 
respectively.  The glycosaminoglycan (GAG) heparin, was added as it is thought to 
enhance Klotho-dependent FGF23 activity by stabilising the FGF23-Klotho-FGFr complex 
(Urakawa et al. 2006).  Concentrations of Klotho, heparin and FGF23 were based on those 
used in previous publications (Farrow et al. 2010; Goetz et al. 2010; Shalhoub et al. 2011; 
Smith et al. 2012). 
Preparation of the Percoll Gradient for Isolating Primary Renal Cells 
The Percoll gradient stock solution and gradients were prepared fresh on day of use under 
sterile conditions in a laminar flow tissue culture hood (BIOQUELL, ABS1200CLS2-MK2).  
For a roughly 1cm3 sample of human kidney cortex, four Percoll gradients were prepared.  
The volumes required each of the gradient densities is described below.  Into each 50ml 
polypropylene, conical bottom tube (Corning®, 430829), 7ml of the 1.07 density solution 
was added.  With the 50ml tube at a 45° angle, 7ml of the 1.04 density solution was slowly 
pipetted down the inside of the tube, such that the 1.04 density solution sat on top of the 
1.07 density solution.  In a similar manner, 5ml of the cell suspension was then layered 
on top of the 1.04 density solution. 
Percoll Stock Solution: 
10X HBSS (Invitrogen; 14065-049)   4ml 
Percoll (GE Healthcare; GZ17089102)  36ml 
Percoll Gradient Density 1.04: 
Percoll Stock Solution     10ml 
RMPI 1640 Medium (VWR; 733-1708)  24ml 
Percoll Gradient Density 1.07: 
Percoll Stock Solution     20ml 
1X PBS (Invitrogen; 10010-015)   16ml 
  
  
 
34 
 
Preparation of Collagenase Type-IV for Enzymatic Cell Isolation 
The collagenase type-IV (Worthington, LS004188) for enzymatic cell digestion was 
prepared under sterile conditions in a laminar flow tissue culture hood (BIOQUELL, 
ABS1200CLS2-MK2).  25ml of RMPI 1640 isolation medium (Lonza, BE12-702F) was added 
to a 2.5g pot of collagenase type-IV (Worthington, LS004188) powder and repeatedly 
pipetted up and down to fully suspend to powder into a 100mg/ml stock solution.   The 
stock solution was filter-sterilised though a 0.20µm pore size Minisart® syringe filter 
(Sartorius Stedium Biotech, Germany, 16534), after which 1ml aliquots were made in 
sterile 15ml tubes (Corning, 430791) and stored at -20°C.  One aliquot was defrosted for 
use as and when required.  To obtain the working concentration of collagenase type-IV 
(0.67mg/ml) needed for isolation of renal cells, 250µl of the 100mg/ml stock solution was 
added to 37.5ml RMPI 1650 isolation medium (Lonza, BE12-702F). 
Preparation of Collagen-Coated Glass Coverslips for Cell Culture  
13mm Ø borosilicate glass coverslips (VWR, 631-0149) were stored until required in 
copious 100% ethanol (Sigma, 458600).  Under sterile conditions in a laminar flow hood 
(BIOQUELL, ABS1200CLS2-MK2), and using autoclave-sterilised metal tweezers, the 
13mm Ø borosilicate glass coverslips (VWR, 631-0149) were individually placed into the 
wells of a 24-well tissue culture-treated plate (ThermoScientific, NunclonTM, 142475).  
During this process, coverslips were balanced at an angle against the side of each well to 
enable any ethanol on the coverslips to evaporate away.  When all the ethanol had 
evaporated away (up to 1 hour later), the tissue culture plate containing the ethanol-
sterilized coverslips, was further sterilized using the UV irradiation setting on the laminar 
flow tissue culture hood (BIOQUELL UK LTD, ABS1200CLS2-MK2) for 20 minutes. 
All coverslips used for human renal cell cultures, were then coated with tissue culture 
grade collagen type–IV (Sigma, C5533).  A 1mg/ml collagen stock solution was prepared 
from 5mg of lyophilized collagen type-IV powder in 5ml of 0.5M sterile acetic acid (Fisher 
Scientific, A/0360/PB17).  The 1mg/ml stock solution was always prepared at least 24 
hours in advance of requirement to allow for the collagen to completely dissolve, and was 
kept at 4°C.  A working concentration of 0.1mg/ml collagen type-IV was prepared from 
the 1mg/ml stock solution using tissue culture grade distilled water (Invitrogen; 15230-
  
 
35 
 
089).  200µl of 0.1mg/ml collagen type-IV solution was pipetted directly onto each 13mm 
Ø borosilicate glass coverslip (VWR, 631-0149) and left for 2 hours.  After this time, the 
0.1mg/ml collagen type-IV working concentration solution was removed, and the 
coverslips rinsed three times with sterile 1X PBS (Invitrogen, 10010-015) to remove any 
remaining traces of acetic acid.  The final 1X PBS wash was left in the wells until just before 
renal cells were ready for plating. 
Cell Proliferation Assay 
The incorporation and immunofluorescent detection of 5-bromo-2'-deoxyuridine (BrdU), 
a thymidine analogue, into cellular DNA was used to investigate the percentage of cells 
undergoing proliferation, at day 5, day 8, day 10 and day 15 of culture.  5-bromo-2'-
deoxyuridine (BrdU; Sigma, B5002) was added at a final concentration of 10µM to the 
culture medium 24 hours before cell fixation (i.e. on day 4, day 7, day 9 an day 14).  Cells 
were removed from the incubator and transferred to the lab bench where the culture 
medium was then removed.  Cells were fixed using 2% (w/v) paraformaldehyde (PFA; 
Sigma, 15,812-7) in 1X PBS pH 7.4 (10 minutes) at 4°C.  2% PFA stocks were pre-prepared 
and stored at -20°C.  Aliquots were defrosted slowly on ice as and when required.  
Following fixation, cells were washed with 1X PBS pH 7.4 (3 X 5 minutes) at room 
temperature.  Cells were permeabilised using 1X PBS pH 7.4 containing 0.05% (v/v) 
Tween-20 (Sigma, P5927) pH 7.4 (PBST) (5 minutes).  Antigen retrieval was performed by 
incubating cells with 1N HCl (prepared from a 37% HCl stock solution (Sigma, 258148)) at 
37°C (30 minutes) in a benchtop incubator (Techne Hybridiser, HB-1D).  The antigen 
retrieval solution was removed and cells washed with PBST (3 X 5 minutes).  Non-specific 
antibody binding sites were blocked using blocking buffer (1% (w/v) bovine serum 
albumin (BSA; Sigma, A7906), 3% (v/v) SeaBlockTM (EastCoast Bio, PP83-K1574) in PBST) 
at room temperature (1 hour).  The blocking buffer was removed and cells incubated with 
an anti-BrdU primary antibody (mouse IgG; Abcam; ab8039) diluted 1:200 in blocking 
buffer (1 hour).  To remove unbound antibodies, PBST washes were subsequently 
performed (3 X 5 minutes).  Furthermore in darkness, Alexa Fluor® 594-conjugated 
secondary antibody diluted 1:400 in blocking buffer (goat anti-mouse IgG; Invitrogen; 
A11032) was applied to cells (1 hour).  Again, to remove unbound antibodies, PBST 
washes performed (3 X 5 minutes).  In order to identify all cell nuclei, cells were incubated 
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with 0.1µg/ml Hoechst 33342 (Invitrogen; H1399), a nucleic acid stain, diluted in blocking 
buffer (10 minutes).  Cells underwent further PBST washes (3 X 5 minutes) to remove 
excess Hoechst 33342.  Cells were briefly rinsed with distilled H20, before excess H20 was 
tapped off and coverslips mounted on slides using ProLong® Gold reagent (Invitrogen; 
P36930), a fluorescent anti-fade mounting medium.  Slides were allowed to air-dry in 
darkness.  Snapshots of slides were captured using a BX61 microscope (Olympus, Japan) 
and the percentage of proliferating cells out of the total number of cells was determined. 
A minimum of 500 cells at each time point were counted. Results were plotted graphically 
and analysed using Prism (GraphPad Software Inc., USA).  To identify changes in 
proliferation over time, a one-way analysis of the variance (ANOVA) and a post-hoc Tukey 
multiple comparison test was performed.  Results were deemed statistically significant 
when p<0.05 (*), P<0.01 (**) and p<0.001 (***). N=3, n=3. 
Cell Apoptosis Assay 
The percentage of human renal cells undergoing apoptotic cell death at day 5, day 8, day 
10 and day 15 of culture, was determined using the DeadEndTM Colorimetric Apoptosis 
Detection Kit (Promega, G7360).  At each time point, cells were removed from the 
incubator and transferred to lab bench where the culture medium was then removed. 
Cells were fixed using 2% (w/v) paraformaldehyde (PFA; Sigma, 15,812-7) in 1X PBS pH 
7.4 (10 minutes) at 4°C.  2% PFA stocks were pre-prepared and stored at -20°C.  Aliquots 
were defrosted slowly on ice as and when required.  Following fixation, cells were washed 
with 1X PBS pH 7.4 (3 X 5 minutes) at room temperature.  Cells were then treated with 
the kit equilibration buffer (containing 200mM Potassium cacodylate, 25mM Tris-HCl, 
0.2mM DTT, 0.25mg/ml BSA, 2.5mM cobalt chloride) at room temperature (5 minutes).  
Biotinylated nucleotides were incorporated at the 3’-OH end of fragmented, apoptotic 
DNA by recombinant terminal deoxynucleotidyl transferase (rTdT) at 37°C (1 hour).  This 
rTDT reaction mix contained 1% (v/v) kit biotinylated nucleotide mix and 1% (v/v) kit rTdT 
enzyme in equilibration buffer.  To terminate the TUNEL reaction, cells were then 
incubated with 2X saline sodium citrate (SSC) (15 minutes) at room temperature.  2X SSC 
was prepared by diluting the 20X SSC solution supplied with the kit 1:10 with deionised 
water before use.  After cells were washed with 1X PBS pH 7.4 (3 X 5 minutes), 
endogenous peroxidases were quenched by treating cells with 0.3% (v/v) H2O2 (Fisher 
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Scientific, H/1750/15) (5 minutes).  1X PBST washes were subsequently repeated (3 X 5 
minutes).  Cells were incubated with kit streptavidin-HRP diluted 1:500 in 1X PBST (30 
minutes).  Following, further 1X PBST washes (3 X 5 minutes), immunoreactive sites were 
detected using the kit 3,3'-diaminobenzidine (DAB) (1 minute).  The working 
concentration of DAB was achieved by diluting the 20X DAB Chromogen 1:20 in DAB 
substrate buffer.  Cells were rinsed with distilled H2O (3 X 5 minutes) and then 
counterstained with haematoxylin (Sigma, HHS16) (1 minute).  Cells were dehydrated 
using 70%, 95%, 100% and 100% (v/v) ethanol (Sigma, 458600) (5 minutes each) and then 
cleared in xylene (Sigma, 534056) (2 X 5 minutes).  Coverslips were allowed to air dry, and 
then mounted on glass slides using DPX mounting medium (Sigma, 44581).  Images were 
captured using a DMRB microscope (Leica, Germany) and the number of apoptotic cells 
out of the total number of cells was determined.  A minimum of 500 cells at each time 
point were counted.  Results were plotted graphically and analysed using Prism 
(GraphPad Software Inc., USA).  To identify changes in apoptosis over time, a one-way 
analysis of the variance (ANOVA) and a post-hoc Tukey multiple comparison test was 
performed.  Results were deemed statistically significant when p<0.05 (*), P<0.01 (**) 
and p<0.001 (***).  N=3, n=3. 
Determination of the Percentage of Proximal to Distal Tubule Cell in Culture 
Fluorescence activated cell sorting (FACS) analysis was used to determine the proportion 
of proximal and distal tubule cells at the point of isolation (i.e. at day 0), in addition to 
confirming that the cells isolated were indeed of proximal and distal tubule cell origin.  
Cells were fixed using 2% (v/v) paraformaldehyde (PFA, Sigma, 15,812-7) in PBS pH 7.4 
(10 minutes).  Following fixation, cells were spun in a benchtop centrifuge at 100g 
(Eppendorf, 5415D) (3 X 2 minutes) and each time resuspended in PBS pH 7.4.  Non-
specific binging sites were blocked using 5% (v/v) goat serum (Sigma, G9023) in PBS pH 
7.4 for 1 hour.  Cells were centrifuged at 100g (1 X 2 minutes) and then incubated with 
either anti-E-cadherin primary antibody (mouse IgG; 1:200 in blocking buffer; Abcam; 
ab1416) or anti N-cadherin primary antibody (rabbit IgG; 1:100 in blocking buffer; Abcam; 
ab12221) for 1 hour.  To remove unbound antibodies, cells were centrifuged at 100g (3 X 
2 minutes) and each time resuspended in PBS pH 7.4.  Cells were then incubated with 
Alexa Fluor 488-conjugated secondary antibody (goat anti-mouse IgG; 1:1000 in blocking 
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buffer; Invitrogen; A11001) or Alexa Fluor 488-cojugated secondary antibody (goat anti-
rabbit IgG; 1:1000 in blocking buffer; Invitrogen; A11034) for 1 hour.  To remove unbound 
antibodies, cells were centrifuged at 100g (3 X 2 minutes).  Throughout, cells were kept 
in darkness and all incubations were performed on ice.  Following immunolabelling, cell 
suspensions were filtered through a 40μm pore nylon strainer (BD Biosciences, UK; 
352340) and examined using a BD FACSCantoTM benchtop flow cytometer (BD 
Biosciences, UK) using BD FACSDivaTM software (BD Biosciences, UK).  Gating of samples 
was based on size and granularity, and in order to standardise output, a minimum of 
10,000 events were recorded per sample.  Results were plotted graphically using Prism 
(GraphPad Software Inc., USA). N=3, n=3. 
Immunofluorescent detection of E- and N-cadherin as phenotypic markers of distal and 
proximal tubule cells respectively was then used to assess the maintenance of distinct 
renal cell phenotypes after 5, 8, 10 and 15 days in culture.  Cells were fixed using 2% (w/v) 
PFA in PBS (10 minutes) at 4°C and washed with PBS (3 x 5 minutes).  Cells were 
permeabilised using PBST (5 minutes).  Non-specific binding sites were blocked using 1% 
(w/v) BSA, 3% (v/v) SeaBlockTM (EastCoast Bio) PBST blocking buffer for 1 hour. Cells were 
incubated with anti-E-cadherin primary antibody (mouse IgG; 1:200 in blocking buffer; 
Abcam; ab1416) for 1 hour.  Following PBST washes (3 x 5 minutes), and furthermore in 
darkness, Alexa Fluor 488-conjugated secondary antibody (goat anti-mouse IgG; 1:400 in 
blocking buffer; Invitrogen; A11001) was applied to cells for 1 hour.  Cells were washed 
with PBST (3 x 5 minutes) before the process was repeated using anti N-cadherin primary 
antibody (rabbit IgG; 1:100 in blocking buffer; Abcam; ab12221) and Alexa Fluor 594-
cojugated secondary antibody (goat anti-rabbit IgG; 1:400 in blocking buffer; Invitrogen; 
A11012).  Cell nuclei were stained with 0.1µg/ml Hoechst (Invitrogen) in blocking buffer 
(10 minutes) before cells were washed with PBST (3 x 5 minutes).  Coverslips were 
mounted on slides using Prolong Gold (Invitrogen; P36930) and allowed to dry overnight.  
Snapshots of slides were captured using a BX61 microscope (Olympus, Japan) and the 
percentage of proliferating cells out of the total number of cells was determined.  A 
minimum of 500 cells at each time point were counted. Results were plotted graphically 
and analysed using Prism (GraphPad Software Inc., USA).  N=3, n=3. 
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To identify any differences in the number of E-Cadherin positive cells versus the number 
of N-Cadherin positive cells over time (i.e. at day 0, 5, 8, 10 and 15), a two-way ANOVA 
and Bonferroni post-test was performed.  Results were deemed statistically significant 
when p<0.05 (*), P<0.01 (**) and p<0.001 (***).  N=3, n=3. 
Identification of Proximal Tubule Microvilli by Electron Microscopy 
After 5 days in culture, cells grown on 0.4µm pore size polyethylene terephthalate (PET) 
transwells (VWR, 353180) were rinsed with 1X PBS pH 7.4 (Invitrogen; 10010-015) (5 
minutes) before fixation in 1% (w/v) glutaraldehyde (Agar Scientific, AGR1013) at 4°C (10 
minutes).  Cells were rinsed in ddH2O (3 X 5 minutes), dehydrated using 50%, 70%, 90%, 
100% and 100% ethanol (Sigma, 458600) (10 minutes each) and then treated with 
hexamethyldisilazane (TAAB Laboratories, H028) (HMDS; 3 x 5 minutes) to remove any 
remaining liquid from the sample, and then air dried.  In the electron microscopy unit at 
Cardiff University, samples were attached to aluminium stubs (Elektron Technology, 
G301) with adhesive carbon tabs (Elektron Technology, G3347N), and then coated in gold 
(Elektron Technology, B7191) in a sputter coater (BioRad, SC500).  Scanning electron 
microscopy was carried out by an electron microscopy technician at 5kV using a JEOL 
840A scanning electron microscope (Samuel Roberts Nobel Microscopy Laboratory, USA).  
Images of proximal tubule cell brush border membranes were captured.  N=2 (n=4, n=3). 
Von Kossa’s Mineral Deposition Assay 
Von Kossa’s mineralisation assay was used to assess the extent of mineral deposition by 
cultured renal cells over the culture time course.  In von Kossa’s mineralisation assay, 
silver cations react with phosphates and carbonates in calcium deposits and then reduced 
to black metallic silver by UV light.  After 5, 8, 10 and 15 days in culture, cells were fixed 
using 2% (w/v) PFA in 1X PBS (10 minutes) at 4°C and washed with 1X PBS (3 x 5 minutes).  
Cells were incubated with 1% (w/v) silver nitrate (Sigma, S8157) under UV light (20 
minutes) with any remaining unreacted silver ions subsequently removed by treatment 
with 5% (w/v) sodium thiosulphate (Sigma, S7026) (5 minutes).  Cells were rinsed with 
distilled H2O before 0.1% (w/v) Nuclear Fast Red (Acros Organics, 211980010) was used 
as a cellular counterstain (5 minutes).  Following further H2O rinses (3 x 5 minutes), cells 
were dehydrated using 70%, 95%, 100% and 100% ethanol (5 minutes each) and cleared 
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in xylene (Sigma, 534056) (2 X 5 minutes).  Coverslips were mounted on slides using DPX 
mounting medium (Sigma).  2.5mM β-glycerophosphate (Sigma, G9422) was added to the 
culture medium 24 hours prior to cell fixation to induce mineralisation and act as a 
positive control.  10µM U0126 MEK inhibitor (Promega, V1121) was also added to the 
culture medium 24 hours prior to cell fixation to investigate the effect of inhibiting 
mineral ion regulation on mineral ion deposition.  Images were captured using a DMRB 
microscope (Leica, Germany) from which the degree of mineralisation was determined 
by counting the number of cells that possess mineral deposits out of the total number of 
cells.  A minimum of 500 cells at each time point for each condition were counted.  Results 
were plotted graphically and analysed using Prism (GraphPad Software Inc.).  To identify 
changes in the percentage of cells possessing mineral deposits in control and β-
glycerophosphate-treated cells at each time point, a two-way analysis of the variance 
(ANOVA) and Bonferroni post-teat was performed.  Results were deemed statistically 
significant when p<0.05 (*), P<0.01 (**) and p<0.001 (***).  To identify differences in the 
number of cells possessing mineralisation over time for each condition, spearate one-way 
ANOVA and post-hoc Tukey multiple comparison tests were performed.  Results were 
deemed statistically significant when p<0.05 (*), P<0.01 (**) and p<0.001 (***).  For MEK 
inhibitor studies N=1, n=1, control and β-glycerophosphate studies N=3, n=3. 
Preparation of Solutions for Von Kossa’s Mineral Deposition Assay 
1% Aqueous Silver Nitrate Solution: 
1g Silver Nitrate (ACROS Organics, 197680250) in 100ml ddH20.  The solution was 
prepared in advance and stored in darkness at room temperature. 
5% Sodium Thiosulphate Solution: 
5g Sodium thiosulphate (Sigma, S-1648) in 100ml distilled H2O.  The solution was 
prepared in advance and stored at room temperature. 
0.1% Nuclear Fast Red Solution: 
0.1g Nuclear Fast Red (ACROS Organics, 211980010) and 5g Aluminium sulphate (Fisher 
Scientific, A/1840/60) in 100ml ddH2O.  The solution was prepared in advance and stored 
at room temperature. To prepare, both the aluminium sulphate and Nuclear Fast Red 
were added to the distilled H20.  In a glass beaker over a Bunsen burner, the solution was 
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slowly heated until boiling and then allowed to cool to room temperature.  The solution 
was then filtered through filter paper (Whatman, 1001-150) and stored at room 
temperature until required. 
Protein Regulation by Pi and FGF23 – Immunocytochemistry 
Primary human renal cells were grown as described earlier to day 7 in regular growth 
medium (renal epithelial growth medium (REGM; Lonza, CC3191) containing the REGM 
SingleQuot kit supplements and growth factors (Lonza; CC4127).  At this time, the 
medium was replaced with one of three different test media; i. regular growth medium 
(termed Pi-containing medium), ii. regular growth medium plus 1μg/ml FGF23, 0.1μg/ml 
Klotho and 10μg/ml heparin (termed Pi-containing medium plus FGF23) or iii. Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen; 11971-025) with added REGM SingleQuot 
kit supplements and growth factors (Lonza; CC4127) (termed Pi-free medium).  Following 
24 hours in one of the three different media, cells at day 8 of culture were fixed using 2% 
(w/v) PFA (Sigma, 15,812-7) in 1 X PBS pH 7.4 (10 minutes) at 4°C, washed with 1 X PBS 
pH 7.4 (3 x 5 minutes) and permeabilised using 1X PBS pH 7.4 containing 0.05% (v/v) 
Tween-20 (Sigma, P5927) pH 7.4 (PBST).  0.3% (v/v) H2O2 (Fisher Scientific, H/1750/15) 
PBST pH 7.4 was used to quench endogenous peroxidase activity (5 minutes).  A 
peroxidase EnvsionTM kit (Dako, Denmark; K5361) was used.  Non-specific binding of the 
antibody to tissue sections was prevented using serum-free protein block (20 minutes).  
Individually diluted in antibody diluent (Dako, S2022) (as per Table 1.2), primary 
antibodies raised against FGFr1, FGFr2, FGFr3, FGFr4, Klotho, NaPi IIa, NCX1 and PMCA1 
were applied to cells for 1 hour.  Excess antibodies were removed by washing cells with 
PBST (3 x 5 minutes).  Cells were incubated for 30 minutes with anti-rabbit horseradish 
peroxidise (HRP)-conjugated polymer (Dako, K4065).  PBST washes (3 x 5 minutes) were 
repeated to remove unbound antibodies and immunoreactive sites visualised using 3-3’-
diaminobenzidine (DAB) chromogen substrate solution (Dako, K3468) (1 minute).  Cells 
were briefly rinsed with distilled H2O, counterstained with haematoxylin (Sigma, HH316) 
(1 minute), dehydrated using 70%, 95%, 100% and 100% ethanol (Sigma, 458600) (5 
minutes each) and cleared in xylene (Sigma, 534056) (20 seconds).  Coverslips were 
mounted on slides using DPX mounting medium (Sigma, 44581).  Slides were scanned 
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using a Mirax scanner (Zeiss, Germany) and images captured using Panoramic Viewer 
software (3DHISTECH Kft, Hungary). 
Detection of Vimentin  
Vimentin is a filament protein expressed by dedifferentiated renal cells (Bonventre 2003; 
Hallman et al. 2008).  To determine if primary human renal cells undergo 
dedifferentiation in culture over time, lysates were obtained from cells cultured or 5, 8, 
10 and 15 days.  On removal from the incubator, cells were briefly rinsed with 1X PBS 
before ice-cold RIPA buffer (Millipore; 20-188) was used to lyse cell membranes (10 
minutes).  The RIPA buffer was supplemented with a complete mini protease inhibitor 
cocktail tablet (Roche, 11836153001) to minimise protein degradation.  Cell lysates were 
centrifuged (Sigma Laboratory Centrifuge SK18; SciQuip; UK) at 15000g for 10 minutes at 
4°C, with the resultant supernatants aliquoted and stored at -80°C until prepared for 
Western blotting (protocol described below).  The primary antibody used was anti-
vimentin (rabbit IgG; 1:1000; abcam; ab92547) and the secondary antibody used was 
ImmunoPure goat anti-rabbit HRP-conjugated antibody (1:1000; Thermo Scientific; 
31462).  Human cortex lysate (prepared from a fresh human kidney sample from the 
Wales Cancer Bank) and recombinant human vimentin (abcam; ab73843) were used as 
positive controls.  N=1, n=1. 
ERK Activation by FGF23 – Western Blotting 
Extracellular signal related kinase 1/2 (ERK1/2) is phosphorylated on residues thr202 and 
tyr204 following activation of FGFr by FGF23 (H. Li et al. 2011).  To examine if this functional 
response is maintained in vitro, and whether this response could be blocked using a MEK 
inhibitor (MEK is upstream of ERK in FGF23 signalling pathway (Diaz et al. 2012)), an ERK 
activation assay was carried out.  To equilibrate cells and reduce ERK activation to base 
line levels, cells were incubated for 30 minutes in a serum free physiological control buffer 
(20mM HEPES, 125mM NaCl, 4mM KCl, 0.5mM CaCl2, 0.5mM MgCl2, 5.5mM glucose, H20, 
pH 7.4).  The buffer was quickly removed and replaced with; i. control buffer, ii. control 
buffer plus 1µg/ml FGF23, 0.1μg/ml Klotho and 10μg/ml heparin, or iii. control buffer plus 
1µg/ml FGF23, 0.1μg/ml Klotho, 10μg/ml heparin and 10µM U0126 MEK inhibitor.  After 
10 minutes at 37°C, experimental buffers were removed, cells were quickly rinsed with 
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1X PBS to enable protein extraction using radioimmunoprecipitation (RIPA) buffer 
(Millipore; 20-188) for 10 minutes on ice with gentle agitation.  The RIPA buffer was 
supplemented with a complete mini protease inhibitor cocktail tablet (Roche, 
11836153001) and a PhosSTOP tablet (Roche, 04906837001) to minimise both protein 
and phosphoprotein degradation.  Cell lysates were centrifuged (Sigma Laboratory 
Centrifuge SK18; SciQuip; UK) at 15000g for 10 minutes at 4°C, with the resultant 
supernatants aliquoted and stored at -80°C until used for Western blotting (general 
Western blotting protocol described below).  The primary antibody used was anti-active 
MAPK (rabbit IgG; 1:1000; Promega; V8031) and the secondary antibody used was 
ImmunoPure goat anti-rabbit HRP-conjugated antibody (1:5000; Thermo Scientific; 
31462).  To ensure equal loading, the Western blot membrane was stripped and re-
probed using a primary antibody raised against Total-ERK (1:1000; mouse IgG; Santa Cruz; 
sc-135900) and an ImmunoPure goat anti-mouse HRP-conjugated antibody (1:5000; 
Thermo Scientific; 31446).  N=1, n=1. 
NaPi IIa Regulation by Pi – Western Blotting 
Following a 24 hour treatment with i. Pi-containing medium or ii. Pi-free medium, cells at 
day 8 of culture were quickly rinsed with 1X PBS to enable protein extraction using RIPA 
buffer (Millipore; 20-188) for 10 minutes on ice with gentle agitation.  The RIPA buffer 
was supplemented with a complete mini protease inhibitor cocktail tablet (Roche, 
11836153001) to minimise protein degradation.  Cell lysates were centrifuged (Sigma 
Laboratory Centrifuge SK18; SciQuip; UK) at 15000g for 10 minutes at 4°C, with the 
resultant supernatants aliquoted and stored at -80°C until used for Western blotting 
(general Western blotting protocol described below).  The NaPi IIa primary antibody 
(rabbit IgG; 1:2000) used was a gift from Professor Jürg Biber, University of Zurich, 
Switzerland.  The secondary antibody used was ImmunoPure goat anti-rabbit HRP-
conjugated antibody (1:5000; Thermo Scientific; 31462). N=1, n=1. 
General Western Blotting Protocol 
The protein concentration of each sample was quantified using a colourimetric 
bicinchoninic acid (BCA) assay (Pierce, USA; 23227).  Samples were mixed with 4X NuPage 
LDS sample buffer (Invitrogen; NP0007) and 10X NuPage reducing agent and heated at 
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70°C for 10 minutes.  Samples of interest were loaded into separate lanes before 
separation by molecular weight was carried out by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis for 35 minutes at 200V using NuPage Novex 10% Bis-
Tris gels (Invitrogen; NP0301) using NuPage MES (Invitrogen; NP0002) SDS running buffer.  
Novex Sharp pre-stained protein standards (Invitrogen; LC5800) were used to estimate 
protein molecular weights.  Resolved proteins were transferred to 0.2μm pore 
polyvinylidene fluoride (PVDF) membranes (BioRad; 162-0177) for 75 minutes at 40V.  
Successful transfer and equal protein loading was confirmed using 0.1% (w/v) Ponceau S 
(Sigma, P-3509) (1 minute).  Non-specific antibody binding was reduced by incubating 
membranes in blocking buffer (5% non-fat dried milk (w/v) (Marvel Milk Powder) 1 X Tris 
(Sigma, RDD008)-buffered saline containing 0.05% Tween-20 (Sigma, P5927) (TBST)) 
overnight at 4°C.  Membranes were exposed to a primary antibody diluted in blocking 
buffer for 1 hour at room temperature, before unbound antibodies were washed away 
with TBST (3 x 10 minutes).  Membranes were subsequently incubated for 1 hour with a 
HRP-conjugated secondary antibody diluted in blocking buffer, before unbound 
antibodies were again washed away with TBST (3 x 10 minutes).  Membranes were then 
incubated with enhanced chemiluminescence (ECL) detection reagents (VWR; RPN2232) 
before signals were subsequently developed on Amersham Hyperfilm ECL film (GE 
Healthcare; 28906838) or using a Gel DocTM XR+ system (Bio-Rad Laboratories, Inc. USA). 
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1.6 Results 
Human, Rat and Mouse Epitope Sequence Alignment for FGFr1, FGFr2, FGFr3 and FGFr4 
Antibodies. 
Sequence alignment was performed for the epitopes targeted by antibodies raised 
against each of FGFr1, FGFr2, FGFr3 and FGFr4 to determine how specific the selected 
antibodies were for each of the three different species. 
 
FGFr1 
The anti-FGFr1 antibody used was a rabbit polyclonal antibody.  The datasheet from the 
supplier states that it reacts with human and rat FGFr1, and that it is expected to react 
with mouse FGFr1.  It is raised against a synthetic peptide conjugated to KLH derived from 
within residues 350-450 of human FGFr1.  Figure 1.3 shows that the epitope in rat differs 
from that of human by 1 amino acid (valine 396 in human FGFr1 is replaced with 
isoleucine 396 in rat FGFr1), and that the epitope in mouse differs by two amino acids 
(valine 391 and valine 396 in human FGFr1 are replaced with leucine 391 and isoleucine 
396 in mouse FGFr1). 
 
HUMAN 350 SHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMK 400 
401 SGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLS 450 
RAT 350 SHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIIYKMK 400 
401 SGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLS 450 
MOUSE 350 SHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMLGSVIIYKMK 400 
401 SGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLS 450 
 
Figure 1.3.  FGFr1 Epitope Sequence Alignment.  Sequence alignment reveals one 
difference in the amino acid sequence of the epitope detected by the FGFr1 antibody 
between human and rat, and two between that of human and mouse.  Differences are 
highlighted in yellow.  Valine 396 in human FGFr1 is replaced with isoleucine 396 in rat 
FGFr1, and valine 391 and valine 396 in human FGFr1 are replaced with leucine 391 and 
isoleucine 396 in mouse FGFr1.  UniProt accession numbers used: Human (P11362), Rat 
(Q04589), Mouse (P16092).  Sequence alignments performed by RW. 
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FGFr2 
The anti-FGFr2 antibody used was a rabbit polyclonal antibody.  The datasheet from the 
supplier states that it reacts with human, rat and mouse FGFr2.  It was raised against a 
synthetic peptide corresponding to amino acids 362-374 of human FGFr2. 
 
HUMAN  362 APGREKEITASPD 374 
RAT  301 APVREKEITASPD 313 
MOUSE  362 APVREKEITASPD 374 
 
Figure 1.4.  FGFr2 Epitope Sequence Alignment.  Sequence alignment reveals one 
difference in the epitope detected by the antibody between human, and rat and mouse.  
Glycine 364 in human is replaced with valine 364 in rat mouse.  A sequence identical to 
the mouse FGFr2 sequence exists between amino acids 301 and 313 of rat FGFr2.  Like 
mouse, this sequence differs from that of human FGFr2 by one amino acid; glycine 364 in 
human is replaced with valine 303 in rat.   Differences are highlighted in yellow.  UniProt 
accession numbers used: Human (P21802), Rat (Q63238), Mouse (P21803).  Sequence 
alignments performed by RW. 
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FGFr3 
The anti-FGFr3 antibody used was a rabbit polyclonal antibody.  The datasheet from the 
supplier states that it reacts with human FGFr3, but does not mention that of rat or mouse 
FGFr3.  Raised against a 15 amino acid synthetic peptide corresponding to a region of 
human FGFr3, it detects an epitope beginning at alanine 359 and ending at valine 372.  
Figure 1.5 shows that the epitopes in rat and mouse FGFr3 differ from that of the epitope 
in human FGFr3 by two amino acids each. 
 
HUMAN 359 AEEELVEADEAGSV 372 
RAT   353 AEEELMEVDEAGSV 366 
MOUSE 353 AEEELMETDEAGSV 366 
 
Figure 1.5.  FGFr3 Epitope Sequence Alignment.  Sequence alignment reveals two 
differences in the epitope detected by the antibody between human, rat and mouse.  Rat 
differs from human by two amino acids (valine 364 and alanine 366 in human FGFr3 are 
replaced methionine 364 and valine 366 in rat FGFr3).  Mouse also differs from human by 
two amino acids (valine 364 and alanine 366 in human FGFr3 are replaced with 
methionine 364 and threonine 366 in mouse FGFr3).  Differences are highlighted in 
yellow. UniProt accession numbers used: Human (P22607), Rat (Q9JHX9), Mouse 
(Q61851).  Sequence alignments performed by RW.  
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FGFr4 
The anti-FGFr4 antibody used was a rabbit polyclonal antibody.  The datasheet from the 
supplier states that it reacts with human FGFr4, but does not mention rat or mouse FGFr4.  
Raised against a synthetic peptide corresponding to amino acids 100 to 200 of human 
FGFr4, it detects an epitope beginning at leucine 100 and ending at isoleucine 200.  Figure 
1.6 shows that the epitopes in rat and mouse FGFr4 differ from that of the epitope in 
human FGFr4 by several amino acids. 
 
HUMAN 100 LCLARGSMIVLQNLTLITGDSLTSSNDDEDPKSHRDPSNRHSYPQQAPYWT 
HPQRMEKKLHAVPAGNTVKFRCPAAGNPTPTIRWLKDGQAFHGENRIGGI 200 
RAT 97 LCLARGSMTVVHNLTLIMDDSLPSINN-EDPKTLSSSSSGHSYLQQAPYWT 
HPQRMEKKLHAVPAGNTVKFRCPAAGNPMPTIHWLKNGQAFHGENRIGGI 196 
MOUSE 97 LCLARGSMTVVHNLTLLMDDSLTSISNDEDPKTLSSSSSGHVYPQQAPYWT 
HPQRMEKKLHAVPAGNTVKFRCPAAGNPMPTIHWLKDGQAFHGENRIGGI 196 
 
Figure 1.6.  FGFr4 Epitope Sequence Alignment.  The epitope detected by the antibody 
falls between amino acids 100 and 200 of human FGFr4.  Corresponding sequences 
differing by several amino acids is present in the rat and mouse FGFr4 sequences between 
amino acids 97 and 196.  Differences are highlighted in yellow.  UniProt accession 
numbers used: Human (P22455), Rat (Q498D6), Mouse (Q03142).  Sequence alignments 
performed by RW. 
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FGFr1-4 Immunolocalisation in Human, Rat and Mouse Kidney Cortex 
The immunolocalisation of FGFr1, FGFr2, FGFr3 and FGFr4 in formalin-fixed, paraffin-
embedded (FFPE) adult human, rat and mouse kidney cortex are shown in representative 
images in Figures 1.7 – 1.10.  A summary of the localisation patterns for each antibody 
across each species can be found in Tables 1.3-1.6.  Figure 1.11 shows the 
immunolocalisation of Klotho, NaPi IIa, NCX1 and PMCA1 in FFPE human kidney cortex, 
and confirms the specificity of these antibodies for use in the primary human cell 
characterisation work.  A summary of the localisation patterns for each of these 
antibodies in human kidney cortex can be found in Table 1.7. 
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FGFr1 
 
Figure 1.7.  Immunolocalisation of FGFr1 in formalin-fixed, paraffin-embedded (A-D) 
Human, (E) Rat and (F) Mouse Kidney Cortex.  (A-D) FGFr1 was localised in human kidney 
cortex samples to the distal tubule, where it appeared punctate pattern in a subset of 
cells (insert, arrows).  N=4, n=4.  (E) FGFr1 was localised in rat kidney cortex to both the 
proximal and distal tubule.  N=1, n=1.  (F) FGFr1 was localised in mouse kidney to the 
proximal tubule.  N=1, n=1.  In all cases, immunoreactivity for the protein of interest 
appears brown and the haematoxylin co-stain identifying cell nuclei appears blue.  All 
images are representative of one section per sample.  Human kidney cortex TMA images 
are representative of one field of view (A-C), with the larger human kidney cortex sample 
image (D) and rat (E) and mouse (F) kidney cortex images being representative of 10 fields 
of view.  IHC performed by LS (A-C) and JG (D-F).  Images captured by RW.  Image analysis 
by RW.  P = proximal tubule, D = distal tubule, G= glomerulus.  Bars = 100µm.  Insert Bars 
= 60 µm.  
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Receptor Species PT (% positive) DT (% positive) 
FGFr1 
Human 
Human 
Human 
Human 
0 
0 
 
0 
 
0 
100 
 
100 
 
100 
 
100 
FGFr1 Rat 100 100 
FGFr1 Mouse 100 0 
 
Table 1.3.  Summary of the expression pattern of FGFr1 in formalin-fixed, paraffin-
embedded human, rat and mouse kidney sections.  In human kidney cortex samples, 
FGFr1 was expressed in 100% of distal tubules viewed (N=4, n=4; 19/19, 14/14, 17/17, 
306/306) and 0% of proximal tubules viewed (N=4, n=4; 0/41, 0/46, 0/41, 0/559).  In rat 
kidney cortex, FGFr1 immunoreactivity was detected in 100% of proximal tubules viewed 
(N=1, n=1; 303/303) and 100% of distal tubules viewed (N=1, n=1; 148/148).  In mouse 
kidney cortex, FGFr1 immunoreactivity was detected in 100% of proximal tubules viewed 
(N=1, n=1; 476/476) and 0% of distal tubules viewed (N=1, n=1; 0/131).  All data are 
representative of one section per sample.  Values presented are representative of all 
proximal and distal tubules observed in human kidney cortex TMA sections obtained from 
one field of view, or representative of 10 fields of view in larger human kidney cortex 
sections and rat and mouse kidney cortex sections.  Quantification performed by RW. 
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FGFr2 
 
Figure 1.8.  Immunolocalisation of FGFr2 in formalin-fixed, paraffin-embedded (A-C) 
Human, (D) Rat and (E) Mouse Kidney Cortex.  (A) FGFr2 was localised in human kidney 
cortex to the distal tubule, where it appeared punctate in a subset of cells (insert, arrow). 
N=1, n=1. (B) FGFr2 was localised in human kidney cortex to the distal tubule, where it 
appeared punctate pattern in a subset of cells N=1, n=1.  (C) FGFr2 was localised in human 
kidney cortex to the distal tubule. N=1, n=1.  (D) FGFr2 was localised in rat kidney cortex 
to the distal tubule.  N=1, n=1.  (E) FGFr2 was localised in mouse kidney cortex to the 
distal tubule.  N=1, n=1.  In all cases, immunoreactivity for the protein of interest appears 
brown and the haematoxylin co-stain identifying cell nuclei appears blue.  All images are 
representative of one section per sample.  The human kidney cortex TMA image is 
representative of one field of view (B), with larger human kidney cortex sample images 
(A&C) and rat (E) and mouse (F) kidney cortex images being representative of 10 fields of 
view.  IHC performed by LS (A&B) and JG (C-E).  Images captured by RW.  Image analysis 
performed by RW.  P = proximal tubule, D = distal tubule, G = glomerulus.  Bars = 100µm.  
Insert Bars = 60µm 
  
 
53 
 
Receptor Species PT (% positive) DT (% positive) 
FGFr2 
Human 
Human 
Human 
0 
0 
 
0 
100 
 
28 
 
100 
FGFr2 Rat 0 100 
FGFr2 Mouse 0 100 
 
Table 1.4.  Summary of the expression pattern of FGFr2 in formalin-fixed, paraffin-
embedded human, rat and mouse kidney sections.  In human kidney cortex samples, 
FGFr2 immunoreactivity was detected in 100% of distal tubules viewed in human kidney 
in two samples (N=2, n=2; 128/128, 206/206) and 28% of distal tubules viewed in one 
sample (N=1, n=1; 8/20).  In all samples, 0% of proximal tubules viewed were positive 
(N=3, n=3; 0/254, 0/33, 0/598).  In rat kidney cortex, FGFr2 immunoreactivity was 
detected in 0% of proximal tubules viewed (N=1, n=1; 0/359) and 100% of distal tubules 
viewed (N=1, n=1; 180/180).  In mouse kidney cortex, FGFr2 immunoreactivity was 
detected in 100% of distal tubules viewed (N=1, n=1; 211/211) and 0% of proximal tubules 
viewed (N=1, n=1; 0/506).  All data are representative of one section per sample.  Values 
presented are representative of all proximal and distal tubules observed in human kidney 
cortex TMA sections obtained from one field of view, or representative of 10 fields of 
view in larger human kidney cortex sections and rat and mouse kidney cortex sections.  
Quantification performed by RW.  
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FGFr3 
 
Figure 1.9.  Immunolocalisation of FGFr3 in formalin-fixed, paraffin-embedded (A-D) Human, 
(E) Rat and (F) Mouse Kidney Cortex.  (A) In human kidney cortex, FGFr3 was localised to proximal 
tubule brush border membranes (arrow head).  Fainter immunoreactivity is also seen in distal 
tubule cell cytoplasm.  N=1, n=1.  (B) In human kidney cortex, FGFr3 was localised to proximal 
tubule brush border (arrow head).  Fainter immunoreactivity is also seen in distal tubule cell 
cytoplasm.  N=1, n=1.  (C) In human kidney cortex, FGFr3 was localised to proximal tubule brush 
border membranes (arrow head).  Fainter immunoreactivity is also seen in distal tubule cell 
cytoplasm. N=1, n=1. (D) In human kidney cortex, FGFr3 was localised to the proximal tubule 
brush border membrane (arrow). N=1, n=1.  (E) In rat kidney cortex, FGFr3 was localised to 
proximal tubule brush border membranes (arrow).  N=1, n=1.  (F) In mouse kidney cortex, FGFr3 
immunoreactivity was localised to the distal tubule cell cytoplasm.  N=1, n=1.  In all cases, 
immunoreactivity for the protein of interest appears brown and the haematoxylin co-stain 
identifying cell nuclei appears blue.  All images are representative of one section per sample.  
Human kidney cortex TMA images are representative of one field of view (A-C), with the larger 
human kidney cortex sample (D) and rat (E) and mouse (F) kidney cortex samples being 
representative of 10 fields of view.  IHC performed by LS (A-C) and JG (D-F).  Images captured by 
RW.  Image analysis performed by RW.  P = proximal tubule, D = distal tubule, G= glomerulus.  
Bars = 100µm.  Insert Bar = 60µm. 
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Receptor Species PT (% positive) DT (% positive) 
FGFr3 
Human 
Human 
Human 
Human 
100 
100 
 
100 
 
100 
100 
 
100 
 
100 
 
0 
FGFr3 Rat 100 0 
FGFr3 Mouse 100 74.2 
 
Table 1.5. Summary of the expression pattern of FGFr3 in formalin-fixed, paraffin-
embedded human, rat and mouse kidney sections.  FGFr3 was expressed in 100% of 
human proximal tubules viewed (N=4, n=4; 56/56, 50/50, 57/57, 663/663).  FGFr3 was 
expressed in 100% of distal tubules in 3 out of 4 human kidneys (N=4, n=4; 23/23, 24/24, 
32/32, 0/247).  In rat kidney, FGFr3 was expressed 100% of proximal tubules (N=1, n=1; 
1450/1450) and 0% of distal tubule cells (N=1, n=1; 0/363).  In mouse kidney, FGFr3 was 
expressed 100% of proximal tubules (N=1, n=1; 673/673) and 74.2% of distal tubule cells 
(N=1, n=1; 161/217).  Values presented are representative of all proximal and distal 
tubules observed in human kidney cortex TMA sections obtained from one field of view, 
or representative of 10 fields of view in larger human kidney cortex sections and rat and 
mouse kidney cortex sections.   Quantification performed by RW. 
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FGFr4 
 
Figure 1.10.  Immunolocalisation of FGFr4 in formalin-fixed, paraffin-embedded (A-D) Human, 
(E) Rat and (F) Mouse Kidney Cortex.  (A) In human kidney cortex, FGFr4 was localised to proximal 
and distal tubule where it had a punctate appearance.  N=1, n=1.  (B) In human kidney cortex, 
FGFr4 was localised to proximal and distal tubule where it had a punctate appearance.  N=1, n=1.  
(C) In human kidney cortex, FGFr4 was localised to proximal and distal tubule where it had a 
punctate appearance.  N=1, n=1.  (D) In human kidney cortex, FGFr4 was localised to proximal and 
distal tubule where it had a punctate appearance. N=1, n=1.  (E) In rat kidney cortex, FGFr4 was 
localised to proximal tubule where it had a punctate appearance.  N=1, n=1.  (F) In mouse kidney 
cortex, FGFr4 was localised to proximal tubule where it had a punctate appearance.  N=1, n=1.  In 
all cases, immunoreactivity for the protein of interest appears brown and the haematoxylin co-
stain identifying cell nuclei appears blue. All images are representative of one section per sample.  
The human kidney cortex TMA image is representative of one field of view (A), with larger human 
kidney cortex samples (B-D) and rat (E) and mouse (F) kidney cortex samples being representative 
of 10 fields of view.  IHC performed by LS (A-C) and JG (D-F).  Images captured by RW.  Image 
analysis performed by RW.  P = proximal tubule, D = distal tubule, G= glomerulus.  Bars = 100µm.  
Insert bars = 60µm. 
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Receptor Species PT (% positive) DT (% positive) 
FGFr4 
Human 
Human 
Human 
Human 
100 
100 
 
100 
 
100 
100 
 
100 
 
100 
 
100 
FGFr4 Rat 100 0 
FGFr4 Mouse 100 0 
 
Table 1.6. Summary of the expression pattern of FGFr4 in formalin-fixed, paraffin-
embedded human, rat and mouse kidney sections.  FGFr4 was expressed in 100% of 
human proximal tubule viewed (N=4, n=4; 37/37, 167/167, 668/668, 562/562).  FGFr4 
was expressed in 100% of human distal tubules (N=4, n=4; 18/18, 71/71, 224/224, 
190/190).  In rat kidney, FGFr4 was expressed 100% of proximal tubules (N=1, n=1; 
433/433) and 0% of distal tubule cells (N=1, n=1; 0/136).  In mouse kidney, FGFr4 was 
expressed 100% of proximal tubules (N=1, n=1; 613/613) and 0% of distal tubule cells 
(N=1, n=1; 0/197).  Values presented are representative of all proximal and distal tubules 
observed in human kidney cortex TMA sections obtained from one field of view, or 
representative of 10 fields of view in larger human kidney cortex sections and rat and 
mouse kidney cortex sections.  Quantification performed by RW. 
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Klotho, NaPi IIa, NCX1 and PMCA1 Immunolocalisation in Human Kidney Cortex 
The expression patterns of Klotho, sodium/phosphate co-transporter type IIa (NaPi IIa), 
sodium/calcium exchanger type 1 (NCX1) and plasma membrane calcium ATPase type 1 
(PMCA1) in the kidney are well documented in the literature (Biber et al. 1996; 
Glendenning et al. 2000; Magyar et al. 2002; Murer et al. 2003; Palm et al. 2010).  As such, 
to confirm the specificity of antibodies selected for use in the primary human renal cell 
characterisation work, immunohistochemistry was performed for each protein in FFPE 
human kidney sections.  A non-commercially available antibody raised against human 
NaPi IIa was used (the antibody was a gift from Professor Jürg Biber, University of Zurich, 
Switzerland).  NaPi IIa expression was specific to the proximal tubule (Figure 1.11C and 
11.1D); 100% of proximal tubule cells were positive for NaPi IIa and 100% of distal tubule 
cells were negative (Table 1.7).  Commercially available antibodies were used for Klotho, 
NCX1 and PMCA1.  Klotho exhibited both proximal and distal tubule expression (Figure 
1.11A and 1.11B); 100% of proximal tubule cells were positive for Klotho and 100% of 
distal tubule cells were negative (Table 1.7).  Expression was, however, stronger in the 
distal tubule as indicated by the darker brown immunoreactivity in those tubules.  NCX1 
and PMCA1 were both localised to the distal tubule.  Both proteins exhibited strong 
basolateral distal tubule expression (Figure 1.11E and 1.11F, respectively).  For both, 
100% of proximal tubules were negative and 100% of distal convoluted tubule cells were 
positive (Table 1.7). 
  
  
 
59 
 
Klotho, NaPi IIa, NCX1 and PMCA1 
 
Figure 1.11.  Immunolocalisation of Klotho, NaPi IIa, NCX1 and PMCA1 in formalin-fixed, 
paraffin-embedded human kidney.  (A&B) Klotho immunoreactivity was localised to the 
distal tubule and proximal tubule cell cytoplasm.  In both samples, immunoreactivity was 
stronger in the distal tubule than the proximal tubule as evidenced by darker brown 
staining. N=2, n=2.  (C&D) In both samples, NaPi IIa immunoreactivity was localised to the 
proximal tubule.  N=2, n=2.  (E) NCX1 was localised to distal convoluted tubule cell 
cytoplasm and basolateral membrane (arrow head).  N=1, n=1.  (F) PMCA1 was localised 
to distal convoluted tubule cell cytoplasm and basolateral membrane (arrow head).  N=1, 
n=1. In all cases, immunoreactivity for the protein of interest appears brown and the 
haematoxylin co-stain identifying cell nuclei appears blue.  All images are representative 
of 10 fields of view of one section per sample.  IHC performed by LS.  Images captured by 
RW.  Image analysis performed by RW.  P = proximal tubule, D = distal tubule, G= 
glomerulus.  Bars = 100µm.  Insert bars = 60µm. 
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Protein Species PT (% positive) DT (% positive) 
Klotho 
Human 
Human 
100 
100 
100 
100 
NaPi IIa 
Human 
Human 
100 
100 
0 
 
0 
NCX1 Human 0 100 
PMCA1 Human 0 100 
 
Table 1.7. Summary of the expression pattern of NaPi IIa, NCX1 and PMCA1 in formalin-
fixed, paraffin-embedded adult human kidney sections.  Klotho was localised to 100% of 
human proximal (N=2, n=2; 242/242, 208/208) and distal (N=2, n=2; 145/145, 84/84) 
tubules viewed.  NaPi IIa was expressed in 100% of human proximal tubules viewed (N=2, 
n=2; 332/332, 283/283) and 0% of distal tubules viewed (N=2, n=2; 0/157, 0/94).  NCX1 
was expressed in 0% of proximal tubules viewed (N=1, n=1, 0/158) but was expressed in 
100% of distal tubules viewed (N=1, n=1, 75/75).  PMCA1 was expressed in 0% of proximal 
tubules viewed (N=1, n=1, 0/286), but was expressed in 100% of distal tubules viewed 
(N=1, n=1, 141/141).  All data are representative of one section per sample.  All values 
presented are representative of all proximal and distal tubules observed in human kidney 
cortex in 10 representative fields of view.  Quantification performed by RW. 
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Proliferation and Apoptosis Viability Assays 
The incorporation of 5-bromo-2'-deoxyuridine (BrdU) into actively proliferating cell 
nuclei, and terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labelling 
(TUNEL) of apoptotic cell nuclei, was used to assess the overall viability of renal cells in 
culture over time.   
A representative immunofluorescent image of BrdU incorporation into new DNA within 
proliferating cell nuclei is shown in Figure 1.12A.  At day 5 of culture, the percentage of 
BrdU-positive cell nuclei was 12.93 ± 1.36% (mean ± SD; N=3, n=3) of total cell nuclei.  By 
day 15, the percentage of BrdU-positive cell nuclei had significantly increased to 84.07 ± 
4.99% (mean ± SD; N=3, n=3; p < 0.001 ***) compared to that at day 5, as determined 
using a one-way ANOVA and a post-hoc Tukey test (Figure 1.12C). 
A representative light microscopy image of apoptotic cell nuclei in culture is shown in 
Figure 1.12B.  At day 5 of culture, the percentage of cells undergoing apoptosis was 0.87 
± 0.12% (mean ± SD; N=3, n=3) of total cells.  By day 15, the percentage of total cells 
undergoing apoptosis was not significantly different (1.20 ± 0.40%; mean ± SD; N=3, n=3; 
P > 0.05) to that at day 5, as determined using a one-way ANOVA and a post-hoc Tukey 
test (Figure 3.2D). 
Overall, human renal cell viability was high throughout the culture time course as 
determined by high percentage of cells undergoing proliferation and a low percentage of 
cells undergoing apoptosis any each time point assessed. 
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Figure 1.12.  Assessment of primary human proximal and distal tubule cell co-culture 
viability using proliferation and apoptosis assays.  (A) A representative image of 
proliferating cell nuclei after 8 days in culture.  All cell nuclei are Hoechst positive (blue) 
and proliferating cell nuclei are also BrdU-positive (red; circled).  Bar = 50µm.  (B) A 
representative image of apoptotic TUNEL cell nuclei after 8 days in culture.  All cell nuclei 
are haematoxylin positive (blue) and apoptotic cell nuclei also appear DAB positive 
(brown; circled).  Bar = 50µm.  (C) At day 5, 12.93 ± 1.36% (mean ± SD; N=3, n=3) of all 
cell nuclei were BrdU-positive.  At day 8, there was a significant increase in BrdU-positive 
cell nuclei (42.28 ± 5.15%; mean ± SD; N=3, n=3; p < 0.01 **) compared to that at day 5.  
Significant increases in BrdU-positive cell nuclei were also seen at day 10 (56.57 ± 9.47%; 
mean ± SD; N=3, n=3; p < 0.001 ***) and day 15 (84.07 ± 4.99; mean ± SD; N=3, n=3; p < 
0.001 ***) compared to day 5.  Significant differences were identified using a one-way 
ANOVA and a post-hoc Tukey test.  Random snapshots were taken such that a minimum 
of 100 total cells were counted at each time point per coverslip.  (D) At day 5, 0.87 ± 0.12% 
(mean ± SD; N=3, n=3) of cells were apoptotic.  At day 8, there was no significant 
difference in the percentage of apoptotic cells (0.60 ± 0.20%; mean ± SD; N=3, n=3; p > 
0.05 ns) compared to that at day 5.  No significant difference in the percentage of 
apoptotic cells was seen at day 10 (1.00 ± 0.20%; mean ± SD; N=3, n=3; p > 0.05 ns) nor 
at day 15 (1.20 ± 0.40%; mean ± SD; N=3, n=3; p > 0.05 ns) when compared to that at day 
5.  A one-way ANOVA and a post-hoc Tukey test was used to test for significant differences 
between time points.  Random snapshots were taken such that a minimum of 500 total 
cells were counted per coverslip at each time point.  Cell culture and assays performed 
by RW and LS.  Counting of cell nuclei performed by LS.  Statistical analysis performed by 
RW.  
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Maintenance of Phenotype and Morphology 
Cadherins are calcium-dependent adhesion proteins (Prozialeck et al. 2004).  N-Cadherin 
is the predominant cadherin in the proximal tubule whilst E-Cadherin is the predominant 
cadherin in the distal tubule (Prozialeck et al. 2004).  In this study, immunohistochemistry 
on formalin-fixed, paraffin-embedded human kidney sections is in agreement with the 
literature; N-Cadherin was localised to the proximal tubule (Figure 1.13A) and E-Cadherin 
to distal tubule (Figure 13.3B).  In the section stained for N-Cadherin, 100% of proximal 
tubules were positive, and 100% of distal tubules were negative (Figure 1.13A).  In the 
section stained for E-Cadherin, 100% of proximal tubules were negative, and 100% of 
distal tubules positive (Figure 1.13B).  Further confirmation of the antibody specificity for 
each tubule type was provided using dual immunofluorescence on a snap-frozen adult 
human kidney section (Figure 1.13C), where again, N-Cadherin was localised to the 
proximal tubule, and E-Cadherin to the distal tubule.  As such, both antibodies were used 
to respectively identify the presence of primary human proximal and distal tubule cells in 
culture by dual immunofluorescence (Figure 1.13D).  To confirm the presence of both cell 
types in culture over the culture time course, snapshots of dual immunofluorescent 
stainings were taken, and by counting cells individually (a minimum of 500 cells at each 
time point were counted), the percentage of proximal and distal tubule cells out of the 
total number of cells at day 5, day 8, day 10 and day 15 of culture was determined.  Results 
are plotted graphically in Figure 1.13E.  At day 0, the percentage of proximal and distal 
tubule cells was 57.9 ± 4.3 and 42.1 ± 4.3 (mean ± SD; N=3, n=3). After 5 days in culture, 
the percentage of proximal and distal tubule cells was 47.9 ± 4.8% and 52.1 ± 4.8% (mean 
± SD; N=3, n=3), at day 8, it was 46.6 ± 2.7% and 53.4 ± 2.7% (mean ± SD; N=3, n=3), at 
day 10, it was 43.1 ± 3.4% and 56.9 ± 3.4% (mean ± SD; N=3, n=3), and at day 15 it was 
40.7 ± 3.4% and 59.3 ± 3.4% (mean ± SD; N=3, n=3), respectively.  A two-way ANOVA with 
Bonferroni post-test revealed a significant difference in the percentage of proximal and 
distal tubule cells at day 0 (P<0.001 ***), at day 10 (P<0.01 **) and at day 15 (P<0.001 
***).  No significant difference in the two populations of cells were identified at day 5 or 
day 8. 
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Figure 1.13.  N-Cadherin and E-Cadherin Expression in FFPE human kidney cortex and primary human proximal and distal tubule 
cells.  (A) In FFPE human kidney cortex, N-Cadherin was specifically localised to the proximal tubule.   100% of proximal tubules viewed 
were positive (N=1, n=1, 325/325) and 100% of distal tubules viewed were negative (N=1, n=1, 173/173).  N-Cadherin appears brown 
and the haematoxylin co-stain identifying cell nuclei appears blue. Image presented is representative of five fields of view from one 
section.  Bar = 100µm.  Insert bar = 60µm.  (B) In FFPE human kidney cortex, E-Cadherin was specifically localised to the distal tubule.  
100% of distal tubules viewed were positive (N=1, n=1, 186/186) and 100% of proximal tubules viewed were negative (N=1, n=1, 
278/278).  E-Cadherin appears brown and the haematoxylin co-stain identifying cell nuclei appears blue.  Note the clear cell membrane 
staining (arrow heads).  Image presented is representative of five fields of view from one section.  Bar = 100µm. Insert bar = 60µm. 
(C) In fresh frozen human kidney cortex, immunofluorescence localised N-Cadherin to the proximal tubule and E-Cadherin to the distal 
tubule. N-Cadherin appears red, E-Cadherin appears green, and the Hoechst co-stain identifying cell nuclei appears blue.  Image 
presented is representative of five fields of view from one section.  N=1, n=1.  Bar = 200µm.  (D) Dual immunofluorescence confirmed 
the presence of N-Cadherin-positive proximal tubule cells and E-Cadherin-positive distal tubule cells in primary human kidney cell 
culture. N-Cadherin appears red, E-Cadherin appears green, and the Hoechst co-stain identifying cell nuclei appears blue. Note the 
clear membrane staining (arrow heads).  Bar = 20µm.  (E) At day 0, the percentage of proximal and distal tubule cells was 57.9 ± 4.3 
and 42.1 ± 4.3 (mean ± SD; N=3, n=3).  At day 5, the percentage of proximal and distal tubule cells was 47.9 ± 4.8% and 52.1 ± 4.8% 
(mean ± SD; N=3, n=3), at day 8 it was 46.6 ± 2.7% and 53.4 ± 2.7% (mean ± SD; N=3, n=3), at day 10 it was 43.1 ± 3.4% and 56.9 ± 
3.4% (mean ± SD; N=3, n=3), and at day 15 it was 40.7 ± 3.4% and 59.3 ± 3.4% (mean ± SD; N=3, n=3).  A two-way ANOVA with a 
Bonferroni post-test revealed significant differences between the percentage of proximal and distal tubule cells at day 0 (P<0.001 
***), day 10 (P<0.01 **) and day 15 (P<0.001 ***).  No significant difference in the two populations of cells was identified at day 5 or 
day 8 (P>0.05 ns).  ns = not significant.  P = proximal tubule. D = Distal tubule.  IHC/IF performed by LS.  Images captured by RW.  
Quantification of tubules performed by RW.  Cell culture and assays performed by RW and LS.  Quantification of E- and N-Cadherin 
positive cells performed by LS.  Statistical analysis performed by RW. 
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Figures 1.14A and 1.14B show the typical morphological appearance of primary human 
renal cells cultured in vitro.  Note the typical cobblestone morphology previously 
associated with cultured primary human renal cells (Wilmer et al. 2010).  Scanning 
electron microscopy revealed the presence of microvilli, which are characteristic of the 
proximal tubule cells in vivo, on the cell membranes of day 5 proximal tubule cells grown 
on semi-permeable transwells (Figure 1.14C and 1.14D).  Additionally, expression of 
vimentin, a filament protein expressed by dedifferentiated renal cells (Bonventre 2003; 
Hallman et al. 2008) was assessed.  Although Western blotting of cell lysates prepared 
from cells cultured for 5, 8, 10 and 15 days did reveal the presence of vimentin, expression 
did not increase over time indicating that dedifferentiation did not occur (Figure 1.14E).  
Human kidney lysate and recombinant human vimentin were used as positive controls 
and confirm antibody specificity.  
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Figure 1.14.  Maintenance of primary human renal cell morphology and differentiation 
in culture.  (A&B) Light microscopy images of primary human renal cells displaying typical 
cobblestone morphology.  N=1, n=1.  Images presented are representative of 5 fields of 
view.  (C&D) Scanning electron microscopy of day 5 cells grown on semi-permeable 
transwells shows the presence of microvilli (arrow heads) on a proximal tubule cell 
membranes. Arrows = microvilli.  Circles = 0.4µm pores on the semi-permeable 
transwells. TW = transwell. Bars = 2µm. N=2 (n=3, n=4). Images presented are 
representative of 4 fields of view and 10 fields of view respectively.  (E) Vimentin Western 
blot showing a decrease in the expression of vimentin in cell lysates over the culture time 
course (day 5 to day 15).  Lane 1 –   5µg human cortex lysate; Lane 2 – 0.2µg recombinant 
human vimentin; Lane 3 – 1.25µg total protein from day 5 cells; Lane 4 – 5µg total protein 
from day 8 cells; Lane 5 – 5µg total protein from day 10 cells; Lane 6 – 5µg total protein 
from day 15 cells.  The single band observed is at the expected molecular weight of 57kDa. 
N=1, n=1.  (F) Ponceau S staining of the same Western blot membrane showing the 
protein loading in each lane.  Cell culture, SEM and Western blot performed by RW. 
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ERK Activation and Mineralisation Assays 
Acute (10 minute) treatment with buffer containing 1µg/ml FGF23 induced ERK activation 
in primary human renal cells at 8 days in culture, an effect that could be blocked by co-
incubation with buffer also containing 10µg/ml of a commercially available MEK inhibitor 
(U1026) (Figure 1.15A).  Western blotting of respective cell lysates shows a more intense 
phosphorylated-ERK (pERK) band in the lysate of cells treated with buffer containing 
1µg/ml FGF23 compared to that of control cells (buffer alone) and cells treated with 
buffer containing 10µg/ml MEK inhibitor (U1026).  Equal loading of protein in each lane 
was confirmed by stripping the membrane and re-probing for total-ERK (Figure 1.15A).  
As FGF23 signals though FGFr via the MAPK pathway (White et al. 2001), the fact that the 
cultured cells respond in the same fashion provides evidence that the cells functionally 
similar to those in vivo.  Von Kossa’s mineralisation assay revealed mineral deposition in 
primary human renal cells under control conditions (Figure 1.15K-N).  Over time there 
was a gradual increase in mineral deposition as determined using a one-way ANOVA and 
post-hoc Tukey test; compared to cells at day 5 of which 4.4 ± 0.2% (mean±SD; N=3, n=3) 
possessed mineral deposits, 5.2 ± 0.4% (mean±SD; N=3, n=3; p> 0.05; ns) of day 8 cells 
had mineral deposits, 5.8 ± 0.4% (mean±SD; N=3, n=3; p< 0.01; **) of day 10 cells had 
mineral deposits, and 6.5 ± 0.3% (mean±SD; N=3, n=3; p> 0.01; ***) of day 15 cells had 
mineral deposits (Figure 1.15B).  Von Kossa’s mineralisation assay also revealed mineral 
deposition in primary human renal cells treated for 24 hours with medium containing 
2.5mM βGP (a mineralising agent) (Figure 1.15C-F).  Over time, a gradual increase in 
mineral deposition was identified a one-way ANOVA and post-hoc Tukey test; compared 
to cells at day 5 of which 13.9 ± 0.6% (mean±SD; N=3, n=3) possessed mineral deposits, 
15.2 ± 0.4% (mean±SD; N=3, n=3; p> 0.05; ns) of day 8 cells had mineral deposits, 16.5 ± 
0.4% (mean±SD; N=3, n=3; p< 0.01; **) of day 10 cells had mineral deposits, and 18.9 ± 
0.5% (mean±SD; N=3, n=3; p> 0.01; ***) of day 15 cells had mineral deposits (Figure 
1.15B).  A two-way ANOVA and Bonferroni post-test, revealed a significant increase in 
mineral deposition between control and βGP-treated cells at each time point (N=3, n=3; 
P<0.01; ###) (Figure 1.15B). Von Kossa’s mineralisation assay revealed mineral deposition 
in cells treated for 24 hours with medium containing 10µg/ml of a commercially available 
MEK inhibitor (Figure 1.15 G-J).  The MEK inhibitor, increased mineralisation over time, 
and in comparison to time-matched controls (N=1, n=1) (Figure 1.15B). 
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Figure 1.15. Functional characterisation of in vitro primary human renal cells.  (A) Western blot shows 
that in comparison to cells treated with control buffer alone (lane 1), 10 minute treatment with buffer 
containing 1µg/ml FGF23 induced ERK activation (lane 2), a response that could be inhibited by co-
incubation with buffer also containing 10 µg/ml of a commercially available MEK inhibitor (lane 3).  5µg 
total protein was loaded per lane. Total ERK bands confirm equal protein loading in each lane. (N=1, n=1).  
(B) Using a one-way ANOVA and post-hoc Tukey test, the number of cells with mineral deposits (as 
determined using von Kossa’s mineralisation assay) increased from 4.4 ± 0.2% to 6.5 ± 0.3% (N=3, n=3; 
mean ± SD; p<0.001 ***) in cells treated with control medium from day 5 to day 15 of culture, respectively.  
Likewise, the number of cells with mineral deposits increased from 13.9 ± 0.6% to 18.9 ± 0.5% (N=3, n=3; 
mean ± SD; p<0.001 ***) in cells treated for 24 hours with medium containing 2.5mM βGP from day 5 to 
day 15 of culture, respectively.  In cells treated for 24 hours with medium containing 10µg/ml MEK inhibitor, 
10.2% of cells showed mineral deposits at day 5 compared to 15.9% of cells at day 15 (N=1, n=1).  Using a 
two-way ANOVA and Bonferroni post-test, mineralisation was increased in βGP-treated cells compared to 
control cells at each time point assessed (N=3, n=3; P<0.001; ###).  Images of mineral deposition (black 
dots; arrow heads) using von Kossa’s mineralisation assay in (K-N) control cells, (G-J) 10µg/ml MEK inhibitor-
treated cells, and (C-F) 2.5mM β-GP treated cells at day 5, 8, 10 and 15 days in culture, respectively.  Images 
are representative of 5 random fields of view from which 500 cells were assessed.  Bars = 50µm.  Cell culture 
and assays performed by RW and LS.  Western blot by LS.  Quantification of mineral deposition performed 
by LS.  Statistical analysis performed by RW. 
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Expression of FGFr1-4, Klotho, NaPi IIa, NCX1 and PMCA1 in Cultured Cells 
Using the same antibodies that were used in the earlier localisation study, the expression 
of FGFr1, FGFr2, FGFr3, FGFr4, Klotho, NaPi IIa, NCX1 and PMCA1 were identified in day 8 
primary human renal cells (Figure 1.16 and 1.17).  Day 8 was chosen as the time point to 
investigate Pi- and FGF23-induced changes in protein expression, as it represented a time 
in culture when cells were neither too  sparse nor too confluent (day 10 and day 15 cells 
were confluent and began to form domes and ridges i.e. they were not monolayers). 
FGFr1-4 Immunocytochemistry 
Fibroblast growth factor receptors 1-4 (FGFr1-4) were expressed by primary human renal 
cells cultured on collagen type-IV coated glass coverslips after 8 days culture under 
control conditions (Figure1.16A, D, G and J, respectively).  Control culture conditions 
denote cells grown in Pi-containing medium.  Whether Pi and FGF23 manipulations of the 
culture medium affect the expression of FGFr1-4, was investigated in cells at day 8 of 
culture in one of three treatment conditions.  The three treatment conditions were; i. Pi-
containing medium (control culture medium), ii. Pi-free medium, or iii. Pi-containing 
medium (control culture medium) plus FGF23.  Figure 1.16 shows that for each receptor, 
expression was not regulated by removal of Pi from, nor the addition of FGF23 to the 
culture medium, compared to that of cells grown under normal conditions in Pi-
containing medium; the immunocytochemical staining (the brown DAB colour) appears 
similar for each individual receptor across each of the treatment conditions. 
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Figure 1.16.  Expression of FGFr1-4 in day 8 primary human renal cells cultured for 24 hours in Pi-
containing medium, Pi-free medium or Pi-containing medium plus FGF23, Klotho and heparin.  (A, B, C) 
Immunoreactivity of FGFr1, (D, E, F) FGFr2, (G, H, I) FGFr3 and (J, K, L) FGFr4 in day 8 primary human renal 
cells cultured for 24 hours in (A, D, G, J) Pi-containing medium, (B, E, H, K) Pi-free medium and (C, F, I, L) Pi-
containing medium plus 1µg/ml FGF23, 0.1µg/ml Klotho and 10µg/ml heparin. Immunoreactivity for the 
proteins of interest appears brown, and the haematoxylin co-stain identifying cell nuclei appears blue.  No 
changes in protein expression were observed for each of the individual receptors in any condition.  Images 
are representative of 5 fields of view, and of cells grown collagen type IV-coated glass coverslips.  N=1, n=1 
(FGFr1), N=1, n=1 (FGFr2), N=2, n=2 (FGFr3), N=2, n=2 (FGFr4).  Bars = 150µm.  Cell culture and assays 
performed by RW and LS.   
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Klotho, NaPi IIa, NCX1 and PMCA1 Immunocytochemistry 
Klotho and NaPi IIa were expressed by primary human renal cells cultured normal on 
semi-permeable filter supports (transwells) after 8 days culture under control conditions 
(Figure 1.17A and 1.17D, respectively).  NCX1 and PMCA1 were expressed by primary 
human renal cells cultured on collagen type-IV coated glass coverslips after 8 days culture 
under control conditions (Figure 1.17G and 1.17J, respectively).  Normal culture 
conditions denote cells grown in Pi-containing medium.  Whether Pi and FGF23 
manipulations of the culture medium affect the expression of Klotho, NaPi IIa, NCX1 and 
PMCA1, was investigated in cells at day 8 of culture in one of three treatment conditions.  
The three treatment conditions were; i. Pi-containing-medium (control culture medium), 
ii. Pi-free medium, or iii. Pi-containing (control culture medium) medium plus FGF23.  No 
differences in Klotho immunoreactivity were observed in any of the conditions (Figure 
1.17A-C).  NaPi IIa immunoreactivity was increased by culturing incubating cells in Pi-free 
medium (Figure 1.17E) compared to cells cultured in Pi-containing medium (Figure 1.17D).  
No difference was seen for NaPi IIa following incubation with FGF23 (Figure 1.17F).  NCX1 
immunoreactivity was detected in the cell cytoplasm of cells cultured control Pi-
containing medium (Figure 1.17G) and Pi-free medium (Figure 1.17H).  Incubation with 
FGF23 induced NCX1 immunoreactivity at the cell membrane (Figure 1.17I).  Compared 
to cells grown in Pi-containing medium (Figure 1.17J) and those grown in Pi-containing 
medium plus FGF23 (Figure 1.17L), PMCA1 immunoreactivity appeared to be upregulated 
in cells cultured in Pi-free medium (Figure 1.16K), where it was localised predominantly 
to the cell membrane.  Expression was assessed by comparing the immunocytochemical 
staining (the brown DAB colour) across each of the treatment conditions. 
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Figure 1.17.  Expression of Klotho, NaPi IIa, NCX1 and PMCA1 in day 8 primary human renal cells cultured for 24 hours in Pi-
containing medium, Pi-free medium or Pi-containing medium plus FGF23, Klotho and heparin.  Immunoreactivity of (A, B, C) Klotho, 
(D, E, F) NaPi IIa, (G, H, I) NCX1 and (J, K, L) PMCA1 in day 8 cells cultured for 24 hours in (A, D, G, J) Pi-containing medium, (B, E, H, K) 
Pi-free medium and (C, F, I, L) Pi-containing medium plus 1µg/ml FGF23, 0.1µg/ml Klotho and 10µg/ml heparin.  (A-C) No difference in 
Klotho immunoreactivity was observed across each of the treatment conditions.  (D-F) NaPi IIa immunoreactivity was increased in cells 
treated with Pi-free medium compared to the other treatment conditions. (G-I) NCX1 immunoreactivity was increased at the cell 
membrane in cells treated with medium containing FGF23 compared to the other treatment conditions (arrow heads). (J-L) PMCA1 
immunoreactivity was increased at the cell membrane in cells treated with Pi–free medium compared to other treatment conditions 
(arrow heads).  Immunoreactivity for the proteins of interest appears brown, and the haematoxylin co-stain identifying cell nuclei 
appears blue.  Images are representative of cells grown on transwells (Klotho and NaPi IIa) or collagen type IV-coated glass coverslips, 
(NCX1 and PMCA1), and are representative of 5 fields of view.  N=1, n=1 (Klotho), N=3, n=3 (NaPi IIa +Pi, -Pi), N=1, n=1 (NaPi IIa 
+Pi+FGF23), N=1, n=1 (NCX1), N=1, n=1 (PMCA1).  Bars = 100µm.  Cell culture and assays performed by RW and LS. 
  
 
73 
 
NaPi IIa Immunoreactivity (Biological Replicates) 
 
Figure 1.18. Modulation of NaPi IIa expression primary human renal cells at day 8 of 
culture in response to 24-hour treatment with Pi-containing medium, Pi-free medium 
or Pi-containing medium plus FGF23, Klotho and heparin.  NaPi IIa immunoreactivity in 
Pi-containing medium (A, C, E), Pi-free medium (B, D, F) and Pi-containing medium plus 
1µg/ml FGF23, 0.1µg/ml Klotho and 10µg/ml heparin.  Compared to cells cultured in Pi-
containing medium, NaPi IIa immunoreactivity within each biological sample is increased 
in cells treated with Pi-free medium (A vs B, C vs D, E vs F, respectively) (arrow heads). 
N=3, n=3 for Pi-containing and Pi-free conditions.  N=1, n=1 for Pi-containing conditions 
plus FGF23.  Images are representative of cells grown on transwells, and of 5 fields of 
view.  NaPi IIa immunoreactivity appears brown, and the haematoxylin co-stain 
identifying cell nuclei appears blue.  Bars = 50µm.  Cell culture and assays performed by 
RW and LS. 
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NaPi IIa Western Blotting 
The increase in NaPi IIa expression observed in primary human renal cells at day 8 of 
culture following 24-hour treatment with Pi–free medium compared to cells cultured in 
Pi-containing medium, was also detected by Western blotting of cell lysates (Figure 1.19). 
 
Figure 1.19.  NaPi IIa Western blot of primary human renal cell lysates obtained from 
cells at day 8 of culture following 24-hour treatment with Pi-containing medium or Pi-
free medium.  The Western blot shows a clear NaPi IIa protein band in the cell lysate of 
cells cultured in Pi-free medium (-Pi) compared to that of cell cultured in Pi-containing 
medium (+Pi).  The ~75kDa band corresponding to the expected molecular mass of NaPi 
IIa protein based on its amino acid sequence is indicated with an arrow.  5µg total protein 
was loaded per lane.  The anti-human NaPi IIa primary antibody used was a gift from 
Professor Jürg Biber, University of Zurich, Switzerland.  (N=1, n=1).  Cell culture and assay 
performed by RW and LS.  Western blot by LS.  
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In summary, immunocytochemistry confirmed the expression of eight key proteins 
involved in mineral ion metabolism by the kidney (FGFr1, FGFr2, FGFr3, FGFr4, NaPi IIa, 
Klotho, NCX1 and PMCA1) in day 8 primary human renal cells.  FGFr1, FGFr2, FGFr3, 
FGFr4, NCX1 and PMCA1 were expressed by day 8 cells cultured on collagen type IV-
coated glass coverslips.  NaPi IIa and Klotho were expressed by day 8 cells cultured on 
semi-permeable filter supports (transwells).  No changes in protein expression were 
observed for FGFr1, FGFr2, FGFr3, FGFr4 or Klotho when cultured in Pi-free medium or Pi-
containing medium supplemented with FGF23 compared to that of cells cultured in Pi-
containing medium alone.  Expression of NaPi IIa and PMCA1 increased following 24 hours 
of culture in Pi-free medium compared the expression of both proteins in control Pi-
containing medium.  Expression of NCX1 increased at the cell membrane following 24-
hour culture in Pi-containing medium supplemented with FGF23 compared to the control 
Pi-containing medium alone.  The increase in NaPi IIa expression in Pi-free medium 
compared to Pi-containing medium was also detected by Western blotting of cell lysates. 
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1.7 Discussion 
Soft tissue mineralisation owing to the blockade of FGF23-mediated Pi regulation, is a 
dose-limiting toxicity of novel anti-cancer FGFr inhibitors (Turner and Grose 2010).  
Rodents are one of the species used during the preclinical safety assessment of such drugs 
(non-human primates are also used), but how closely do they parallel the in vivo human 
situation?  It is currently unknown which FGFr (or group of FGFrs) mediates the 
homeostatic effects of FGF23, and indeed therefore, which FGFr (or group of FGFrs) 
evokes ectopic mineral deposition when inhibited.  In addition, rodents are frequently 
used to model chronic kidney disease-mineral bone disorder (CKD-MBD) (S. Moe et al. 
2009; Shalhoub et al. 2012; Yang et al. 2010), but their utility for this application has not 
been directly assessed in terms of the similarity in FGFr localisation along the nephron.  
Previous data concerning the expression patterns of FGFr1-4 in adult human, rat and 
mouse kidneys are limited.  As such, a comparison of the expression patterns of FGFr1-4 
in adult human, rat and mouse kidneys, identifying similarities and/or differences 
between species in terms of nephron segments and subcellular compartments (i.e. apical 
membrane, basolateral membrane or cytoplasm), using the antibodies selected for use in 
the following cell characterisation, was performed. 
FGFr1 was localized in adult human kidney to the distal tubule which is consistent with 
previous literature (Floege et al. 1999) and adds to other previous literature where it is 
merely reported as being expressed in the kidney (Hughes 1997).  Using the same 
antibody, FGFr1 was detected in both proximal and distal tubule cytoplasm in rat.  
Previously, FGFr1 has been localized to the adult rat distal tubule but not the adult rat 
proximal tubule (Cancilla et al. 2001).  The observation of FGFr1 immunoreactivity in the 
proximal tubule in adult mouse kidney in this study is consistent with previous reports 
(Andrukhova et al. 2012; Gattineni et al. 2009), with lack of distal tubule immunoreactivity 
in contrast to previous reports (Andrukhova et al. 2012; Liu et al. 2008). 
FGFr2 was localised in adult human kidney to the distal tubule where it appeared in a 
punctate pattern, and was not observed in the proximal tubule.  This adds to current 
literature where FGFr2 is merely reported as being expressed in the kidney at a low level 
with no specific localisation (Hughes 1997).  In both adult rat and adult mouse kidney, 
FGFr2 was expressed in the distal tubule.  This is in agreement with previous literature 
  
 
77 
 
(Andrukhova et al. 2012; Cancilla et al. 2001).  However, no immunoreactivity was 
detected in the proximal tubule which contrasts with previous literature (Andrukhova et 
al. 2012; Cancilla et al. 2001). 
FGFr3 was predominately localized in human kidney to the proximal tubule brush border 
membrane with fainter immunoreactivity in distal tubule cell cytoplasm (comparison 
within samples).  This is in contrast to literature where FGFr3 has only been reported as 
being expressed at a low to no amount in the adult human kidney with no specific 
information regarding its specific localisation (Hughes 1997) but in line with a more recent 
literature where it was localized to both the proximal and distal tubule (but with no 
subcellular localisation i.e. at the brush border membrane) (Mutsaers et al. 2014).  Using 
the same antibody, FGFr3 was also detected in adult rat kidney at the proximal tubule 
brush border membrane.  However in contrast, no distal tubule staining was observed.  
FGFr3 has previously been reported to be expressed in both the proximal and distal tubule 
in adult rat kidney (Cancilla et al. 2001).  In this study, mouse FGFr3 immunoreactivity was 
detected in the distal tubule cytoplasm, but not in the proximal tubule.  Mouse FGFr3 has 
previously been reported to be expressed in both tubule types (Andrukhova et al. 2012; 
Cancilla et al. 2001; Liu et al. 2008). 
FGFr4 was localised in adult human kidney to both the proximal and distal tubule cell 
cytoplasm, where it appeared in a punctate pattern, and within each sample, was more 
abundant in the proximal tubule.   This adds to current literature where FGFr4 expression 
in adult human kidney has been reported as being expressed, but has not been localised 
to specific tubules (Fuhrmann et al. 1999; Hughes 1997; Mutsaers et al. 2014).  In adult 
rat kidney, FGFr4 was localised only to the proximal tubule where it also appeared in a 
punctate pattern.  Although FGFr4 has been reported as being expressed in adult rat 
kidney (Horlick et al. 1992), to the best of my knowledge, it has not been localised to 
specific tubules before.  In adult mouse kidney, FGFr4 expression was localised to the 
cytoplasm of the proximal tubule only, where again it appeared in a punctate pattern.  
This result in agreement with previous reports of FGFr4 expression in mouse proximal 
tubules (Andrukhova et al. 2012; Gattineni et al. 2009) but in contrast with previous 
reports of FGFr4 expression mouse distal tubules (Andrukhova et al. 2012; Liu et al. 2008). 
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No cross-species comparison of FGFr1-4 localisation in adult human, rat and mouse 
kidney using the same antibodies has been reported in the literature to date.  This study 
has highlighted that even when using the same antibodies (that are predicted to work in 
all three species), differences in expression patterns between species are seen.  
Additionally, this study has localised each FGFr1-4 to specific subcellular in the human 
kidney for the first time.  Differences in FGFr expression patterns between species begs 
the question, how relevant are rodent models at modelling signalling through FGFrs in 
humans?  Differences in expression patterns could indicate differences in the relative 
requirement or involvement of each receptor in each species.  An in vitro human model, 
expressing FGFr1-4 and Klotho, as well as other proteins involved in mineral ion 
metabolism by the kidney (including NaPi IIa, NCX1 and PMCA1) would be more 
appropriate for studying mineral ion metabolism specifically by human kidney cells. 
Current opinion is that expression of Klotho (both mRNA and protein) is confined to the 
distal tubule (Farrow et al. 2009; Kato et al. 2000; S. Li et al. 2004).  However, my studies 
shows that in humans, although strong Klotho immunoreactivity was indeed identified in 
the distal tubule, additional faint immunoreactivity was also identified in the proximal 
tubule.  This result adds to the growing literature base indicating that Klotho is actually 
also expressed by the proximal tubule, albeit to a lesser extent (Andrukhova et al. 2012; 
Hu et al. 2010). In addition, in this study, NaPi IIa was localised to the proximal tubule, 
and NCX1 and PMCA1 were both localised to the distal tubule of human kidney cortex 
tissue. 
No currently available renal cell lines express all the key proteins involved in Pi 
homeostasis by the kidney, and as such, they cannot be accurately used to study Pi 
homeostasis by the kidney.  Whilst it may possible to transfect cell lines from other 
species such as Madin-Darby Canine Kidney (MDCK) cells and Lilly Laboratories Culture-
Pig Kidney (LLC-PK1) cells with ‘missing’ proteins, there are a number of associated 
problems.  For example, transfecting MDCK cells with NaPi IIa, results in protein 
expression on both apical and basolateral membranes (Quabius et al. 1996), an 
expression pattern not consistent with that found in vivo where expression is confined to 
apical membranes (Gattineni et al. 2009).  In addition, MDCK strain 1 cells have a distal 
tubule background (Svennevig et al. 1995), and distal tubule cells do not express NaPi IIa 
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naturally.  Although human kidney cell lines also exist (e.g. human clear cell renal cell 
carcinoma (Caki-1) (Glube et al. 2007)) as do primary cultures of pure proximal tubule 
cells (Qi et al. 2007), such cell culture models are also not suitable.  Pi homeostasis in vivo 
requires the presence of both distal and proximal tubule cells and using a single cell type 
model cannot, by nature, fulfil this requirement. 
Therefore, the second part of this study was to characterise an in vitro primary human 
proximal and distal tubule cell co-culture model, based on a previously established model 
(C. Brown et al. 2008).  The high viability of cells in culture was determined by the 
observation of high levels of proliferation and low levels of apoptosis.  In the Brown et al. 
study, the ratio of proximal to distal tubule cells at the point of isolation was roughly 80% 
and 20% respectively, whereas in this study, it was roughly 60% and 40% respectively.  
Primary cultures are inherently associated with great variability owing to the different 
genetics, age and degrees of health of the patients from which the cells are obtained, and 
this could explain the differences seen.  Interestingly, however, in addition to the fact that 
a greater proportion of distal to proximal tubule cells was obtained at the point of 
isolation, cells in this study also appeared to undergo a gradual ‘distalisation’ (in terms 
overall cell numbers, not phenotype) over time.  This may be due to slight methodological 
differences between studies.  In the Brown et al. study, cell phenotype was assessed when 
cells were grown on polycarbonate transwell filter supports, whilst in this study, it was 
assessed when cells were grown on collagen type IV-coated glass coverslips.  Perhaps, 
proximal tubule cells adhere better to/detach less from transwells rather than coverslips, 
or preferentially grow better on transwells.  In addition, α-Minimal Essential Medium (α-
MEM; Life Technologies) modified according to Gibson-D’Ambrosio (Gibson-D'Ambrosio 
et al. 1987) supplemented with 10% fetal calf serum was used in the Brown et al. study, 
whereas Renal Epithelial Growth Medium (REGM; Lonza) was used in this study.  Although 
the components of the culture medium used in this study are optimised for the specific 
culture of renal cells, they may have favoured the survival and growth of the distal tubule 
cell population over that of the proximal tubule cell population such that the percentage 
of proximal to distal tubule cells in culture changed over time.  In any case, the presence 
of microvilli and the expression of N-cadherin (a proximal tubule marker protein) within 
the culture model together provide evidence that the ‘distalisation’ of the cell culture was 
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not a result of proximal tubule cell dedifferentiation.  Primary renal cells also displayed a 
cobblestone morphology in culture comparable to that of primary renal cells reported by 
others (Wilmer et al. 2010).  Further evidence indicating that cells in this model were not 
undergoing dedifferentiation was provided by the detection of no increase in vimentin (a 
marker of dedifferentiation (Hallman et al. 2008)) by Western blotting of cell lysates over 
time in culture. 
Functional responses to known physiological stimuli were also assessed in the culture 
model.  This first of these was FGF23-induced ERK phosphorylation.  In vivo FGF23 signals 
the for the downregulation of NaPi IIa through ERK; mice treated with recombinant FGF23 
display ERK phosphorylation in distal tubules after 10 minutes followed by 
downregulation of NaPi IIa protein in proximal tubules after 30-60 minutes (Farrow et al. 
2010).  In vitro studies have also shown the ability of FGF23 to phosphorylate ERK 
(Yamazaki et al. 2010), and as ERK is part of the RAF/MEK/ERK pathway, it is also 
interesting to note that mice treated with inhibitors of MEK, have a similar phenotype to 
FGF23-/- or Klotho-/- mice (Diaz et al. 2012) (i.e. MEK is required for downstream FGF23 
signalling).  In the current study, primary human renal cells displayed an increase in ERK 
phosphorylation following a 10 minute incubation with medium containing FGF23, a 
response that could be inhibited by co-incubation with medium containing a 
commercially available MEK inhibitor, thus confirming that cells in the model respond in 
a physiological manner. 
The second functional assay was to screen cultured cells for their ability to undergo 
mineralisation.  β-glycerophosphate (βGP) is a well-documented mineralising agent 
(Olesen et al. 2007; Shioi et al. 1995), and as such was used as a positive control.  In the 
kidney, βGP is hydrolysed by alkaline phosphatase (ALP) whereupon inorganic phosphate 
(Pi) (which can be visualised using von Kossa’s assay) is released (Prasad et al. 2005).  
Primary cultures of human renal cells exhibited βGP-induced mineralisation.  In vivo, 
inhibiting MEK either directly or upstream with a pan-FGFr inhibitor has been shown to 
induce mineralisation of soft tissues such as the stomach mucosa, skeletal muscles and 
the kidney (Diaz et al. 2012; Yanochko et al. 2013).  In the current study, primary human 
renal cells displayed an increase in mineral deposition following treatment with medium 
containing a MEK inhibitor compared to that of untreated cells.  The ability to identify 
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mineral deposition in primary cultures in response to MEK (or FGFr) inhibition, suggests 
a potential use of this model in the preclinical screening of novel anti-cancer MEK or FGFr 
inhibitors for their likelihood to induce mineralisation in humans in vivo.  Such data could 
be used alongside in vivo studies in preclinical species to guide compound selection for 
use in later clinical trials.  For example, compounds that do not produce mineralisation in 
rodents in vivo nor in primary cultures of human renal cells in vitro, could progress to in 
vivo human studies. 
The third functional test was to screen for NaPi IIa upregulation under Pi-free conditions.  
Sodium-dependent phosphate transport by renal epithelial cells was first shown by Biber, 
Brown and Murer using cultured LLC-PK cells (Biber et al. 1983).  Using the same cells, it 
was later shown that sodium-dependent phosphate transport could be regulated by 
phosphate (Caverzasio et al. 1984).  NaPi IIa upregulation under low Pi conditions is also 
a known in vivo phenomenon (rats fed a low Pi diet have significantly higher NaPi IIa 
expression compared to rats fed a high Pi diet (Riccardi et al. 2000; Ritthaler et al. 1999).  
In this study, primary cultures of human renal cells displayed NaPi IIa upregulation in 
response to culture in Pi-free medium by both immunocytochemistry and Western 
blotting of cell lysates, which again confirms their ability to respond to known 
physiological stimuli.  Interestingly, the exact mechanism by which no/low Pi levels induce 
NaPi IIa upregulation, is yet to be determined (Lanaspa et al. 2013).  What is known, 
however, is that NaPi IIa protein expression at the proximal tubule brush border 
membrane increases between 2 and 4 hours, before an increase in NaPi IIa mRNA is 
detectable (Ritthaler et al. 1999) indicative of protein stores.  Use of the cell model 
described in the current study has potential to be used for studying this aspect of Pi 
homeostasis.  In addition, it would be useful to investigate whether NaPi IIa is not merely 
expressed at the protein level, but is fully functional.  This could be achieved in future 
studies by performing NaPi IIa Pi uptake experiments akin to those performed by other 
groups (C. Brown et al. 2008; Wilmer et al. 2010). 
Although NaPi IIa is the most characterised proximal tubule Pi transporter, it is by no 
means the only proximal tubule Pi transporter; NaPi IIc and two type III Pi transporters 
(PiT-1 and PiT-2) also exist (Lanaspa et al. 2013).  NaPi IIa is the predominant Pi transporter 
in mice, being responsible for the reabsorption of roughly 70% of filtered Pi (Iwaki et al. 
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2008).  Interestingly, lack of NaPi IIc in mice does not induce hyperphosphaturia or 
hypophosphatemia (Segawa et al. 2009), whilst in humans, however, lack of NaPi IIc 
results in patients suffering hypophospatemic rickets (Bergwitz et al. 2006; Lorenz-
Depiereux et al. 2006).  As NaPi IIc clearly plays a much more important role in Pi 
homeostasis in humans than in mice, it would be useful for future studies to investigate 
whether NaPi IIc is also upregulated in primary human renal cells when cultured in Pi-free 
conditions, and proceed to use the model to study how exactly both are Pi upregulated 
when Pi levels are low. 
Following viability and phenotypic assessment, the expression of key proteins known be 
involved in mineral ion homeostasis (FGFr1-4, NaPi IIa, Klotho, NCX1 and PMCA1) was 
investigated in cells after 8 days in culture.  FGFr1-4, NCX1 and PMCA1 were found to be 
expressed by primary human renal cells cultured on collagen type IV-coated glass 
coverslips.  However, NaPi IIa and Klotho were only expressed by cells at day 8 of culture 
when cultured on semi-permeable filter supports (transwells).  This difference in protein 
expression between cells grown on collagen type IV-coated coverslips and transwells 
suggests that all future experiments be performed exclusively on transwells in an attempt 
to further recapitulate the in vivo renal proteome present with in the cell model more 
closely.  Transwells have been reported to enhance cell polarisation (i.e. the presence of 
distinct apical and basolateral membranes) (C. Brown et al. 2008; Lash et al. 2006), and 
maintenance of cell polarisation could be a necessary requirement for the maintenance 
of Klotho and NaPi IIa expression.  Future studies using cells grown on transwells aim to 
provide additional confirmation of the utility of this model for studying mineral ion 
homeostasis by the kidney. 
In this study, changes in the protein expression in response to FGF23 and Pi manipulations 
of the culture medium were observed for NCX1 and PMCA1.  Whilst FGF23-treatment 
appeared to induce expression of NCX1 at the plasma membrane, lack of Pi in the culture 
medium appeared to induce PMCA1 expression at the plasma membrane.  To the best of 
my knowledge, respective FGF23- and Pi-induced changes in NCX1 and PMCA1 expression 
have not been reported in previous published literature and are novel.  These are exciting 
findings as they point towards previously unknown regulatory functions of FGF23 and Pi 
on these proteins and their involvement in mineral ion homeostasis.  As above, future 
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studies aim to confirm these findings in cells grown on transwells, as well as show these 
changes quantitatively by image analysis using recently developed software 
(TissueGnostics, Medical &  Biotech Solutions, Austria).  Interestingly, FGF23 has recently 
been shown to modulate TRPV5 expression (Andrukhova et al. 2014).  Like NCX1 and 
PMCA1 (Magyar et al. 2002), TRPV5 is expressed in the distal convoluted tubule 
(Hoenderop et al. 1999) where it too is involved in calcium reabsorption from the 
glomerular filtrate into the blood.  Andrukhova et al. show both that TRPV5-transfected 
MDCK cells have increased membrane expression of TRPV5 in response to FGF23 
treatment, and that FGF23 knockout mice have reduced membrane expression of TRPV5.  
Together, these data highlight a previously unknown function of FGF23 on renal calcium 
transport; that FGF23 positively modulates TRPV5 expression.  The authors suggest that 
FGF23 can increase Pi excretion whilst simultaneously conserve extracellular Ca2+.  They 
point out, however, that this may have pathophysiological relevance in diseases such as 
chronic kidney disease.  In this case, both elevated PTH and FGF23 levels can contribute 
to the calcium accumulation and vascular calcification observed in such patients.  It would 
be interesting to observe the reported FGF23-induced increase in TRPV5 expression in 
that study in the primary human cells model characterised in this study.  In addition, the 
observation of FGF23- and Pi-induced changes in NCX1 and PMCA1 changes in vivo would 
likewise validate the use of the cell model as a useful tool for studying mineral ion 
homeostasis by the kidney. 
In the current study, the effects of FGF23 and Pi on the expression of FGFr1-4, Klotho, 
NaPi IIa, NCX1 and PMCA1 proteins were assessed.  However, the cell model could also 
be used to study the effects of 1,25(OH)2D3, PTH and Ca2+ on these proteins.  In addition, 
the effects of FGF23, 1,25(OH)2D3, PTH, Ca2+ and Pi itself on the expression of other 
proteins known to be involved in mineral ion metabolism by the kidney such as the Pit-2 
(Villa-Bellosta et al. 2009), Calcium-Sensing Receptor (CaSR) (Riccardi et al. 2000), 
Calbindin D28 (Cal28) (Zheng et al. 2004) and Transient Receptor Potential Cation Channel 
Subfamily V Member 5 (TrpV5) (Topala et al. 2009).  In the current study, an attempt was 
made to assess the production of 1,25(OH)2D3 by proximal tubule cells in the presence of 
FGF23 and the absence of Pi.  No data were generated using an commercially available 
assay (1,25-Dihydroxy Vitamin D enzyme-linked immunosorbant assay (EIA) from 
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Immunodiagnostic Systems, UK) and this was likely due to the fact that it was optimised 
for serum and plasma samples, and cell lysates were used in the is this study.  It will not 
be possible to investigate 1,25(OH)2D3 directly in cultured human renal cells until more 
applicable assays become available.  However, 1,25(OH)2D3 production/degradation 
could be looked at indirectly by assessing the expression patterns of 1α-hydrolase and 
25-hydroxylase by immunocytochemistry or Western blotting of cell lysates. 
In summary, this study localised FGFr1-4 and Klotho to formalin-fixed, paraffin-embedded 
human kidney nephron segments adding important information to the field of mineral 
ion metabolism by the human kidney to that currently available in the literature.  In 
addition, an in vitro mixed population of primary human proximal and distal tubule cells 
as a novel tool for studying mineral ion metabolism specifically by the human kidney was 
characterised.  Cells were shown to possess high proliferation and low apoptosis 
indicating high viability, and maintained differentiated as evidenced by maintenance of 
expression of phenotypic marker proteins, morphology and functional responses to 
known stimuli (FGF23-induced ERK phosphorylation, MEK inhibitor-induced 
mineralisation and modulation of NaPi IIa expression by Pi).  Future studies aim to confirm 
these findings using cells grown on transwells.  Overall, this model has the potential to be 
used for studies of mineral ion homeostasis specifically by the human kidney, as well as a 
tool to guide pharmaceutical drug development. 
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CHAPTER 2 
Tissue Expression and Correlation of a Panel of Urinary 
Biomarkers Following Cisplatin-Induced Kidney Injury in Rats 
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2.1 Abstract 
In recent years there has been a large effort to identify and validate urinary biomarkers 
of nephrotoxicity as non-invasive measurements with greater sensitivity and specificity 
than traditional biomarkers such as serum creatinine and blood urea nitrogen.  In this 
study, cisplatin-treated rats were used to evaluate the possible use of tissue biomarkers 
in studies where urine samples are not available, such as retrospective studies in drug 
safety testing, by correlating tissue biomarker levels with urinary biomarker levels.  In 
other words, the aim of this study was to correlate tissue and urine expression of the 
same biomarkers, such that identification of one, could indicate the presence of the 
other.  
Six novel acute kidney injury biomarkers were investigated, and all except one (β2-
microglobulin) showed a significant increase (KIM-1, osteopontin and clusterin) or 
decrease (αGST and trefoil factor-3) in tissue expression 5 days after 1.0mg/kg or 
2.5mg/kg cisplatin treatment.  After eight days, these changes persisted, except those 
seen for αGST which no longer showed significant differences compared to control 
animals, despite more severe histopathology.  All of the biomarkers, except β2-
microglobulin, showed utility as tissue biomarkers but KIM-1 and osteopontin were the 
best at predicting proximal tubule necrosis (as shown by the area under the curves from 
receiver operating characteristic curves).  Kidney KIM-1 and OPN measurements also 
correlated closely with their corresponding urinary biomarker measurements, indicating 
that these urinary markers are sensitive and specific for tissue injury.  
Future studies are needed to determine the wider application of tissue and urinary KIM-
1 and osteopontin for detecting renal toxicity following the administration of other 
nephrotoxicants. 
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2.2 Introduction 
Acute Kidney Injury Overview 
Each human kidney contains roughly 1.25 million functional units called nephrons which 
together filter 150 – 180 litres of plasma per day and process it in order to regulate body 
fluid, electrolyte, and pH balance, as well as metabolise and eliminate waste products in 
the urine (Bonventre et al. 2010).  Acute kidney injury (AKI) is a common condition with 
many aetiologies including tubulo-interstitial inflammation and edema, ischaemia, and 
drug-induced toxicity (Vaidya et al. 2008).  It is characterised by a decrease in the ability 
of the kidney to carry out its physiological functions, and as such, is associated with a 
decrease in urine output (oliguria or anuria) and a build-up of waste products of 
metabolism such as creatinine and urea in the blood (azotaemia) (Bellomo et al. 2012; 
Kellum 2008).  However, due to the large functional reserve of the kidney, these changes 
are only observed once the reserve has been depleted (De Loor et al. 2013).  As a result, 
the term ‘acute kidney injury’ has largely replaced the term ‘acute renal failure’ (ARF) to 
highlight the fact that injury can occur long before functional impairment/failure is seen 
(Van Biesen et al. 2006).  Acute kidney injury is a massive problem both in preclinical and 
clinical settings (Vaidya et al. 2008). 
Diagnosing Acute Kidney Injury 
Creatinine is a by-product of muscle metabolism and in healthy individuals is excreted by 
the kidney at a fairly constant rate.  Measurements of creatinine in the blood (serum 
creatinine; SCr) can therefore be used to indirectly estimate glomerular filtration rate 
(GFR), which is an index of overall kidney function (Inker et al. 2012).  In healthy males, 
SCr is between 0.7 – 1.3mg/dL (Charney et al. 2005) and GFR is between 90 – 120 
ml/min/1.73cm2 (Harris and Stribling 2007).  A decline in GFR, reflected by a rise in SCr, 
indicates impaired kidney function/kidney injury.  In addition, decreased urine output can 
indicate AKI (Legrand and Payen 2011). 
A decade ago, while these pathological changes in serum creatinine and urine output 
were well known, roughly 30 different definitions of acute kidney injury, based on the 
degree by which each must change in order for a diagnosis to be made, were present in 
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the literature (Bellomo et al. 2001; Kellum et al. 2002).  This meant that there was a large 
variation in the reported incidence of acute kidney injury and its associated mortality rate 
(Hoste et al. 2006).  In 2004, the lack of a universally agreed definition of acute kidney 
injury led The Acute Dialysis Quality Initiative (ADQI) Group to introduce the Risk (R), 
Injury (I), Failure (F), Loss (L) of function, End stage renal disease (E) (also known as RIFLE) 
criteria in a bid to standardise its diagnosis (Bellomo et al. 2004).  Each stage (R, I, F, L and 
E) described the degree by which serum creatinine or urine output should change for a 
diagnosis of AKI at a certain stage to be made.  In 2007, the Acute Kidney Injury Network 
(AKIN) Group modified the RIFLE criteria adding that a diagnosis of AKI be made when 
even small changes in serum creatinine (≥ 0.3mg/dl) are seen within 48 hours.  This 
amendment reflected studies showing that even small increases in serum creatinine are 
associated with an increased risk of mortality.  These criteria were termed the Acute 
Kidney Injury Network (AKIN) criteria (Mehta et al. 2007).  In 2012, building on both the 
RIFLE and AKIN criteria, the Kidney Disease: Improving Global Outcomes (KDIGO) 
organisation then released the clinical practise guidelines for diagnosing AKI 
(doi:10.1038/kisup.2012.7).  Table 2.1 summarizes the KDIGO criteria for diagnosing AKI. 
 
Stage Serum Creatinine Criteria Urine Output Criteria 
1 
Increase in SCr ≥ 0.3mg/dL in 48 hr OR 
1.5- to 1.9-fold increase from baseline 
< 0.5ml/kg/hr for > 6hr 
2 2- to 2.9-fold increase from baseline < 0.5ml/kg/hr for > 12hr 
3 
SCr ≥ 4.0mg/dL with acute increase of ≥ 
0.5mg/dL OR 3-fold increase from 
baseline 
< 0.3ml/kg/hr for 24hr OR anuria 
for 12hr 
Table 2.1.  Kidney Disease: Improving Global Outcomes (KDIGO) organisation clinical practise 
guidelines for diagnosing acute kidney injury.  Detailed are the clinical practise guidelines for 
diagnosing different stages (stage 1-3 (stages of severity)) of acute kidney injury (AKI) based on 
measurements of serum creatinine (Scr) and urine output, as recommended by the Kidney 
Disease: Improving Global Outcomes organisation.  Adapted from (doi:10.1038/kisup.2012.7). 
  
  
 
89 
 
As mentioned previously, it is recognised that even a small rise in serum creatinine is 
associated with increased risk of mortality (Chertow et al. 2005; Waikar and Bonventre 
2009; H. Wang et al. 2012), and indeed, the greater the rise in serum creatinine, the 
greater the risk of mortality (Weisbord et al. 2006).  The main reason for this, is that serum 
creatinine is neither specific nor sensitive enough to detect kidney injury early.  In terms 
of specificity, serum creatinine is influenced by factors independent of renal function 
including age, gender, muscle mass, activity level and hydration state (Baxmann et al. 
2008).  In terms of sensitivity, serum creatinine is a late marker of kidney injury; levels 
can remain (up to a point) within a normal range following injury (Baxmann et al. 2008; 
de Geus et al. 2012) because the kidneys possess an extensive renal functional reserve 
(Ferguson et al. 2008; Parikh and Devarajan 2008).  A further limitation of using creatinine 
as a tool for assessing renal function is that in addition to being passively filtered at the 
glomerulus, it is actively secreted from peritubular capillaries into the kidney filtrate by 
proximal tubule cell organic cation transporter 2 (OCT2) (Ciarimboli et al. 2012; Urakami 
et al. 2004).  As such, clearance of creatinine in the urine (another measure of kidney 
function) overestimates glomerular filtration rate (GFR) by as much as 20% (Legrand and 
Payen 2011).  In addition, inhibition of OCT2 by some xenobiotics, inhibits creatinine 
secretion and increases serum creatinine levels independently of reduced kidney function 
(Ciarimboli et al. 2012; Lepist et al. 2014). 
In a similar manner, issues arise when diagnosing acute kidney injury (AKI) based on 
decreased urine output; a decrease in urine output can simply be a physiological response 
to maintain body volume during dehydration.  Measurements of blood urea nitrogen 
(BUN) are also used clinically to assess kidney function.  BUN is a measure of the nitrogen 
present in blood that comes from the waste product urea, and in healthy males is roughly 
8 – 21 mg/dL (Charney et al. 2005).  Blood urea nitrogen is increased in kidney injury, and 
like serum creatinine and urine output, can be affected by factors independent of kidney 
injury such as the consumption of a protein-rich meal or dehydration (Edelstein 2008). 
It is evident that the current markers (serum creatinine and urine output) used to assess 
renal function and diagnose acute kidney injury are limited.  Although criteria such as the 
KDIGO criteria have standardised and improved the diagnosis AKI, the fact is that they are 
still based on measurements of serum creatinine and urine output.  Biomarkers with 
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higher sensitivity and specificity than serum creatinine and urine output are required if 
the detection, monitoring and prevention of acute kidney is to be improved even further. 
Drug-Induced Acute Kidney Injury: A Preclinical and Clinical Problem 
The kidney is one of the main organs involved in excretion of drugs and drug metabolites 
from the body, and also has drug metabolising capacity itself.  It is not surprising, 
therefore, that drug-induced toxicity giving rise to acute kidney injury arises more 
frequently there than in many other organs.  Indeed, drug-induced acute kidney injury is 
a big problem for both preclinical drug development and clinical therapeutics.  One of the 
main reasons that compounds are dropped from development is due to the discovery of 
drug-induced toxic side effects (Kola and Landis 2004).  As such, pharmaceutical 
companies aim to identify such compounds early during development in order to prevent 
late stage attrition, with associated loss of time, energy and investment (Bonventre et al. 
2010).  The gold-standard for determining whether a novel compound does or does not 
induce acute kidney injury in preclinical species, is histopathological observation 
following termination (Bonventre et al. 2010).  In the clinic, drug-induced acute kidney 
injury contributes to 8-60% of all cases of acute kidney injury, depending on patient 
population studied (Schetz et al. 2005).  Halting the progression of acute kidney injury is 
important as it is considered a serious risk factor for progression to end-stage renal 
disease (ESRD) (Gammelager et al. 2013), and is associated with an increased risk of death 
(Chertow et al. 2005; H. Wang et al. 2012).  While histopathological observation is also 
the gold-standard for diagnosing acute kidney injury in humans, it requires an invasive 
biopsy, and as such, is only used in rare instances (Bonventre et al. 2010).  Rather, despite 
their limitations, increases in serum creatinine (SCr) and blood urea nitrogen (BUN) are 
used alongside urinalysis (Star 1998).  
Drug Metabolism and Excretion in the Kidney: Cisplatin 
A common route of drug excretion from the body is in urine produced by the kidney.  
Many drugs (and drug metabolites) undergo elimination via passive filtration at the 
glomerulus and/or paracellular or transcellular secretion.  During proximal tubule 
transcellular secretion, drugs pass from the peritubular capillaries through proximal 
tubule cell basolateral and apical membranes and into the glomerular filtrate (Khurana 
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2005).  Cisplatin (cis-diammine-dichloro-platinum (II)), is chemotherapeutic drug used 
for treating solid tumours including those of the head, neck, lung, testis, ovary and breast 
(Blanchard 2012; Miller et al. 2010) is excreted from the body by both glomerular 
filtration and proximal tubule transcellular secretion (Blanchard 2012; Yao et al. 2007).  
During the process of transcellular secretion, it is transported across the proximal tubule 
basolateral membrane via organic cation transporter-2 (OCT2) (Ciarimboli et al. 2005) and 
copper transporter-1 (CTR1) (Ishida et al. 2002; Lin et al. 2002).  Efflux of cisplatin at the 
apical membrane is mediated by multidrug and toxin extrusion 1 (MATE1) (Nakamura et 
al. 2010).  
Cisplatin has a notorious dose-limiting nephrotoxic side effect (Blanchard 2012) which is 
thought to be a result of its biotransformation (metabolism) into a more toxic metabolite.  
Indeed, few drugs are excreted by the body unchanged; most undergo biotransformation 
into metabolites via phase I metabolism (which includes, for example, hydroxylation, 
reduction or oxidation reactions) or phase II metabolism (which includes, for example, 
methylation, acetylation, glucuronidation or sulfation reactions) (Moscovitz and 
Aleksunes 2013).  Cisplatin is thought to undergo biotransformation (metabolism) in the 
kidney to a glutathione-conjugate, to a cysteinyl-glycine-conjugate, to a cysteine-
conjugate and finally to a reactive thiol (Miller et al. 2010; Townsend et al. 2003).  In 
addition, sensitivity to cisplatin appears to correlate with mitochondrial density (Qian et 
al. 2005) and proximal tubule cells have high density of mitochondria (Hall et al. 2008).  
Toxicity is also thought to be a result of a change in mitochondrial membrane potential, 
mitochondrial fragmentation, and subsequent release of apoptotic factors (C. Brooks et 
al. 2009).  Despite its toxic side effects, cisplatin continues to have widespread clinical use 
as an effective anti-cancer agent in the clinic.  In preclinical studies, cisplatin 
nephrotoxicity can be exploited as a reliable method for inducing renal injury in rodent 
models to study biomarkers of drug-induced toxicity.   
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Cisplatin’s Therapeutic Mechanism 
To exert its cytotoxic therapeutic actions, cisplatin forms interstrand and intrastrand 
cross-links between DNA purine bases (Oliver et al. 2010).  In highly proliferative cancer 
cells, this prevents DNA replication and arrests tumour growth (Harder and Rosenberg 
1970; Harder et al. 1976), and additionally results in the activation of signal transduction 
pathways involving ATM- and Rad3-related protein (ATR), p53, p57, mitogen-activated 
protein kinase (MAPK) and which induce cellular apoptosis (Siddik 2003).  
Kidney Injury Biomarkers 
As a result of the lack of sensitivity and specificity of SCr, BUN and urine output for 
diagnosing AKI, large collaborations between pharmaceutical and biotechnology 
industries, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA 2010) and academia (Bonventre et al. 2010), have 
led to the discovery of many novel diagnostic biomarkers of AKI.  A biomarker, as defined 
by the Biomarkers Definitions Working Group, is ‘a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to therapeutic intervention’ (Group. 2001).  
Before qualification for use by regulatory authorities, novel biomarkers require extensive 
characterisation to validate them in terms of their full capacity.  The Predictive Safety 
Testing Consortium (PSTC) Working Group propose that ideal biomarkers must:  
1. Detect injury early (i.e. before changes in SCr, urine output and/or BUN are seen, 
and even before histopathological changes are seen) 
2. Localise the site of injury (i.e. is the injury confined to the proximal or distal tubule 
only, or it is affecting the whole nephron?) 
3. Reflect the degree/extent of injury 
4. Be applicable to many species (translational) so that they can be used both to 
guide drug development during preclinical safety testing and assist with patient 
management in clinical settings 
5. Be easily accessible in tissue/fluids (Bonventre et al. 2010). 
 
  
 
93 
 
Urinary biomarkers are of particular interest because urine is readily accessible; no 
invasive kidney biopsy, or needle puncture is required.  In addition, repeated urinary 
measurements can be made from patients thereby enabling the onset (when known) of, 
progression of, and recovery from injury to be tracked over time.  
In terms of drug-induced AKI, biomarkers are required not only for improving the safety 
assessment of novel compounds in preclinical and clinical settings, but for monitoring 
kidney injury associated with drugs already marketed for human use (e.g. cisplatin).  
When assessing the diagnostic power of a novel biomarker to identify AKI, Receiver 
Operating Characteristic (ROC) Analyses are performed and ROC Curves created.  A ROC 
curve is a graphical plot of the true positive rate (sensitivity) versus the false positive rate 
(1 – specificity) for a variable (i.e. a biomarker) against a classifier (i.e. AKI) (Cook 2010).  
The area under the curve (AUC) indicates how sensitive and specific a biomarker is at 
correctly identifying AKI.  For example, a biomarker with an AUC of 0.5 is essentially 
random, whilst a biomarker with an AUC of 1.0 would correctly identify AKI 100% of the 
time (perfect ability). The area under the curve can be used to compare the ability of a 
number of different biomarkers against each other as well as against current standards 
such as SCr (Warnock and Peck 2010).  
Highlighted below are of some of the most promising tissue and urinary biomarkers of 
drug induced-AKI, some of which have already been qualified for use in certain settings 
by the FDA and EMEA (Dieterle et al. 2010b).  
Kidney injury molecule-1 
Kidney injury molecule-1 (KIM-1) is a type 1 membrane-spanning protein with a six 
cysteine immunoglobulin (Ig)-like domain and a single mucin domain (Han et al. 2002; 
Ichimura et al. 1998).  It is also known as T-cell immunoglobulin mucin domains-1 (TIM-1) 
and hepatitis A virus receptor 1 (HAVCR-1) (Waanders et al. 2010).  KIM-1 mRNA and 
protein are either undetectable (van Timmeren et al. 2006) or present at extremely low 
levels (Ichimura et al. 2004) in healthy kidneys but are massively upregulated following 
ischaemia (Ichimura et al. 1998), nephrotoxicity (Chiusolo et al. 2010; Ichimura et al. 
2004) and protein overload nephropathy (van Timmeren et al. 2006).  It is an especially 
good biomarker because it is expressed de novo in the kidney in response to injury.  
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Expressed in dedifferentiated, proliferating epithelial cells found within regenerating 
tubules (Ichimura et al. 1998), the KIM-1 ectodomain is shed into the kidney filtrate 
(urine) in a metalloproteinase-dependent manner (Bailly et al. 2002; Han et al. 2002) 
where it is thought to modulate the immune response and repair process after injury 
(Bonventre and Yang 2010).  Its presence in urine means that it can serve as a non-invasive 
urinary biomarker of AKI; urinary levels can be monitored before injury, during injury and 
during recovery when the initial onset of injury is known.  As such, it was qualified by the 
FDA and EMA in 2009 as a sensitive and specific urinary biomarker of drug-induced AKI 
for use in preclinical studies and on case-by-case phase 1 and phase 2 clinical trials using 
the KIM-1 urine dipstick test, RenaStick (Vaidya et al. 2009).  KIM-1 is also a good 
biomarker for predicting kidney transplant rejection (Jin et al. 2013).  
Osteopontin 
Osteopontin (OPN) is a highly phosphorylated glycoprotein component of the mineralised 
extracellular matrices of both bone and teeth (Sodek et al. 2000).  However, it is also 
widely expressed by other tissues including lung, liver, bladder, pancreas and kidney (Xie 
et al. 2001b).  In healthy kidneys, expression of OPN is localised to the loop of Henle and 
the distal tubule (Hudkins et al. 1999; Xie et al. 2001a), where it is secreted into the urine 
to prevent the nucleation, growth and precipitation of minerals such as calcium oxalate 
monohydrate thereby preventing the formation of urinary stones (Asplin et al. 1998; 
Wesson et al. 2003). Upregulation of osteopontin in the kidney occurs following 
ischemia/reperfusion (Persy et al. 1999), nephrotoxicity (Verstrepen et al. 2001) and 
protein overload proteinuria (Eddy and Giachelli 1995) and is thought to be 
renoprotective.  For example, following 30 minutes of ischemia, OPN -/- mice exhibit 
more severe kidney injury in association with greater inducible nitric oxide synthase 
(iNOS) expression compared to that of wild type mice (Noiri et al. 1999).  As such, one of 
the ways OPN may be renoprotective is by reducing oxidative stress.  Indeed, it has 
recently also been shown that ischemia/reperfusion induced kidney injury in rats is 
attenuated by inhibition of iNOS (P. Wang et al. 2013). 
Alpha glutathione S-transferase 
Glutathione S-transferases are small, cytosolic enzymes involved in detoxification, steroid 
hormone synthesis and aromatic amino acid catabolism (Hayes and Pulford 1995; Hayes 
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et al. 2005).  The alpha isoform (alpha glutathione S-transferase; αGST) is highly and 
constitutively expressed throughout the proximal tubule and urinary levels are highest in 
people with well-preserved renal function (Branten et al. 2000).  Increased urinary 
excretion of αGST is associated with proximal tubule brush border damage and decreased 
tissue expression (Branten et al. 2000).  The time course of this increase is thought to be 
short; once the available αGST has been shed into the urine, no further shedding is 
possible (Endre and Pickering 2013).  
Clusterin 
Clusterin is a glycosylated protein with anti-apoptotic and pro-survival actions (Dieterle 
et al. 2010a).  Although it is constitutively expressed by almost all mammalian tissues and 
is a major protein component of physiological fluids (Jones and Jomary 2002), it is only 
expressed in the kidney under pathophysiological conditions.  Its relatively high molecular 
weight (75-80Kda) prevents it undergoing glomerular filtration under physiological 
conditions and therefore its presence in urine is indicative of kidney injury (Dieterle et al. 
2010a; Silkensen et al. 1997).  De novo gene expression of clusterin in the kidney can be 
induced by ischemia/reperfusion injury (W. Zhou et al. 2010) and drug nephrotoxicity 
(Betton et al. 2012; Kharasch et al. 2006; Vinken et al. 2012).  As such, urinary clusterin 
has been formally qualified by the EMEA and FDA as a proximal tubule injury biomarker 
(Dieterle et al. 2010a).  Clusterin is thought to play a role in renal regeneration following 
injury (Gobé et al. 1995).  
Trefoil factor-3 
Trefoil factor-3 (TFF3) is a small molecular weight peptide hormone secreted by mucous 
producing cells and epithelial tissues (Madsen et al. 2007).  In the kidney it is expressed 
in collecting ducts of the outer stripe of the outer medulla and it is thought to play a 
protective role, although its exact function is as yet unknown (Astor et al. 2011).  TFF3 
urinary levels decrease following drug-induced acute kidney injury (Yu et al. 2010). 
Beta 2-microglobulin 
Beta 2-microglobulin (β2MG) is the light chain component of major histocompatibility 
(MHC) class 1 molecules present on the cell membranes of most nucleated cells (Musialik 
1989).  It is freely filtered by the glomerulus and almost completely reabsorbed by 
proximal tubular cells (Miyata et al. 1998) such that only 0.3% of filtered β2MG is excreted 
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in urine (Dieterle et al. 2010a).  In the kidney, it is localised to the sub-apical endosomes 
of the proximal tubule that process it (Dieterle et al. 2010a).   Levels of β2MG in the urine 
can be increased in different ways depending on the type of kidney injury.  When treated 
with toxins primarily affecting the glomerulus, for example, leakage of high molecular 
weight proteins into the filtrate compete with β2MG for uptake in the proximal tubule 
(Thielemans et al. 1994).  The problem associated with the use of β2MG which thereby 
limits its use as a non-invasive urinary biomarker is, however, the fact that it degrades in 
urine samples at 37°C, pH6 (Davey and Gosling 1982). 
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2.3 Project Overview 
Despite significant progress in identifying, validating and utilising urinary biomarkers, 
there is still little information for many of these on how they perform in tissue-based 
assays.  For pharmaceutical companies, tissue-based assays offer the advantage that they 
can be carried out on retrospective samples from drug safety testing studies (or other 
relevant studies), where samples are usually formalin-fixed, paraffin-embedded and may 
be archived for long periods of time.  As it is important that urinary biomarkers of kidney 
injury reflect the expression of the same biomarkers in kidney tissue, tissue-based assays 
offer the advantage that they can confirm that a protein detected in urine has indeed 
originated from the kidney (and not been filtered at the glomerulus, for example).  
Furthermore, when used alongside standard histopathology, tissue-based 
immunohistochemistry assays can be used to localise biomarkers to specific sites within 
the kidney and/or relate them to particular types of injury.  Immunohistochemistry assays 
can therefore provide complimentary information to the urinary assays using 
corresponding antibodies. 
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2.4 Aims 
This study was a retrospective study using formalin-fixed paraffin embedded kidney 
samples and urine samples collected as part of an earlier study at AstraZeneca where the 
nephrotoxic drug cisplatin was used to induce kidney injury in rats (Pinches et al. 2012b; 
Pinches et al. 2012a; Pinches et al. 2012c). 
The aims of this study were: 
1. To investigate changes in tissue biomarkers of kidney injury in a cisplatin-
treated rat model of nephrotoxicity using positive pixel analysis 
2. To determine the ability of tissue biomarkers to correlate with standard 
histopathology by constructing receiver operating characteristic curves 
3. To determine the ability of tissue biomarkers to correlate with the same 
biomarkers in urine (where available). 
 
KIM-1, osteopontin, αGST, clusterin, TFF3 and β2MG were selected for investigation, all 
of which are becoming widely used as urinary biomarkers of nephrotoxicity (Bandele et 
al. 2013; Dieterle et al. 2010a; Tonomura et al. 2010; Yu et al. 2010; Y. Zhou et al. 2008). 
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2.5 Materials and Methods 
In vivo Study Design 
The in vivo study (from which immunohistochemistry data in the current study was 
generated), was carried out at AstraZeneca, UK, according to the Animals (Scientific 
Procedures) Act (1986) and AstraZeneca Standard Operating Procedures (SOPs). A total 
of 80, ten-week-old, male, Han Wistar rats were used (Harlan, UK) in the study.  A 
maximum of 5 animals were housed per cage, and animals were subject to a 12 hour 
light/dark cycle with temperature and humidity maintained between 19°C and 23°C, and 
40% and 70% respectively.  Unlimited access to RM1 (E) SQC food pellets and water was 
provided, except during the 6 hour urine collection periods when food was temporarily 
withdrawn. 
Animals were randomised into 10 different experimental groups with 5 animals per each 
vehicle-treated group and 10 animals per each cisplatin-treated group.  Cisplatin (Sigma, 
UK) was formulated in a 0.9% (w/v) sodium chloride vehicle solution.  On day 1, all animals 
received a single intra-peritoneal (i.p.) dose of the vehicle solution or 0.1mg/kg (low 
dose), 1.0mg/kg (mid dose) or 2.5mg/kg (high dose) of cisplatin.  The different doses of 
cisplatin used in the study were based on earlier dose-finding exploratory studies at 
AstraZeneca.  Animals were then either maintained for 5 days (all groups), 8 days (all 
groups) or 22 days (control and high dose groups only).  Individual 6 hour metabowl urine 
collections were made 4 days before dosing and 2, 4, 7 and 21 days after dosing, and 
individual 18 hour metabowl urine collections were made 3 days before dosing and 3, 5, 
8, 15 and 22 days after dosing.  Urine samples were stored at -80°C until analysed.  
Following the appropriate duration of study for each group, animals were killed by 
administration of halothane.  The kidneys were removed, fixed for 48 hours in 10% 
neutral-buffered formalin (NBF) and embedded in paraffin.  Table 2.2 outlines the study 
plan. 
 
Novel immunohistochemistry biomarker data in the current study was generated using 
the formalin-fixed, paraffin-embedded kidneys collected as described above. 
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Group Animals/Group Dose (mg/kg) Urine Collection Day Necropsy Day 
1 5 0 -4 (-3), 2 (3) and 4, (5) 5 
2 10 0.1 -4 (-3), 2 (3) and 4, (5) 5 
3 10 1.0 -4 (-3), 2 (3) and 4, (5) 5 
4 10 2.5 -4 (-3), 2 (3) and 4, (5) 5 
5 5 0 -4 (-3), 2 (3), 4 (5) and 7 (8) 8 
6 10 0.1 -4 (-3), 2 (3), 4 (5) and 7 (8) 8 
7 10 1.0 -4 (-3), 2 (3), 4 (5) and 7 (8) 8 
8 10 2.5 -4 (-3), 2 (3), 4 (5) and 7 (8) 8 
9 5 0 -4 (-3), 2 (3), 4 (5), 7 (8), 14 (15) and 21 (22) 22 
10 10 2.5 -4 (-3), 2 (3), 4 (5), 7 (8), 14 (15) and 21 (22) 22 
 
Table 2.2. In Vivo Cisplatin Study Design.  Details regarding the group number, the number of animals per group, the dose (mg/kg) of 
cisplatin that animals in each group received via intraperitoneal inject on day 1, the days that urine collections were made for each group, 
and the day animals were killed by administration of halothane and subsequently necropsied, is presented.  Ten different groups of animals 
were used in this study (groups 1-10), with 5 animals in each group treated with 0mg/kg cisplatin, and 10 animals in each group treated with 
0.1mg/kg, 1.0mg/kg and 2.5mg/kg cisplatin.  A total of 85 animals were used in the study.  Urine samples were collected from animals in 
each group for 6 hours (or 18 hours) at the days indicated.  Animals in each group were culled 5, 8 or 22 days post treatment, at which point 
kidney tissue from each animal was fixed in 10% neutral buffered formalin for 24 hours and processed into paraffin blocks.  This table is 
adapted from Pinches et al. 2012.
  
 
101 
 
Histopathology 
For each of the animals in the study (N=85), 4µm-thick kidney sections in the transverse 
plane were cut and air-dried onto strongly adhesive slides (Leica, Germany).  Sections 
were deparaffinised in xylene (Sigma, 33817) (2 x 3 minutes) and rehydrated to water 
using 100% (1 x 2 minutes) and 70% (1 x 2 minutes) ethanol (Sigma, 458600).  Sections 
were incubated in haematoxylin (Clin-Tech Ltd, 642300) (6 minutes), washed in running 
tap water (2 minutes), dipped in 0.2% acid water, washed in running tap water (2 
minutes), incubated in Scott’s Tap Water (1 minute) and then washed again in running 
water (2 minutes).  Sections were incubated in eosin (Thermo Scientific, 6766008) (3 
minutes) and then dehydrated using 70% (20 seconds) and 100% (15 seconds) and then 
cleared in xylene (Sigma, 33817) (3 x 1 minute).  Coverslips were mounted on slides using 
histomount (TAAB Labs, Aldermaston, UK).  Slides were examined by light microscopy and 
histopathological assessments made based on the following pathology scoring system for 
proximal tubule necrosis: 0 = no necrosis, 1 = minimal necrosis, 2 = mild necrosis, 3 = 
moderate necrosis and 4 = severe necrosis.  Histopathological assessments of proximal 
tubule necrosis were made by a pathologist (Dr Huw Jones) in the pathology group at 
AstraZeneca, UK. 
Immunohistochemistry 
In the present study, tissue biomarker data for all control animals (N=5 0mg/kg cisplatin 
at day 5, N=5 0mg/kg cisplatin at day 8, N=5 0mg/kg cisplatin at day 22), and the first five 
animals from each of the cisplatin-dosed groups (N=5 animals treated with 0.1mg/kg 
cisplatin at day 5 and day 8, N=5 animals treated with 1.0mg/kg cisplatin at day 5 and day 
8, N=5 animals treated with 2.5mg/kg cisplatin at day 5, day 8 and day 22) was generated 
using immunohistochemistry (N=50 animals in total).  Six tissue biomarkers (KIM-1, OPN, 
αGST, clusterin, TFF3 and β2MG) were investigated in this study.  Therefore, 6 formalin-
fixed, paraffin-embedded kidney tissue sections were required per animal so that one 
section could be used per biomarker for immunohistochemistry. 
For immunohistochemistry, antigen retrieval pre-treatments and antibody dilutions were 
optimised for use on formalin-fixed, paraffin-embedded control (for OPN, αGST, TFF3 and 
β2MG) or 2.5mg/kg cisplatin-treated (for KIM-1 and clusterin) rat kidney sections, before 
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use in the current study.  Control rat kidney was used to optimise the 
immunohistochemical staining of OPN, αGST, TFF3 and β2MG, as these proteins are 
expressed in healthy kidney tissue.  Kidney tissue from a 2.5mg/kg cisplatin-treated rat 
was used to optimise the immunohistochemical staining for KIM-1 and clusterin, as there 
is little to no expression of these proteins in healthy kidney tissue.  
Four µm-thick formalin-fixed, paraffin-embedded rat kidney sections in the transverse 
plane were cut and air-dried onto strongly adhesive slides (Leica, Germany), 
deparaffinised in xylene (Sigma, 33817) (2 X 5 minutes) and rehydrated to water using 
100% (2 x 5 minutes) and 95% (1 x 5 minutes) ethanol (Sigma, 458600).   Antigen retrieval 
pre-treatment was performed for osteopontin and αGST (Ethylenediaminetetraacetic 
acid (EDTA; Sigma, ED255) pH8 for 2 minutes at 110°C) and TFF3 and β2MG (citrate 
(Sigma, C1090) pH6 for 2 minutes at 110°C) using a RHS-2 Rapid Histoprocessor 
(Milestone, Sorisole, Italy).  No antigen retrieval was required to detect either KIM-1 or 
clusterin.  Following antigen retrieval (if required), sections were rinsed in running tap 
water (10 minutes).  All immunostaining was carried out at room temperature using a 
Labvision autostainer (Labvision, Fremont, USA).  Incubation with 3% H2O2 (Fisher 
Scientific, H/1750/15) 1 x phosphate-buffered saline 0.05% Tween-20 (USB Corporation, 
20605) (PBST) (10 minutes) was used to quench endogenous peroxidase activity before 
non-specific antibody binding was minimised using background blocker with casein (MP-
966-P500; Biocare LLC, Concord, USA) (20 minutes).  Sections were incubated for 1 hour 
with antibodies raised against KIM-1 (goat IgG; 1:400; AF3689, R & D Systems, USA), 
osteopontin (rabbit IgG; 1:100; 18628, IBL Co., Ltd, Japan), αGST (rabbit IgG; 1:1000; B-
3025, Argutus Medical, Dublin, Ireland), clusterin (goat IgG; 1:100; AF2937, R & D 
Systems, USA), TFF3 (rabbit IgG; 1:300; bs_0503, BIOSS Inc., USA) and β2MG (rabbit IgG; 
1:200; LS-b331, Lifespan Biosciences, USA) individually diluted in 1X Tris-buffered saline 
0.05% Tween-20 (USB Corporation, 20605) (TBST).  To remove unbound primary 
antibodies, sections were briefly rinsed twice with TBST.  The X-Cell Plus Universal 
Polymer HRP Kit (MP-XCP-U100, Biocare LLC) and X-Cell Plus Goat HRP-Polymer Kit (MP-
GHRP-K100, Biocare LLC) were used to conjugate HRP to rabbit and goat primary 
antibodies respectively (20 minutes).  To remove unbound secondary antibodies, sections 
were briefly rinsed twice with TBST.  Immunoreactivity was visualised using liquid stable 
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3, 3’ diaminobenzidine (DAB) (MP-860-K25, Biocare LLC) (10 minutes).  Sections were 
briefly rinsed twice with TBST, and running tap water (5 minutes).  Sections were 
counterstained using Carazzi’s haematoxylin (Clin Tech Ltd, UK) (1 minute), dehydrated in 
graded ethanol (Sigma, 458600) (100% (2 x 5 minutes) and 95% (1 x 5 minutes)), and then 
cleared in xylene (Sigma, 33817) (2 X 5 minutes).  Sections were allowed to air dry before 
coverslips were mounted on the slides using histomount (TAAB Labs, Aldermaston, UK).  
Rabbit and goat isotype controls (Dako, Denmark) were used as negative controls.  A 
summary of the antibody supplier, dilutions and antigen retrieval methods used is 
summarized in Table 2.3.   Immunohistochemistry for each biomarker (KIM-1, OPN, αGST, 
clusterin, TFF3 and β2MG) was performed on one section from five animals at each dose 
(0mg/kg cisplatin, 0.1mg/kg cisplatin, 1.0mg/kg cisplatin and 2.5mg/kg cisplatin) and time 
point (day 5, day 8 and day 22). 
 
Antibody Supplier Antigen Retrieval Dilution 
KIM-1 R & D Systems (AF3689) No Antigen Retrieval 1:400 
OPN IBL Co. Limited (18628) 
EDTA pH8 for 2 minutes at 
110°C 
1:100 
αGST Argutus Media (B_3025) 
EDTA pH8 for 2 minutes at 
110°C 
1:1000 
Clusterin R & D Systems (AF2937) No Antigen Retrieval 1:100 
TFF3 BIOSS Inc. (bs_0503) 
Citrate pH6 for 2 minutes at 
110°C 
1:300 
β2MG LifeSpan Biosciences (LS-B331) 
Citrate pH6 for 2 minutes at 
110°C 
1:200 
 
Table 2.3.  Summary of the antibodies, antibody suppliers, antigen retrieval methods 
and antibody dilutions used in this study.  Antigen retrieval pre-treatments and antibody 
dilutions were optimised for use in the current study on formalin-fixed, paraffin-
embedded control (for OPN, αGST, TFF3 and β2MG) or 2.5mg/kg cisplatin-treated (for 
KIM-1 and clusterin) rat kidney tissue beforehand.  EDTA = Ethylenediaminetetraacetic 
acid. 
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Image Analysis 
Image analysis was performed for the immunohistochemistry tissue biomarker data 
generated for all control animals (N=5 0mg/kg cisplatin at day 5, N=5 0mg/kg cisplatin at 
day 8, N=5 0mg/kg cisplatin at day 22), and the first five animals from each of the cisplatin-
dosed groups (N=5 animals treated with 0.1mg/kg cisplatin at day 5 and day 8, N=5 
animals treated with 1.0mg/kg cisplatin at day 5 and day 8, N=5 animals treated with 
2.5mg/kg cisplatin at day 5, day 8 and day 22) (N=50 animals in total). 
Following immunohistochemistry, images of the rat kidney sections were captured using 
a ScanScope Scanner and ImageScope software (Aperio Technologies Incorporated, Vista, 
USA).  Using the ImageScope Software, thresholds were set to detect DAB positivity (the 
brown staining indicating immunoreactivity for the biomarker of interest) in the kidney 
images.  The images were subsequently analysed to determine the proportion of DAB-
positive pixels (i.e. biomarker positive pixels) relative to the total number of pixels.  The 
Arc sine transformation (Snedecor and Cochran 1989) was applied prior to significance 
testing.  This transformation was insufficient to achieve homogeneity of variance across 
the control and cisplatin-treated groups.  Therefore, one-sided, 2-sample t-tests assuming 
unequal variances were performed at the 5% significance level, to test for increases or 
decreases in cisplatin-treated groups compared to day-matched vehicle controls.  
Differences were deemed statistically significant (at the 5% level) when P < 0.05.  Multiple 
pairwise t-test comparisons between control and time-matched cisplatin-treated animals 
were made rather than ANOVAs, as for ANOVA to be valid, the variances between each 
group must be approximately the same.   Pairwise t-tests allow for unequal variances in 
each group to be compared. 
Construction of Receiver Operator Characteristic Curves 
Receiver operating characteristic curves are plots of the false positive rate (1-specificity) 
of a test on the x-axis and the true positive rate (sensitivity) of a test on the y-axis for 
different test values as the boundary between a positive and negative prediction.  In this 
study, a false positive is considered the probability of a biomarker predicting proximal 
tubule necrosis when in fact there is no pathology, and a true positive is considered the 
probability of a biomarker predicting proximal tubule necrosis when indeed there is 
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proximal tubule necrosis.  A diagonal line though the centre of a ROC plot represents ‘no 
discrimination.’  A biomarker with that curve would have no ability to correctly predict 
proximal tubule necrosis beyond that of chance.  The area under curve (AUC) for this ROC 
plot is 0.5.  As such, biomarkers with high sensitivity and specificity, have curves that are 
close to the left and top of the plot, where the AUC is 1.0.  The greater the AUC of a ROC 
curve (i.e. the closer it is to 1.0), the greater the overall accuracy of a biomarker for 
predicting proximal tubule necrosis. 
Using the immunohistochemistry biomarker data generated by positive pixel image 
analysis by myself, and the histopathology data generated by the pathologist Dr Huw 
Jones in the pathology group at AstraZeneca, UK, receiver operating characteristic (ROC) 
curves, to examine the ability of each biomarker studied (KIM-1, OPN, αGST, clusterin, 
TFF3 and β2MG) to correctly predict proximal tubule necrosis (a key feature of cisplatin-
induced kidney injury), were created with the assistance of clinical scientist Dr Mark 
Pinches, AstraZeneca, UK.  Using an Analyse-it software package (Leeds, UK), a ROC curve 
was constructed and the AUC determined for each biomarker based on the method 
described by (DeLong et al. 1988). 
To determine if the AUC for each of the biomarkers was significantly different from that 
of the other biomarkers, the AUC curve for each biomarker was contrasted with that of 
each of the others.  This was again performed with the assistance of Dr Mark Pinches, 
AstraZeneca, UK.  Using an Analyse-it software package (Leeds, UK), each ROC curve was 
compared against each of the other ROC curves based on the method described by 
(DeLong et al. 1988).  Differences were deemed to be significant when p < 0.05 (*). 
Urinary Biomarker Analysis: KIM1, OPN and αGST 
Urinary biomarker analysis for KIM1, OPN and αGST was performed by the clinical 
pathology group at AstraZeneca, UK.  Methods and data regarding these measurements 
has previously been published (Pinches et al., 2012).  Briefly, urinary biomarkers were 
assessed using a multiplex electrochemiluminescence-based MesoScale Discovery (MSD) 
Sector Imager 6000 instrument (MSD, Gaithersburg, MD, USA).  Analysis was conducted 
using two plate options; αGST was assessed using the Argutus acute kidney injury (AKI) 
Test assay kit (MSD, Gaithersburg, MD, USA) according to the manufacturer’s instructions 
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and KIM-1 and OPN were assessed with the kidney injury panel 1 assay kit (MSD; 
Gaithersburg, MD, USA).  Urinary creatinine concentrations in each sample were 
measured on a Roche Modular P analyser (Roche Diagnostics, UK) using the Roche 
Diagnostics Jaffe reaction assay kit (Roche Diagnostics, UK).  The Jaffe reaction is a 
quantitative, colorimetric test for creatinine.  Under alkaline conditions, creatinine and 
picric acid form an orange-red coloured complex, the optical-density of which, can be 
read and used to determine the creatinine concentration (Wyss and Kaddurah-Daouk 
2000).  Urinary levels of each of the biomarkers in each sample were normalised against 
the corresponding urinary creatinine levels. 
Correlation between Tissue and Urinary Biomarkers  
In this study, urinary biomarker data (for KIM-1, OPN and αGST) generated from control 
and cisplatin-treated animals at day 5 and day 8 were correlated with the corresponding 
tissue biomarker data (for KIM-1, OPN and αGST) for each individual animal.  N=5 animals 
for each time point (day 5 and day 8) and dose (0mg/kg, 0.1mg/kg, 1.0mg/kg and 
2.5mg/kg) cisplatin.  The correlation between tissue biomarker data (generated by 
myself) and urinary biomarker data (generated by the clinical pathology group at 
AstraZeneca) was determined by clinical scientist Dr Mark Pinches, AstraZeneca.  
Correlations between tissue biomarker expression (variable 1) and urinary biomarker 
expression (variable 2) were performed using a standard Pearson’s correlation method 
using TIBCO Spotfire® software (Boston, MA, USA). Scatter plots to visualise the 
correlation between the two variables were constructed also using TIBCO Spotfire® 
software.  Pearson’s correlation is a test to measure the association between two 
variables (Pernet et al. 2012); r = +1 (positive correlation), r = 0 (no correlation) and r = -
1 (negative correlation).  In this study, positive correlation denotes a situation where an 
increase in the biomarker level in tissue expression is mirrored by an increase in the 
biomarker level in the urine. 
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2.6 Results 
 
Images presented in Figures 2.1 – 2.7 contain data relating to day 5 vehicle control 
(0mg/kg cisplatin)-treated rats, and day 5, day 8 and day 22 high-dose (2.5mg/kg) cisplatin 
-treated rats.  Only high-dose images are presented as greater differences were seen in 
this group than in lower dose groups.  No differences were seen in biomarker expression 
between vehicle control groups at any time point, and so for simplicity, only day 5 images 
are shown. 
Histopathology  
Representative H&E images of kidneys from vehicle-treated and 2.5mg/kg cisplatin-
treated rats are shown in Figure 2.1.  No major abnormalities in kidneys were observed 
from control animals at any time point (Figure 2.1A & B).  The majority of the effects of 
cisplatin were seen in the S3 segment of the proximal tubule in the outer stripe of the 
outer medulla (OSOM) and appeared in a temporal and dose-dependent manner.  At 5 
days, animals dosed with 2.5mg/kg cisplatin showed high incidence of severe tubular 
necrosis and nuclear pleomorphism (Figure 2.1C & D).  Similar histopathological features 
were observed after 8 days in animals treated with 2.5mg/kg cisplatin (Figure 2.1E and 
2.1F).  However, at 8 days most animals also displayed necrotic S3 proximal tubules, 
tubular proteinaceous contents and necrotic cell debris.  Distal tubules and collecting 
ducts were basophilic which is indicative of regeneration.  By day 22, there was recovery 
from most of the histological findings (Figure 2.1G & H).  At corresponding time points, 
animals dosed with 1.0mg/kg cisplatin showed a similar incidence but reduced severity 
of tissue damage by comparison with that seen in animals dosed with 2.5mg/kg.  
Pathological findings in animals dosed with 0.1mg/kg cisplatin were of low incidence and 
severity. 
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Figure 2.1. Representative H&E images of kidneys from rats treated with a single intra-
peritoneal dose of a vehicle (A and B) or 2.5mg/kg cisplatin after 5 days (C and D), 8 
days (E and F) and 22 days (G and H).  Images are of kidneys sectioned in the transverse 
plane, and display the outer stripe of the outer medulla (OSOM), in the region of the 
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segment 3 (S3) proximal tubules, the region where the main nephrotoxic effect of 
cisplatin are observed. (A & B) Control rat kidney proximal tubules appear normal; brush 
border membranes are intact (arrow heads) and cell nuclei appear uniform in size and 
shape (circles).  (C & D) Five days post cisplatin-treatment, S3 (also known as the pars 
recta or the straight) proximal tubules showed signs of tubular necrosis as indicated by 
nuclear pleomorphism (size variation; circles) and mild basophilia (cells appear more 
purple than pink) (arrows).  (E & F) At day 8, cellular necrosis and nuclear pleomorphism 
had increased in severity and incidence (circles).  Intraluminal cellular casts were also 
present in some tubules (arrow heads).  (G & H) At day 22, much of the histopathology 
had reversed; nuclei were more uniform in size and shape (circles) and brush border 
membranes were present (arrow heads).  One section per animal was stained for H&E. 
The entire section was observed by light microscopy before histopathological 
assessments were made.  Images are representative of N=5, n=5 animals for vehicle-
treated animals (0mg/kg cisplatin) and N=10, n=10 for cisplatin-treated animals 
(2.5mg/kg cisplatin). Bars = 250μm (A, C, E and G), 25μm (B, D, F and H).  
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KIM-1 Immunoreactivity 
KIM-1 immunoreactivity was absent in control animal kidneys except for a few kidneys 
where faint immunoreactivity was identified in isolated tubules (Figure 2.2A).  Five days 
after treatment with 2.5mg/kg cisplatin, KIM-1 immunoreactivity was detected in the S3 
proximal tubule brush border membranes (arrow heads) in the outer stripe of the outer 
medulla (OSOM) on the border with the inner stripe of the outer medulla (ISOM) (Figure 
2.2B).  Positive pixel analysis identified a significant increase in KIM-1 immunoreactivity 
in rats dosed with 2.5mg/kg cisplatin compared to vehicle controls (Table 2.4).  Eight days 
after treatment with 2.5mg/kg cisplatin, the distribution of immunoreactivity extended 
throughout the OSOM with KIM-1 immunoreactivity present on proximal tubule cell 
apical membranes (arrows) (Figure 2.2C).  Some intraluminal proteinaceous contents and 
casts also stained positive (circled).  At day 22, very little KIM-1 immunoreactivity was 
present and there were no statistically significant difference in the amount of 
immunoreactivity detected compared to that of control (Figure 2.2D).  This finding was 
consistent with recovery from kidney injury, as seen by H&E pathology (Figure 2.1). 
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KIM-1 Immunoreactivity 
 
 
 
Figure 2.2. KIM-1 immunoreactivity in the kidneys of rats treated with a single intra-
peritoneal dose of (A) a vehicle or 2.5mg/kg cisplatin after (B) 5 days, (C) 8 days and (D) 
22 days.  Images taken at the region of the S3 proximal tubules, in the outer stripe of the 
outer medulla (OSOM), the region where the nephrotoxic effects of cisplatin occur.  (A) 
Extremely minimal KIM-1 immunoreactivity was detected in control kidneys.  (B) At day 
5, KIM-1 was detected in the brush border membranes of S3 proximal tubules (arrow 
heads) in the outer stripe of the outer medulla (OSOM) on the border with the inner stripe 
of the outer medulla (ISOM) (C) At day 8, KIM-1 immunoreactivity was detected on the 
apical membranes of S3 proximal tubules in the OSOM (arrow head).  Some luminal debris 
(arrows) and proteinaceous content (circled) also stained positive.  (D) By day 22, minimal 
KIM-1 immunoreactivity remained.  KIM-1 immunoreactivity appears brown and the 
haematoxylin co-stain appears blue.  Images representative of N=5, n=5 animals for each 
time point assessed.  Bars = 250μm.  
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Osteopontin Immunoreactivity 
In control rat kidneys, osteopontin was identified throughout the cytoplasm of cells in the 
thin limb of the loop of Henle (Figure 2.3A).  At day 5, additional expression was seen in 
the thick ascending limbs of the loops of Henle, and there was an overall significant 
increase in osteopontin immunoreactivity the kidneys of rats dosed with 2.5mg/kg 
cisplatin compared to time-matched vehicle controls (Figure 2.3B; Table 2.4).  At day 8, 
immunoreactivity for osteopontin was also present in S3 proximal tubules in rats treated 
with 2.5mg/kg cisplatin, and immunoreactivity remained significantly increased 
compared to time-matched vehicle controls (Figure 2.3C; Table 2.4).  By day 22, 
immunoreactivity for osteopontin was comparable to that of control rat kidneys; 
expression was localised to the thin limb of the loop of Henle; no significant difference in 
immunoreactivity was detected compared to time-matched vehicle controls (Figure 2.3D; 
Table 2.4).  This finding was consistent with recovery from kidney injury, as seen by H&E 
pathology (Figure 2.1). 
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Osteopontin Immunoreactivity 
 
 
Figure 2.3. Osteopontin immunoreactivity in the kidneys of rats treated with a single 
intra-peritoneal dose of a (A) vehicle or 2.5mg/kg cisplatin after (B) 5 days, (C) 8 days 
and (D) 22 days.  Images taken at the region of the S3 proximal tubules, in the outer stripe 
of the outer medulla (OSOM), the region where the nephrotoxic effects of cisplatin occur.  
(A) In control animals, osteopontin was confined to the thin limbs of the loop of Henle 
(arrow heads); staining was localised to the inner stripe of the outer medulla (ISOM) and 
the inner medulla (IM).  (B) At day 5, thick and thin ascending limbs were positive for 
osteopontin (arrows heads).  (C) At day 8, osteopontin was detected also detected in the 
S3 proximal tubule (arrow heads).  (D) At day 22, osteopontin immunoreactivity was 
comparable to that of controls, where it was expressed in the thin limbs of the loop of 
Henle (arrow heads).  Osteopontin immunoreactivity appears brown and the 
haematoxylin co-stain appears blue.  Images representative of N=5, n=5 animals for each 
time point assessed.  Bars = 250μm. 
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αGST Immunoreactivity 
In control rat kidneys, αGST immunoreactivity was present in the cytoplasm of proximal 
tubules (Figure 2.4A).  At day 5, there was a decrease in αGST immunoreactivity in S3 
proximal tubules, where immunoreactivity also appeared to be of less uniform.  The 
decrease in immunoreactivity in animals treated with 2.5mg/kg cisplatin was significant 
when compared to that of vehicle-treated time-matched controls (Figure 2.4B; Table 2.4).   
At day 8, immunoreactivity for αGST was very faint or absent in S3 proximal tubules in 
rats treated with 2.5mg/kg cisplatin and remained significantly different compared to 
time-matched vehicle controls (Figure 2.4C; Table 2.4).  No significant changes in staining 
intensity were detected in lower dose groups at this time point suggestive of recovery 
from injury (Figure 2.4D; Table 2.4) consistent with recovery from kidney injury, as seen 
by H&E pathology (Figure 2.1). 
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αGST Immunoreactivity 
 
 
 
Figure 2.4. ɑGST immunoreactivity in the kidneys of rats treated with a single intra-
peritoneal dose of (A) a vehicle or 2.5mg/kg cisplatin after (B) 5 days, (C) 8 days or (D) 
after 8 days when treated with 1.0mg/kg cisplatin.  Images taken at the region of the S3 
proximal tubules, in the outer stripe of the outer medulla (OSOM), the region where the 
nephrotoxic effects of cisplatin occur.  (A) In control animals, ɑGST immunoreactivity was 
present and of uniform intensity in proximal tubules of the cortex and outer stripe of the 
outer medulla (OSOM) (arrow heads).  (B) At day 5, ɑGST immunoreactivity was reduced 
in the S3 proximal tubules and was of much less uniform staining intensity (arrow heads).  
(C) At day 8, there was little αGST immunoreactivity in S3 proximal tubules (arrow heads). 
(D) By day 8, recovery of immunoreactivity comparable to that in control animals had 
occurred in rats treated with 1.0mg/kg cisplatin (arrow heads). aGST immunoreactivity 
appears brown and the haematoxylin co-stain appears blue.  Images representative of 
N=5, n=5 animals for each time point assessed.  Bars = 250μm. 
  
  
 
116 
 
Clusterin Immunoreactivity 
Clusterin immunoreactivity was absent in control animals at every time point (Figure 
2.5A).  In cisplatin-treated animals at day 5, clusterin was localised to S3 proximal tubule 
brush border membranes in the OSOM on the border with ISOM (Figure 2.5B).  Positive 
pixel analysis identified a significant increase in immunoreactivity in rats dosed with 
1.0mg/kg compared to vehicle-treated controls (Table 2.4).  At day 8, minimal 
immunoreactivity was identified in proximal tubule cells, but intraluminal cellular casts 
stained very strongly, as did intraluminal proteinaceous contents (Figure 2.5C). At this 
time point, the staining intensity was only significantly increased compared to controls 
with the highest dose of cisplatin (2.5mg/kg).  By day 22, the amount of clusterin 
immunoreactivity was reduced compared to days 5 and 8 but there remained a 
significantly higher amount of staining compared to time-matched control animals (Figure 
2.5D). 
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Clusterin Immunoreactivity 
 
 
 
Figure 2.5. Clusterin immunoreactivity in the kidneys of rats treated with a single intra-
peritoneal dose of (A) a vehicle or 2.5mg/kg cisplatin after (B) 5 days, (C) 8 days and (D) 
22 days.  Images taken at the region of the S3 proximal tubules, in the outer stripe of the 
outer medulla (OSOM), the region where the nephrotoxic effects of cisplatin occur.  (A) 
In vehicle-treated animals, no clusterin immunoreactivity was detected.  (B) At day 5, very 
minimal clusterin immunoreactivity was detected, but that which was detected, was 
localised to S3 proximal tubule brush border membranes in the OSOM on the border with 
ISOM.  (C) At day 8, intraluminal cellular casts stained very strongly (arrow head), as did 
intraluminal proteinaceous contents (circled).  (D) At day 22, the amount of clusterin 
immunoreactivity was reduced.  Clusterin immunoreactivity appears brown and the 
haematoxylin co-stain appears blue.  Images representative of N=5, n=5 animals for each 
time point assessed.  Bars = 250μm.  
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TTF3 Immunoreactivity 
In control animals, immunoreactivity for TFF3 was detected in S3 proximal tubules in the 
outer stipe of the outer medulla (OSOM) and thick ascending limbs of the loop of Henle 
in the inner stripe of the outer medulla (ISOM) and OSOM (Figure 2.6A).  At day 5, 
immunoreactivity in the S3 proximal tubules was decreased in animals treated with 
2.5mg/kg cisplatin Positive pixel analysis identified a significant decrease in TFF3 
immunoreactivity in this dose group compared to time-matched vehicle controls (Figure 
2.6B; Table 2.4).  TFF3 remained significantly lower in these high dose animals at both 8 
and 22 days when compared to time-matched vehicle controls (Figures 2.6C and 2.6D; 
Table 2.4).  Significant decreases in TFF3 immunoreactivity were also detected in the 
0.1mg/kg and 1mg/kg cisplatin-treated animals at day 8 (but not at day 5 or day 22) (Table 
2.4). 
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TFF3 Immunoreactivity 
 
 
 
Figure 2.6. TFF3 immunoreactivity in the kidneys of rats treated with a single intra-
peritoneal dose of a (A) vehicle or 2.5mg/kg cisplatin after (B) 5 days, (C) 8 days and (D) 
22 days.  Images taken at the region of the S3 proximal tubules, in the outer stripe of the 
outer medulla (OSOM), the region where the nephrotoxic effects of cisplatin occur.  (A) 
TFF3 immunoreactivity was detected in S3 proximal tubules in the OSOM, and in thick 
ascending limbs in the ISOM and OSOM.  (B) At day 5, immunoreactivity in the S3 proximal 
tubules was decreased, and remained lower at both 8 (C) and 22 (D) days.  TFF3 
immunoreactivity appears brown and the haematoxylin co-stain appears blue.  Images 
representative of N=5, n=5 animals for each time point assessed.  P = S3 proximal tubule, 
TAL = thick ascending limb. Bars = 200μm. 
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β2MG Immunoreactivity 
In control animals, β2MG immunoreactivity was localised to S1 proximal tubular cells in 
the kidney cortex, and was distributed within subapical membrane vesicles as determined 
by its punctate appearance (Figure 2.7A).  Although immunoreactivity appeared fainter 
(lighter brown immunoreactivity) positive pixel image analysis identified no change in 
number of pixels staining positive for β2MG at day 5 in rats dosed with 2.5mg/kg cisplatin 
compared to vehicle controls (Figure 2.7B; Table 2.4).  However, at day 8, a significant 
decrease in β2MG immunoreactivity was identified in the 2.5mg/kg cisplatin-treated 
group (Figure 2.7C; Table 2.4).  At day 22, staining appeared similar to that found in 
control animals with no significant change in immunoreactivity identified when compared 
to time-matched vehicle controls (Figure 2.7D).  No changes were detected in lower dose 
groups at any time point. 
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B2MG Immunoreactivity 
 
 
 
Figure 2.7.  β2MG immunoreactivity images of the kidney cortex of rats treated with a 
single intra-peritoneal dose of (A) a vehicle or 2.5mg/kg cisplatin after (B) 5 days, (C) 8 
days and (D) 22 days.  Images taken at the region of the S1 proximal tubules in the outer 
cortex, the region where β2MG immunoreactivity is present in healthy rat kidneys.  (A) In 
vehicle-treated animals, β2MG immunoreactivity was localised to S1 proximal tubule cells 
in the kidney cortex, where it was specifically localised to S1 subapical membrane vesicles 
(as evidenced by its punctate pattern) (arrow heads).   β2MG immunoreactivity at days 5 
(B) and 8 (C) appears fainter than in vehicle-treated animals, although a similar subapical 
membrane distribution is observed (arrow heads).  (D) At day 22, immunoreactivity for 
β2MG has recovered and is comparable to that of vehicle-treated animals (arrow heads).  
Β2MG immunoreactivity appears brown and the haematoxylin co-stain appears blue.  
Images representative of N=5, n=5 animals for each time point assessed.  G = glomerulus. 
P = S1 proximal tubule. Bars = 100μm.   
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Biomarker 
Day 5 (mg/kg) Day 8 (mg/kg) Day 22 (mg/kg) 
0 0.1 1.0 2.5 0 0.1 1.0 2.5 0 2.5 
  ns ns ***  ns * *  ns 
KIM-1 
0.029 
±0.0084 
0.019 
±0.0032 
0.101 
±0.1108 
0.191 
±0.0488 
0.022 
±0.0049 
0.017 
±0.0029 
0.060 
±0.0373 
0.224 
±0.1281 
0.016 
±0.00034 
0.014 
±0.0025 
  ns ns ***  ns ns **  ns 
OPN 
0.001 
±0.0007 
0.001 
±0.0004 
0.005 
±0.0055 
0.012 
±0.0053 
0.001 
±0.0001 
0.001 
±0.0001 
0.002 
±0.0013 
0.016 
±0.0090 
0.002 
±0.0006 
0.001 
±0.0003 
  ns * **  ns ns *   
αGST 
0.749 
±0.0235 
0.750 
±0.0213 
0.652 
±0.0361 
0.651 
±0.0444 
0.636 
±0.0451 
0.695 
±0.0392 
0.703 
±0.0391 
0.562 
±0.0321 
- 
 
- 
 
  ns * *  ns ns *  ** 
Clusterin 
0.00002 
±0.00001 
0.00003 
±0.00002 
0.00003 
±0.00001 
0.00013 
±0.00011 
0.00004 
±0.00002 
0.00005 
±0.00003 
0.00005 
±0.00004 
0.0008 
±0.0008 
0.00002 
±0.00001 
0.00005 
±0.00002 
  ns ns **  * * **  ** 
TFF3 
0.778 
±0.0283 
0.751 
±0.0483 
0.732 
±0.0557 
0.615 
±0.1034 
0.773 
±0.0326 
0.698 
±0.0695 
0.675 
±0.0985 
0.507 
±0.1335 
0.671 
±0.0784 
0.533 
±0.0432 
  ns ns ns  ns ns *  ns 
β2MG 
0.127 
±0.0426 
0.104 
±0.0216 
0.104 
±0.0178 
0.119 
±0.0161 
0.109 
±0.0347 
0.092 
±0.0159 
0.095 
±0.0122 
0.072 
±0.0144 
0.081 
±0.0033 
0.076 
±0.103 
  ns *** ***  ns *** ***  * 
KIM-1 (urine) -6 -2 2350 3308 -8 -7 370 4933 -25 55 
  ns *** ***  ns ** ***  *** 
OPN (urine) -8 -33 513 1197 9 52 328 972 -2 154 
  ns *** ***  ns ns ns  ns 
αGST (urine) 21 -40 206 9970 -49 -36 -31 -52 -23 -66 
Table 2.4. Legend overleaf. 
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Table 2.4.  Mean values for positive pixel quantification of immunohistochemistry (KIM-
1, OPN, αGST, clusterin, TFF3 and β2MG) and urinary (KIM-1, OPN, and αGST) biomarker 
measurements in rats dosed with 0, 0.1, 1.0, or 2.5 mg/kg cisplatin over time (day 5, 
day 8 and day 22).  N=5, n=5 (mean±SD) for each biomarker at each time point and dose 
for immunohistochemistry (where one section per animal per biomarker was analysed), 
N=5, n=5 (mean) for control animal urinary measurements and N=10, n=10 for each 
cisplatin-treated animal urinary measurement.  Pairwise one-sided, 2-sample t-tests 
assuming unequal variances were performed at the 5% significance level, to test for 
increases or decreases in cisplatin-treated groups compared to day-matched vehicle 
controls.  Urinary data were generated in a previous study and are normalized to urinary 
creatinine (ng/mmol creatinine) (Pinches et al. 2012c).  ns = not significant, P < 0.05 *; P 
< 0.01 **; P < 0.001 ***. 
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Receiver Operating Characteristic (ROC) Curve Analysis 
Receiver Operating Characteristic (ROC) curves were constructed (Figure 2.8) to 
determine how sensitive and specific each of the biomarkers were for detecting proximal 
tubule necrosis (the primary histopathological change observed following cisplatin 
treatment (Figure 2.1)).  Figure 2.1 shows that KIM-1 has the largest area under the ROC 
curve when cisplatin-induced proximal tubule necrosis was used as the classifier. 
 
 
 
 
 
Figure 2.8.  ROC curves showing biomarker discrimination (sensitivity and specificity) 
for detecting cisplatin-induced proximal tubule necrosis in rats, using the presence or 
absence of this pathology as a classifier.  Immunohistochemistry data were generated 
from 50 animals per biomarker (where 28 animals did not have proximal tubule necrosis, 
and 22 animals did have proximal tubule necrosis as determined by histopathological 
assessment by Dr Huw Jones, AstraZeneca, UK).  Data presented relates to all doses (0, 
0.1, 1.0 and 2.5mg/kg cisplatin) and all time points (day 5, day 8 and day 22).  The diagonal 
line though the centre of the ROC plot represents ‘no discrimination.’ A biomarker with 
this ROC curve would have no ability to correctly predict proximal tubule necrosis beyond 
that of chance.  The plot reveals KIM-1 (pink curve) to have the largest area under the 
curve (AUC).  ROC curves were generated using the (DeLong et al. 1988) method by Dr 
Mark Pinches, AstraZeneca.  
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Biomarker Area Under Curve 95% Confidence Interval 
KIM-1 0.88 0.78 – 0.98 
OPN 0.78 0.63 – 0.94 
αGST 0.64 0.47 – 0.82 
clusterin 0.64 0.54 – 0.84 
TFF3 0.62 0.46 – 0.79 
β2MG 0.69 0.48 - 0.80 
 
 
Table 2.5.  Area under the receiver operator characteristic curve values for rats treated 
with a single intraperitoneal dose of 0, 0.1, 1.0 or 2.5 mg/kg cisplatin and then killed 
after 5, 8 or 22 days.  Immunohistochemistry data were generated from 50 animals per 
biomarker (where 28 animals did not have proximal tubule necrosis, and 22 animals did 
have proximal tubule necrosis as determined by histopathological assessment by Dr Huw 
Jones, AstraZeneca, UK).  Data presented relates to all doses (0, 0.1, 1.0 and 2.5mg/kg 
cisplatin) and all time points (day 5, day 8 and day 22).   The table shows that KIM-1, OPN 
and clusterin have an area under the curve ± 95% confidence intervals that do not cross 
the 0.5 ‘no discrimination’ point indicating that these biomarkers perform better than 
chance alone.  
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To determine if the area under the curve for each of the biomarkers was significantly 
different from that of each of the others, pairwise comparisons were made using the 
method described by (DeLong et al. 1988), with the assistance of Dr Mark Pinches, 
AstraZeneca, UK (Table 2.6).  KIM-1 had the largest area under the ROC curve.  Significant 
differences between the AUCs for KIM-1 vs αGST, KIM-1 vs clusterin, Kim-1 vs TFF3 and 
KIM-1 vs β2MG were identified, indicating that KIM-1 is better than these biomarkers at 
predicting proximal tubule necrosis.  No significant difference was seen for KIM-1 vs OPN. 
 
Comparison Difference 95% CI SE P value 
KIM-1 v OPN -0.10 -0.24 to 0.04 0.073 0.1770 
KIM-1 v aGST -0.24 -0.40 to -0.08 0.081 0.0030 * 
KIM-1 v Clus -0.19 -0.34 to -0.05 0.075 0.0104 * 
KIM-1 v TFF3 -0.26 -0.43 to 0.09 0.087 0.0032 * 
KIM-1 v B2MG -0.24 0.43 to -0.05 0.098 0.0147 * 
OPN v aGST -0.14 0.33 to 0.05 0.096 0.1423 
OPN v Clus -0.09 -0.23 to 0.04 0.070 0.1836 
OPN v TFF3 -0.16 -0.36 to 0.04 0.101 0.1167 
OPN v B2MG -0.14 -0.36 to 0.08 0.110 0.2056 
aGST v Clus -0.05 -0.21 to 0.11 0.083 0.5581 
aGST v TFF3 0.02 -0.20 to 0.23 0.110 0.8700 
aGST v B2MG 0.00 -0.27 to 0.27 0.140 0.9917 
Clus v TFF3 0.07 -0.12 to 0.25 0.095 0.4843 
Clus v B2MG 0.05 -0.19 to 0.28 0.119 0.6936 
TFF3 v B2MG 0.02 -0.26 to 0.30 0.142 0.8909 
 
Table 2.6. Comparisons of the AUC for each biomarker against that of each of the other 
biomarkers. The table details all pairs of biomarker AUCs compared, the difference in the AUC 
between pair, the 95% confidence interval (CI), the standard error (SE) and the p values. 
Differences were deemed statistically significant when p < 0.05 (*).  Comparisons were made 
using the method described by (DeLong et al. 1988), using Analyse-it Software by Dr Mark Pinches 
(AstraZeneca, UK).  Data were generated from 50 animals per biomarker (where 28 animals 
displayed no proximal tubule necrosis, and 22 animals possessed proximal tubule necrosis as 
determined by histopathological assessment). 
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Correlation of Tissue and Urinary Biomarkers 
For three of the tissue biomarkers investigated (KIM-1, OPN and αGST), urinary biomarker 
data from the same animals has already been published (Pinches et al., 2012).  In order 
to determine whether tissue biomarkers can provide the same information as urinary 
biomarkers when urine samples are not available (such as in retrospective studies), the 
immunohistochemistry tissue biomarker data were correlated with urine biomarker for 
each animal, for all dose groups at day 5 and day 8.  Figure 2.9 shows the relationships 
between the tissue biomarker data and the urinary biomarker data, using the urine 
collection taken on the same day the animals were terminated.  For both KIM-1 and 
osteopontin, the immunohistochemistry biomarker data positively correlated with the 
urinary biomarker data (R2 = 0.883 and 0.560, respectively).  For αGST, there was no 
correlation between the two sets of data.  No urinary data were available to make similar 
correlations for clusterin, TFF3, or β2MG. 
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Figure 2.9.  Correlation of urinary biomarker data with immunohistochemistry data for (A) KIM-1, (B) 
OPN, and (C) αGST following cisplatin-treatment.  Urinary biomarker data represents the values measured 
on the same day (day 5 and day 8) that tissues were taken for immunohistochemistry. Urinary biomarker 
data are normalised to creatinine (Ct) and were generated in a previous study (Pinches et al., 2012).  Red 
circles represent animals treated with 0mg/kg cisplatin, blue circles = 0.1mg/kg cisplatin, green circles = 
1.0mg/kg cisplatin and yellow circles = 2.5mg/kg cisplatin.  Circle size is directly proportional to the severity 
of the pathology, which was graded (by Dr Huw Jones, AstraZeneca, UK) 0-4 for proximal tubule necrosis: 0 
= no necrosis, 1 = minimal, 2 = mild, 3 = moderate, or 4 = severe KIM-1 = kidney injury molecule-1, OPN= 
osteopontin, αGST = alpha-glutathione S-transferase.  N=5, n=5 animals for each time point and dose. 
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2.7 Discussion 
In this study, a cisplatin model of nephrotoxicity was used to examine several renal injury 
biomarkers (KIM-1, osteopontin, αGST, clusterin, TFF3 and β2MG) in rat kidney tissue and 
correlate the expression of these with measurements of the same biomarkers in the urine 
(where possible).  The aim was to determine the utility of tissue biomarkers, which would 
allow biomarker analysis from retrospective studies in the drug discovery process, 
reducing the need for additional animal studies and resource.  Whether the tissue data 
could provide additional information that may complement assessment of nephrotoxicity 
made using urinary biomarkers, and whether these can be used to provide the spatio-
temporal description of the drug-induced damage/regeneration process, was also 
assessed. 
In agreement with other groups (de Borst et al. 2007; Vinken et al. 2012), very low levels 
of KIM-1 immunoreactivity in some control rat kidneys was detected; a finding likely to 
reflect low levels of naturally occurring tubular injury/regeneration.  In animals dosed 
with cisplatin, all animals that exhibited KIM-1 positive immunoreactivity also showed 
histopathological changes.  However, as there was no significant difference in KIM-1 
immunoreactivity in the low dose group, when minimal histopathological changes were 
observed (over no pathology in control animals), it indicates that KIM-1 immunoreactivity 
in tissue was not as sensitive as standard histopathology.  The AUCs from ROC curves 
indicated that KIM-1 was the most predictive of the tissue biomarkers for proximal tubule 
necrosis (the predominant feature of the histopathology); it had had the highest AUC for 
all the tissue biomarkers investigated, and its 95% confidence intervals were above the 
‘no discrimination’ point of 0.5 indicating that it predicts proximal tubule necrosis better 
than chance alone.  Significant differences in group means for tissue KIM-1 were observed 
in the same dose groups that have previously reported significant changes in urinary KIM-
1 (Pinches et al. 2012b).  However, some animals showed increases in urinary KIM-1 in 
the mid-dose cisplatin group, when no increases in tissue KIM-1 were observed.  This 
finding was in line with a previous study that demonstrated occasional increases in 
urinary KIM-1 before nephrotoxic changes were evident by histopathological evaluation 
(Hoffmann et al. 2010).  The authors of this study did not propose that biomarker 
responses preceded the tubule damage, rather that the changes may be associated with 
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a few damaged tubules not evident in the particular histopathological section examined.  
However, in general, a high level of correlation between tissue and urinary KIM-1 was 
observed using a Pearson’s correlation method, suggesting that tissue KIM-1 can be used 
as a predictive biomarker for cisplatin-induced nephrotoxicity, in the absence of urine 
samples. 
Osteopontin expression was restricted to the loop of Henle in control rats, in agreement 
with previous observations (Hudkins et al. 1999; Persy et al. 1999).  Similar to other animal 
models of nephrotoxicity, cisplatin-induced nephrotoxicity induced expression of 
osteopontin in other parts of the kidney (Xie et al. 2001a).  The AUC from the ROC curve 
indicated that osteopontin was also a good predictor of proximal tubule necrosis, as the 
95% confidence interval for OPN fell above the ‘no discrimination’ point of 0.5.  
Furthermore, there was a good correlation between urinary osteopontin levels and 
kidney tissue expression, but as with KIM-1, it was the standard histopathology that 
indicated the earliest signs of nephrotoxicity.  Osteopontin is expressed in a variety of 
tissues including bone and many epithelial tissues (L. Brown et al. 1992; Denhardt and 
Guo 1993), and is also normally detectable in urine (Hedgepeth et al. 2001).  Whilst non-
renal sources of intact osteopontin would be too large to be filtered at the glomerulus, it 
is possible that osteopontin fragments from non-renal sources may become detectable 
in urine.  Therefore parallel detection of osteopontin in both kidney and urine offers the 
advantage of confirming that any urinary changes seen are as a consequence of changes 
occurring in the tissue. 
Clusterin expression was not detectable in control rat kidneys but expression within the 
proximal tubules became evident following treatment with cisplatin, consistent with 
previous reports (Ishii et al. 2007; Silkensen et al. 1997).  Whilst the ROC curves for 
clusterin showed some discrimination for predicting proximal tubule necrosis, the AUC 
was less than that for KIM-1 or osteopontin.  The 95% confidence interval for the clusterin 
was however, above the ‘no discrimination’ point of 0.5 suggesting that it does have 
utility for predicting proximal tubule necrosis. 
In accordance with its role as a cytosolic protein in proximal tubule cells (Bauchet et al. 
2011; Branten et al. 2000; Searchfield et al. 2011), αGST immunoreactivity was observed 
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throughout the proximal tubule in control rat kidney.  αGST was significantly decreased 
in mid- and high-dose animals five days after cisplatin treatment but, by eight days, there 
was only a significant decrease with the high dose group.  The AUC from the ROC curve 
for αGST suggested that this biomarker was not as good as other biomarkers at predicting 
proximal tubule necrosis as its 95% confidence interval crossed the 0.5 ‘no discrimination’ 
point.  There was also poor correlation between the tissue and urinary αGST 
measurements.  Studies with other nephrotoxins looking at urinary αGST have also shown 
a poor correlation between proximal tubule necrosis and αGST (Kharasch et al. 1998; 
Prozialeck et al. 2009).  Despite these findings, tissue and urinary αGST measurements 
have been shown to outperform serum creatinine as a biomarker for cisplatin induced 
nephrotoxicity (Pinches et al. 2012b).  
TFF3 expression was detected in S3 proximal tubules in the OSOM, tubules in the ISOM 
and inner medulla, consistent with in situ hybridisation studies for mRNA in rats (Yu et al. 
2010).  Its expression was however more widespread than that shown by histochemistry 
using a trefoil peptide motif in a beta-galactosidase fusion protein, where expression was 
restricted to the collecting ducts of rat kidney (Chinery et al. 1993).  This observation may 
reflect the different sensitivity of the techniques used.  The AUC from the ROC curve 
showed that TFF3 was able to detect proximal tubule damage but was not as good as 
other biomarkers, as its 95% confidence interval crossed the ‘no discrimination’ point of 
0.5.  A decrease in TFF3 immunoreactivity was observed in cisplatin-treated kidneys, 
similar to that observed with other nephrotoxins, and is most likely a result of a gene 
regulatory response to tubular toxicity (Yu et al. 2010).  In this study, TFF3 was the only 
biomarker to show significant change following low dose cisplatin at eight days.  This 
suggests that kidney levels of TFF3 may be useful in detecting low levels of chronic (long-
term) kidney damage and it would be interesting to study this further.  TFF3 is also highly 
expressed in the gastrointestinal tract (Chinery et al. 1993; Suemori et al. 1991) and is 
small enough to be filtered at the glomerulus.  Therefore immunohistochemistry may be 
useful in confirming that changes in urinary TFF3 originate from the kidney.  
β2MG was expressed in the S1 segment of the proximal tubules in control rats but is 
expressed throughout the body and is freely filtered at the glomerulus.  Following 
filtration it is almost completely reabsorbed so under normal conditions it is not present 
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in the urine.  However, both glomerular and tubular toxicity have been shown to impair 
this process resulting in increases of up to several hundred fold in urine.  Consistent with 
this finding, no changes in β2MG by immunohistochemistry were observed except 8 days 
after a high dose of cisplatin.  This is probably the result of extensive necrosis and 
associated loss of protein from the tubules.  The AUC from the ROC curve reflects this; 
there is some association with proximal tubule necrosis but the sensitivity and specificity 
of this biomarker is less than other biomarkers investigated.  The 95% confidence interval 
for β2MG also crossed the ‘no discrimination’ point of 0.5.  Whilst urinary β2MG appears 
to show utility as a biomarker of nephrotoxicity, tissue β2MG is less sensitive and 
therefore should not be used for measurements in the absence of urine samples.  
One of the key features of novel biomarkers is that they identify injury before changes in 
histopathology are seen.  In this preclinical, retrospective study, the earliest samples 
available were obtained 5 days post cisplatin treatment, a time point when 
histopathological changes were clearly visible.  Repeating the experiment to include 
earlier time points (e.g. days 1 – 5) or even earlier (e.g. 12 hours) would be useful in 
assessing the ability of the biomarkers to indicate injury before changes in histopathology 
are seen.  Although this is important for drug discovery, it is especially important in the 
clinic where urinary biomarkers that can be identified in the urine before 
histopathological injury occurs enables clinicians to intervene (e.g. by lowering drug dose 
or using a different drug) and reduce the likelihood of AKI progression.  A further 
limitation of this study was the sample size.  A larger sample size might enable statistically 
significant differences between the performance of different biomarkers (as determined 
by the AUC from ROC curves) to become apparent. 
In any case, future studies are also needed to determine the wider application of these 
biomarkers for detecting renal toxicity following the administration of other 
nephrotoxicants.  In addition, their utility as broad-spectrum biomarkers of 
nephrotoxicity, biomarkers of nephrotoxicity specific to certain tubules or certain classes 
of drugs, or indeed biomarkers of other types of renal injury, needs addressing.  Many 
other novel protein biomarkers of acute kidney injury exist (aquaporin-2, neutrophil 
gelatinase-associated lipocalin (NGAL), cystatin C, Fetuin A and liver-type fatty acid 
binding protein (LFABP) (Vaidya et al. 2008)) and could also be investigated. 
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In summary, this study investigated changes in tissue biomarkers of kidney injury in a 
cisplatin-treated rat model.  The biomarkers investigated were KIM-1, osteopontin, αGST, 
clusterin, TFF3 and β2MG.  Out of the biomarkers investigated, KIM-1 and osteopontin 
were most predictive of proximal tubule necrosis (as determined AUC ROC analysis) and 
showed correlation with their corresponding urinary biomarkers.  As such, KIM-1 and 
osteopontin offer greater utility as tissue biomarkers in retrospective studies when urine 
samples are not available. 
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CHAPTER 3 
Characterisation of In Vitro and Ex Vivo Models as Tools for 
Studying Drug-Induced Nephrotoxicity 
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3.1 Abstract 
The kidney is a major organ of drug-induced toxicity.  Lack of translational preclinical 
models for predicting nephrotoxicity specifically in humans means that it is often 
detected at late stages of drug development, with significant delays in delivering safe 
drugs to the market.  The availability of better rodent models for use in parallel with 
human models would improve translational drug safety assessment. In this study, two 
models were selected for characterisation as potential tools to meet this need; ex vivo 
kidney slices and in vitro primary renal cells. 
Ex vivo rat kidney slice viability (determined by ATP content) was significantly reduced 
after 24 hours in culture under control conditions compared to the that immediately 
following slicing (1.04±0.07 vs 0.57±0.05 nmoles ATP/mg wet weight respectively 
(mean±SEM; p < 0.01 **; N=3, n=3)).  In addition, histopathological changes indicative of 
loss of cell viability (nuclear condensation, loss of proximal tubule brush border 
membranes, cell sloughing into the tubule lumen) were observed in control slices after 1 
and 24 hours in culture (N=3, n=3).  Together, these data suggest that kidney slices are a 
valuable model only for acute studies.  Future optimisation studies aim to improve slice 
viability in order to fully assess this model. 
In contrast, in vitro primary mouse cells exhibited high viability (determined by high 
proliferation (N=3, n=3) and low apoptosis (N=3, n=3)) for up to 15 days in culture.  After 
8 days in culture, cells displayed a concentration-dependent increase in apoptosis in 
response to 24-hour treatment with medium containing the known nephrotoxins 
cisplatin (1, 3, 5µM), cyclosporin A (1, 3, 5µM) and BEA (3, 10, 30µM), compared to cells 
treated with control medium (N=3, n=3).  In addition, cells exhibited concentration-
dependent loss of cell adhesion to the tissue culture plate in response to treatment with 
cisplatin (1, 3, 10µM), cyclosporin A (1, 3, 10µM) and BEA (1, 3, 30µM) (N=3, n=3).  When 
compared to time-matched control cells, 24-hour treatment with medium containing 
10µM cisplatin, 10µM cyclosporin A and 30µM BEA induced the expression of the kidney 
injury biomarkers, kidney-injury molecule-1 (KIM-1) and osteopontin, but not that of 
clusterin (N=3, n=3).  Compared to control cells of which 3.24 ± 0.05% were KIM-1 
positive, treatment with cisplatin,  cyclosporin A and BEA increased the number of KIM-1 
positive cells to 79.21 ± 5.68% (p < 0.001 ***), 44.02 ± 5.73% (p < 0.001 ***) and 48.83 ± 
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4.89 (p < 0.001 ***), respectively.  Compared to control cells of which 13.82 ± 2.28% were 
osteopontin-positive, treatment with cisplatin,  cyclosporin A and BEA increased the 
number of osteopontin-positive cells to 71.91 ± 8.23% (p < 0.001 ***), 41.76 ± 1.92% (p 
< 0.001 ***) and 35.14 ± 2.47% (p < 0.01 **), respectively (results expressed as mean±SD 
and significance determined by one-way ANOVA and post-hoc Tukey test). 
Primary human renal cells also exhibited high viability (high proliferation/low apoptosis) 
for up to 15 days in culture (N=3, n=3 for both).  After 8 days in culture, 24-hour treatment 
with medium containing 25µM cisplatin induced expression of KIM-1, osteopontin and 
clusterin when compared to cells treated with control medium (N=1, n=1). Exposure to 
cisplatin increased the expression of all tested biomarkers, from 0% to 98% (KIM-1), from 
57% to 95% (osteopontin) and from 4% to 41% (clusterin).  
Differences in the expression of clusterin in response to nephrotoxin-treatment in human 
and mouse models not only highlight species differences, but reinforces the idea that use 
human models would not only improve studies of drug-induced toxicity specifically in 
humans, but when used alongside rodent models, would revolutionise preclinical, 
translational drug safety assessment.  
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3.2 Introduction 
Nephrotoxicity 
Drug toxicity is a leading cause of drug attrition from the development pipeline (Liebler 
and Guengerich 2005).  An essential part of preclinical development is having appropriate 
models to predict the safety of a novel compound before administration to humans.  A 
number of different preclinical animal models including rat, dog and monkey, are used to 
do this (Martignoni et al. 2006).  Although very valuable, differences in drug handling 
between species means that toxicity in animals does not reliably predict toxicity in 
humans, nor safety in animals reliably predict safety in humans.  This is evidenced by the 
fact that nephrotoxicity accounts for only 2% of all drug failures during preclinical studies 
but jumps to 19% of all failures in Phase III clinical studies (Redfern et al. 2010).  In fact, 
results from the International Life Sciences Institute (ILSI) workshop, which set out to 
better understand the concordance of drug toxicity in humans with that of preclinical 
species, revealed that in vivo rat studies correctly predict toxicity in humans only 43% of 
the time (Olson et al. 2000).  Improving translational (animal to human) safety assessment 
by reducing the rate of false positives and false negatives will respectively prevent drugs 
that are toxic to humans, but not animals reaching clinical trials, and drugs that are safe 
in humans but not animals, being mistakenly dropped from development.  As such, to 
improve safety assessment and bridge-the-translational-gap, human models need to be 
used alongside animal models.   
Assessing Nephrotoxicity Using Conventional In Vitro Cell Models 
Currently, there are a number of different in vitro renal cell models that could potentially 
be used for regulatory toxicology studies during preclinical drug development for 
predicting toxicity in humans.  However, most are inherently limited for use for this 
application. 
With regard to the species from which the cells are derived, cell lines such as Madin Darby 
Canine Kidney cells (MDCK; (Ludwig et al. 2004)), Opossum Kidney cells (OK; (Y. Kim et al. 
2005)), Lilly Laboratories Cell-Porcine Kidney-1 cells (LLC-PK1; (Pingle et al. 2004)) and 
Normal Rat Kidney Epithelial cells (NRK-52E; (Rached et al. 2008)), all of which have 
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previously been used for studying drug-induced toxicity, are of animal origin, and as such, 
are not acceptable models for human studies simply due to the fact they are not human. 
With regard to cell lines derived from humans, a number exist, but their utility is 
somewhat limited.  Human Embryonic Kidney (HEK)293 cells, for example, possess the 
neuronal markers neurofilament-M and neurofilament-L (NF-M and NF-L) and α-
internexin (Shaw et al. 2002), and are actually believed to have derived form a neuronal 
population that were amongst the renal cells when targeted for immortalisation (Shaw et 
al. 2002; Tiong et al. 2014).  Their lack of real renal epithelial cell phenotype instantly 
renders them of little use during preclinical drug nephrotoxicity studies.   
Human Kidney (HK)2 is a human papilloma virus (HPV)-immortalised cell line derived from 
adult proximal tubule cells.  It expresses a variety of proximal tubule brush border 
membrane enzymes including acid and alkaline phosphatases (ALP), gamma 
glutamyltranspeptidase (GGT) and leucine aminopeptidase (LAP) (Ryan et al. 1994), as 
well as the proximal tubule drug transporters monocarboxylate transporter 1 (MCT1) and 
organic anion transporter polypeptide 4C1 (OATP4C1) (Jenkinson et al. 2012).  However, 
HK2 cells do not express other key drug transporters including organic anion uptake 
transporters 1 and 3 (OAT1 and OAT3), organic cation uptake transporter 2 (OCT2) 
(Jenkinson et al. 2012; Tiong et al. 2014).  If used in preclinical drug safety assessment, 
the lack of such transporters may result in a potentially nephrotoxic compound not being 
taken up by the cells and its nephrotoxicity not being seen.  Indeed, these results indicate 
that HK2 cells do not fully recapitulate all the features of proximal tubule cells in vivo and 
as such are not a good model for studying nephrotoxicity in vitro.  This is exemplified by 
a recent study in which treatment with the nephrotoxin cisplatin induced apoptosis and 
expression of the known injury biomarker KIM-1 (both features of cisplatin toxicity), but 
not the expression of clusterin (another known biomarker of cisplatin toxicity) (Sohn et 
al. 2013).  Even more recently, HK2 cells have also been used to identify novel biomarkers 
of cisplatin-induced renal injury (pyruvate kinase M1/M2 isoform M2 (PKM2) and 
eukaryotic translation elongation factor 1 gamma (EF-1γ)) (S. Kim et al. 2014), but again, 
results like this must be interpreted with caution. 
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Conditionally immortalised proximal tubule epithelial cell (ciPTEC) lines have been 
developed and characterised in terms of functional influx and efflux transporters from 
both human kidney tissue and proximal tubules cells present in urine (Jansen et al. 2014; 
Wilmer et al. 2010).   ciPTEC isolated from exfoliated renal cells present in mid-stream 
urine, cells underwent immortalisation with the temperature-sensitive mutant U19tsA58 
of SV40 large T antigen (SV40T) and the catalytic subunit of human telomerase (hTERT).  
Cells proliferate at the permissive temperature of 33°C under the control of SV40T, while 
at 37°C, SV40T expression decreases to minimise the effect of transfection on cellular 
functions.  At this point, cells exhibit proximal tubule cell morphology (presence of 
microvilli), functional NaPi IIa, OCT2 and MDR1, and expression of MRP4.  Although 
further characterisation in terms of protein expression and function are needed, ciPTECs 
are the most promising immortalised renal cell model for use in nephrotoxicity studies, 
an application already being explored as part of the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs) CRACK-IT Nephrotube 
Challenge (https://www.crackit.org.uk/challenge-15-nephrotube).  The major limitation 
of using these ciPTECs from urine, however, is that although they are collected from 
healthy volunteers, only 10% of urine samples contain viable primary cells for subsequent 
immortalisation (Wilmer et al. 2010).  The authors state that whilst obtaining cells from 
urine is not ideal (it can be argued that cell damage could have led to their detachment 
from the basement membrane and subsequent sloughing into the urine), it is useful 
source of human material for in vitro research, especially in circumstances when 
obtaining tissue is not possible (i.e. invasive biopsy versus non-invasive collection of cells 
from urine). 
In addition to the aforementioned immortal and conditionally immortal cell lines, stem 
cell-derived proximal tubule-like cells (PTLC) have been generated and undergone initial 
characterisation as a tool for identifying nephrotoxic compounds in vitro  (Y. Li et al. 2014).  
Drug-induced kidney injury (DIKI) is associated with increased pro-inflammatory 
cytokines; cisplatin-induced AKI, for example, is associated with increased interleukin (IL)-
1β, IL-6 and IL-18 (Faubel et al. 2007).  Using stem cell-derived PTLC, Li et al., (2014) 
showed the combination of IL-6 and IL-8 as a readout to be highly predictive of DIKI injury 
(as determined by an area under a receiver operating characteristic curve of 0.80).  
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Although promising, such results must interpreted with caution because the stem cell-
derived PTLC used in the study do not express key drug transporters at the same level as 
the primary human proximal tubule cells also assessed in the study;  they express OAT2 
and OAT3, proton-coupled peptide transporter (PCPT) and MDR1 in at least 3-fold less 
quantities than the primary human proximal tubule cells used (Y. Li et al. 2014), which 
may affect drug uptake and subsequent intracellular events. 
An alternative to the use of cell lines is the use of primary cells.  Although primary cells 
are more difficult to culture and are inherently associated with a degree inter-donor 
variability, they do offer a more physiologically relevant model.  In this respect, primary 
cultures of proximal tubule cells, and co-cultures of proximal and distal tubule cells, have 
already undergone extensive characterisation as a models for drug transport studies (C. 
Brown et al. 2008; Verhulst et al. 2008) and studies of mineral ion homeostasis (see 
Chapter 1 of this thesis).  When grown on semi-permeable filter supports (transwells), 
primary cells maintain apical-basolateral polarity as well as expression of endogenous 
plasma membrane drug transporters at the mRNA, protein and functional level for up to 
10 days (C. Brown et al. 2008).  Figure 3.1 highlights the expression of a range of drug 
transporters present on in vitro proximal tubule cell membranes at the mRNA, protein 
and functional level, compared to the same transporters found in vivo. 
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Figure 3.1.  Expression of proximal tubule cell drug transporters in vitro.  All transporters 
are expressed on human proximal tubule cell membranes in vivo.  Image created from 
data published by (C. Brown et al. 2008). The same transporters were identified on 
primary human proximal tubule cell membranes in vitro in terms of mRNA expression (R), 
protein expression (P), and/or functional expression (F).  ATP-binding cassette (ABC) 
transporters multidrug resistance protein 1 (MDR1), multidrug resistance protein 2 
(MRP2) and breast cancer resistance protein (BCRP) appear in red, organic anion 
transporters (OAT) OAT1, OAT3 and OAT4 appear in green, and organic cation 
transporters (OCT) OCT2 and OCTN2 appear in blue.  Figure created from data published 
by (C. Brown et al. 2008). 
 
The above cell model (aProximateTM) is commercially available under contract service 
from Newcastle University/SOLVO Biotechnology.  One of the major advantages of this 
model over other primary proximal tubule cell models, such that from the contract 
research organisation (CRO) Fluofarma, is that the cells are cultured immediately after 
isolation; they are never frozen.  Maintenance of drug transporter expression makes the 
aProximateTM cell model a powerful tool for studying renal drug handing, drug-
transporter interactions as well as drug-induced nephrotoxicity. 
Whilst primary cultures offer greater utility than other discussed in vitro cell culture 
models currently available, like all in vitro cell culture models, they do not possess the 3D 
architecture of the in vivo tissue or organ of interest.  The kidney is a complex organ made 
up of many different types of cells and cell-cell and cell-matrix interactions, all of which 
are important for maintaining correct cell phenotype and function (Astashkina et al. 
2012). 
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Loss of Cell Adhesion as a Drug-Induced Effect 
Roughly 6 X 104 cells are shed into the urine from the entire urinary tract system in healthy 
male, human, adults every 24 hours, and out of this total number, roughly 13% are viable 
living as determined by Trypan blue exclusion (Lang et al. 2013).  The viable cell 
component of urine has been used in the development of conditionally immortalised 
human proximal tubule epithelial cells (ciPTEC) (Jansen et al. 2014; Wilmer et al. 2010) 
from healthy volunteers, primary human proximal tubule cells from healthy volunteers 
(Rahmoune et al. 2005), as well as well as urine-derived stem cells from healthy 
volunteers (Lang et al. 2013).  This non-invasive method of isolating renal cells is 
particularly useful when biopsies of human kidney tissue (from which one could also 
isolate renal cells) is not possible (Rahmoune et al. 2005).  The reason as to why viable 
renal cells might be present in the in urine is unclear but, it has been proposed to be the 
result of sublethal cell injury resulting in loss of cell adhesion from the basement 
membrane, causing the subsequent detachment into the tubular lumen (Prozialeck et al. 
2007).  The fact that viable cells are shed into the urine in healthy volunteers does, 
however, indicate that it is a normal in vivo physiological phenomenon. 
In response to treatment with nephrotoxic drugs, there is an increase in renal epithelial 
cell detachment from the basement membrane (cell sloughing).  The sloughing of cells 
into the tubular lumen is a well-documented in vivo phenomenon of treatment with, for 
example, the known nephrotoxin, cisplatin (Aleksunes et al. 2008; Huang et al. 2001; 
Wadey et al. 2013).  Remaining epithelial cells repopulate denuded basement 
membranes enabling subsequent tubular regeneration i.e. reformation of the tubular 
epithelial barrier (Prozialeck et al. 2007). 
Akin to the sloughing of renal cells from the basement membrane in vivo, cells grown in 
vitro display a similar detachment phenomenon from the tissue culture plate in response 
to treatment with nephrotoxins.  In response to treatment with cisplatin, in vitro primary 
cultures of porcine proximal tubule cells have been shown to detach from the tissue 
culture substrate (collagen-coated coverslips) and subsequently float in the tissue culture 
medium (Kruidering et al. 1998).  The authors of this paper quantified the number of 
detached cells as a percentage of the total cells i.e. the sum of the floating and attached 
cells.  They propose that sublethal concentrations of cisplatin can induce cytoskeletal 
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changes which thereby affect cell adhesion and induce cell detachment.  Cell detachment 
from the tissue culture substrate in response to cisplatin-treatment has also been shown 
by other groups (Del Bello et al. 2001; Mueller et al. 2003), in addition to other 
nephrotoxins including cyclosporin A (Slattery et al. 2005). 
Assessing Nephrotoxicity Using Other Culture Methods 
As kidney injury is one of the most frequent adverse events reported during drug 
development (Jang et al. 2013), there is great interest in models that closely recapitulate 
the microenvironment and/or structure of the kidney in vivo, thereby inducing a more in 
vivo-like phenotype, in order to guide drug development and improve the rate of late 
stage drug attrition.  As such, alternative models to standard 2D culture models are under 
development. 
Microfluidic Kidney Models 
Microfluidics is a form of cell culture involving the flow (rather than the conventional 
static presence) of medium over cells in culture (Mehling and Tay 2014).  In recent years, 
the use of in vitro microfluidic cell culture has become more popular owing largely to 
recognition of the fact that more physiologically relevant results can be obtained when in 
vivo cellular microenvironments are more accurately modelled. 
In 2013, a paper was published detailing the characterisation of a microfluidic human 
primary proximal tubule on-a-chip model (Jang et al. 2013).  Cultured on extracellular 
matrix-coated semi-permeable filter supports (transwells) to enhance cell polarity, 
primary proximal tubule cells were subjected to microfluidic apical sheer stress mimicking 
the in vivo luminal flow of filtrate through the nephron.  Cells were shown to exhibit 
morphological features (apical-basolateral cell polarity and brush border membranes) 
and functional responses (alkaline phosphatase activity, glucose uptake and MDR1-
mediated calcein-acetoxymethyl-ester (calcein-AM) extrusion) typical of proximal tubule 
cells in vivo.  Highlighting the benefit of using a microfluidic model, enhanced cell recovery 
from cisplatin-induced injury (as determined by the number of viable cells remaining 
attached to transwells 4 days after cisplatin treatment) was observed in comparison to 
the same cells cultured in the same conditions but without apical sheer stress. 
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Bioengineered 3D Human Kidney Tissue 
In 2013, DesRochers et al. described the development and characterisation of a 
bioengineered 3D human kidney tissue model for nephrotoxicity studies (DesRochers et 
al. 2013).  Human kidney epithelial cells were isolated from patients, immortalised by 
serial passaging with hTERT-enriched culture medium, and identified to be of proximal 
tubule cell origin as a result of a number of different functional tests (PTH-induced 
increase in cAMP, γ-glutamyl transpeptidase (GGT) activity and sodium-dependent 
glucose uptake).  When cultured in a 1:1 mix of Matrigel and rat tail collagen type-1 in 12-
well semi-permeable transwells, 3D cell constructs (interconnected tubules) were 
identified after 2 weeks.  Levels of the biomarkers kidney injury molecule-1 (KIM-1) and 
neutrophil gelatinase-associated lipocalin (NGAL) were then assessed in response to 
treatment with the nephrotoxins cisplatin, gentamicin and doxorubicin.  In response to 
cisplatin, expression of both KIM-1 and NGAL were increased compared to control, akin 
to the in vivo response to cisplatin (Gaspari et al. 2010; Vaidya et al. 2010).  However, 
although in contrast to well-documented effects in vivo (Kai et al. 2013; Vaidya et al. 2010; 
Zhang et al. 2008; Y. Zhou et al. 2008), gentamycin and doxorubicin both failed to increase 
levels of KIM-1 and NGAL above that of control.  As such, although this model does appear 
to better recapitulate the in vivo 3D structure of the proximal tubule, it is limited by the 
fact it is based on the use of immortalized cells which do not always fully recapitulate the 
full functionality of renal cells in vivo.  Further optimisation is required to validate it in 
terms of its true capacity as a useful tool for studying drug-induced nephrotoxicity, and 
predicting drug-induced toxicity in humans. 
Kidney Slice Models 
Precision-cut tissue slices have been used to study wide range of soft organs including 
lung (Bourke et al. 2005), liver and intestine (de Graaf et al. 2010), brain (Loryan et al. 
2013) and kidney (Crawford et al. 2012; Peppiatt-Wildman et al. 2012) in an ex vivo set-
up.  The main advantage of using tissue slices for studying organ function is that the 3D 
structure of the organ is preserved, which by supporting the correct cell-cell and cell-
matrix interactions, is likely to enable more physiologically relevant interactions between 
cells to occur (Vickers and Fisher 2004).  As such, precision-cut ex vivo kidney tissue slices 
have previously been used for a wide range of studies including those relating to vasa 
recta properties and function (Crawford et al. 2012), intracellular calcium signalling 
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(Peppiatt-Wildman et al. 2012) and studying mechanisms of drug toxicity (Vickers et al. 
2004). 
Cisplatin, Cyclosporin A and BEA 
The proximal tubule is of particular interest for studies of nephrotoxicity because active 
clearance, reabsorption, intracellular concentration and local interstitial accumulation of 
drugs occurs primarily in this region of the kidney (Jang et al. 2013).  However, owing to 
the expression different transporters, metabolic characteristics and oxygen tensions 
within the kidney, segment-specific sensitivity to drugs is displayed (Bonventre et al. 
2010).  Three drugs used experimentally to induce segment-specific nephrotoxicity are 
cisplatin (a proximal tubule nephrotoxin), cyclosporin A (a distal tubule nephrotoxin) and 
2-bromoethylamine hydrobromide (BEA) (a collecting duct nephrotoxin). 
Cisplatin 
Cisplatin is a clinically used anti-cancer drug with a notorious dose-limiting nephrotoxicity 
(Blanchard 2012).  However, it has been used for inducing renal injury in rodents in order 
to investigate biomarkers of drug-induced acute kidney injury (Pinches et al. 2012b).  Its 
kidney-specific toxicity is thought to arise from its uptake in to the cytoplasm of proximal 
tubule cells via the organic cation transporter 2 (OCT2) and copper transporter 1 (CTR1) 
(Ciarimboli et al. 2005; Ishida et al. 2002), and its subsequent biotransformation into a 
more toxic metabolite (Townsend et al. 2003).  Experimentally, cisplatin has been used in 
vitro at 25-50µM in primary mouse proximal tubule cells (Cilenti et al. 2005), 50-500µM 
in primary porcine renal cells (Kruidering et al. 1997), 100µM in primary human renal cells 
(Jang et al. 2013), and in ex vivo tissue slices as 40-100µM (rat) and 80-500µM (human) 
(Vickers et al. 2004).  It has also been used in other cell types at 1-20µM (Arantes-
Rodrigues et al. 2013). 
Cyclosporin A  
Cyclosporin A is a clinically used immunosuppressant used to prevent organ transplant 
rejection but is associated with a dose-limiting nephrotoxic side effect (Busauschina et al. 
2004).  It is thought to induce ischemic renal injury as a result of afferent arteriole 
vasoconstriction (Busauschina et al. 2004), in addition to inducing tubular acidosis by 
inhibiting the distal tubule H+ pump (Tsuruoka et al. 2003).  Experimentally, it has been 
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used in vitro at 5µM in HEK 293 cells (Lamoureux et al. 2012), and in LLC-PK1 cells at 
concentrations of up to 42µM (Lally et al. 1999) and 83µM (Healy et al. 1998). 
2-bromoethylamine hydrobromide 
2-bromoethylamine hydrobromide (BEA) is a collecting duct nephrotoxin that induces 
renal papillary necrosis (RPN) in a dose-dependent manner (Bach et al. 1983).  Although 
not used clinically, it is a good tool for inducing RPN in animal models in order to mimic 
the type of injury induced by analgesics such as aspirin, and non-steroidal anti-
inflammatory drugs such as ibuprofen, in humans (Atta and Whelton 1997; Brix 2002).  It 
is used experimentally in rodents to induce RPN rather than aspirin or ibuprofen itself, as 
it can induce injury within 24 hours of a single dose (Powell et al. 1991).  It has been used 
studying novel biomarkers of nephrotoxicity in in vivo models (Hildebrand et al. 1999; S. 
A. Price et al. 2010). 
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3.3 Project Overview 
The kidney is a major organ of drug-induced toxicity.  Lack of relevant preclinical models 
for predicting nephrotoxicity specifically in humans means that it is often detected at late 
stages of drug development.  This is evidenced by the fact that nephrotoxicity accounts 
for only 2% of all drug failures during preclinical animal studies but jumps to 19% of all 
failures in Phase III clinical human studies (Redfern et al. 2010).  Characterisation of ex 
vivo/in vitro rodent models for use alongside ex vivo/in vitro human models would 
improve translational drug safety assessment; such models would reduce the risk of drugs 
that are toxic to humans but not animals (false negatives) reaching clinical trials, and 
drugs that are safe in humans but not animals (false positives) being mistakenly dropped 
from development. 
Precision-cut slices of kidney tissue are a physiologically relevant ex vivo model owing to 
the maintenance of correct cell-cell and cell-matrix interactions; they represent a model 
possessing the 3-dimentional cellular complexity of the kidney in vivo.  Ex vivo kidney 
slices have been previously explored as a tool for studying mechanisms of drug-induced 
kidney injury (Vickers et al. 2004).  However, little information regarding changes in ex 
vivo kidney slice injury biomarker expression profiles following treatment with known 
nephrotoxins is available. 
In terms of conventional in vitro models, primary cultures of renal cells are the most 
physiologically relevant.  In vitro primary cultures of human renal cells have been shown 
to possess the full complement and expression level of drug transporters in vivo (C. Brown 
et al. 2008).  However, there is little information regarding the ability of in vitro primary 
renal cells to respond to treatment with known nephrotoxins with changes in kidney 
injury biomarker expression. 
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3.4 Aims 
The aims of this study were: 
1. To characterise an ex vivo rat kidney slice model as a tool for studying drug-
induced nephrotoxicity.  The specific aims were: 
a. Assess slice viability over time using an ATP-content assay and by 
histomorphology. 
b. Assess slice viability over time in response to treatment with medium 
containing the known nephrotoxins cisplatin, cyclosporin A and BEA using an 
ATP-content assay. 
c. Assess changes in kidney injury biomarker expression following treatment 
with the known nephrotoxins cisplatin, cyclosporin A and BEA.  
 
2. To characterise an in vitro primary mouse renal cell model as a tool for studying 
drug-induced nephrotoxicity.  The specific aims were: 
a. Assess cell viability under control conditions over time in culture using 
proliferation and apoptosis assays. 
b. Assess concentration-dependent drug-induced apoptosis following treatment 
with medium containing cisplatin, cyclosporin A and BEA. 
c. Assess concentration-dependent cell detachment from the tissue culture plate 
following treatment with medium containing cisplatin, cyclosporin A and BEA. 
d. Assess changes in kidney injury biomarker (KIM-1, osteopontin and clusterin) 
expression following treatment medium containing cisplatin, cyclosporin A 
and BEA. 
 
3. To characterise an in vitro primary human renal cell model as a tool for studying 
drug-induced nephrotoxicity.  The specific aims were: 
a. Assess changes in kidney injury biomarker (KIM-1, osteopontin and clusterin) 
expression following treatment with medium containing cisplatin. 
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3.5 Materials and Methods 
Mouse Kidney Cell Culture   
One- to 3-month-old male C57Bl/6 mice were killed by schedule 1 cervical dislocation 
following UK Home Office approval and carried out in accordance with the Animals 
(Scientific Procedures) Act 1986.  All metallic tools used were sterilised by autoclaving 
prior to use.  Using scissors, sprung scissors and tweezers, kidneys were excised from mice 
and placed in 4°C 1X phosphate-buffered saline, pH 7.4 (PBS; Invitrogen, 10010-015) in a 
35mm tissue culture-treated polypropylene plate (Falcon®, 353001).  Kidneys were 
placed in 1X PBS (Invitrogen, 10010-015) to wash away any blood.  Furthermore under 
sterile conditions in a laminar flow hood, fatty tissue surrounding the kidneys was 
removed using tweezers and sprung scissors.  Next, the kidneys were decapsulated and 
transferred to another 35mm tissue culture-treated polypropylene plate (Falcon®, 
353001) containing 1X PBS pH7.4 (Invitrogen, 10010-015) at 4°C for a second wash.  Using 
tweezers to hold the kidneys still, a disposable sterile scalpel (Swann-Morton; 0501) was 
used to separate kidney cortical tissue from the rest of the kidney.  Cortical tissue pieces 
were transferred to another 35mm tissue culture-treated polypropylene plate (Falcon®, 
353001), where they were minced into a paste in 200µl 1X PBS pH 7.4 (Invitrogen, 10010-
015) at 4°C.  The resultant tissue paste was divided in half and using a sterile pipette tip 
with the top cut off, each half was placed in one of two 50ml polypropylene, conical 
bottom, tubes (Corning®, 430829) containing 37.5ml isolation medium (RMPI 1640 
medium with L-glutamine (VWR; 733-1708) supplemented with 5% FBS (GE Healthcare, 
UK), 2% Pen/Strep (Invitrogen; 15140-122) and 0.67mg/ml collagenase type-IV 
(Worthington, LS004188)).  (See method of collagenase type-IV preparation below).  The 
two tubes were left at 4°C until the next day.  Gentle agitation of the suspension inside 
the tubes to prevent settling of the tissue was achieved during this time using a cyclic 
rotator (VWR; 444-0502).  Upon warming to 37°C for 15 minutes in a water bath the next 
day, tissue suspensions were vigorously agitated at 200 rotations/minute in a shaking 
incubator (Jencons-PLS, Orbital incubator and shaker, 5150) for 2 hours at 37°C to 
enzymatically and mechanically dissociate the cells into a single cell suspension.  To 
remove any remaining undigested tissue, the cell suspensions were filtered through a 
40μm pore nylon strainer (BD Biosciences, UK; 352340) in to fresh 50ml tubes 
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polypropylene, conical bottom, tubes (Corning®, 430829).  To remove the collagenase 
and end the enzymatic digestion, cells were centrifuged twice at 150g for 7 minutes and 
each time re-suspended in fresh isolation medium (minus the collagenase).  The first time 
cells were re-suspended in 50ml isolation medium, and the second time, in 5ml isolation 
medium.  Cell suspensions were then loaded on top of discontinuous Percoll (GE 
Healthcare, GZ17089102) gradients made up of 1.04 and 1.07g/ml Percoll in isolation 
medium and 1X PBS, respectively (See Percoll Gradient method below).  Cells were then 
centrifuged at 1200g for 25 minutes in a swing out rotor (Eppendorf; Germany; 5720).  
Cells were aspirated from the intersection of the gradients and centrifuged twice at 150g 
for 7 minutes to remove excess Percoll.  The first time, cells were re-suspended in 50ml 
isolation medium (minus collagenase), and the second time, cells were re-suspended in 
5ml renal epithelial growth medium (REGM; Lonza, CC3191) containing the REGM 
SingleQuot kit supplements and growth factors, fetal calf serum (FCS), amphotericin B, 
epinephrine, human epidermal growth factor, hydrocortisone, insulin, transferrin and 
triiodothyronine (Lonza; CC4127). Rather than adding the gentamycin aliquot of the 
REGM SingleQuot kit supplements, 1% Penicillin (100units/ml)/Streptomycin (100µg/ml) 
(Invitrogen; 15140-122), was added to the culture medium.  Gentamycin is a regularly 
used antibiotic in cell culture.  However, it is also a nephrotoxin and it was thought that 
it may induce cell injury.  As such, a combination of Penicillin/Streptomycin was used.  
Once a bottle of Renal Epithelial Growth Medium containing the desired supplements 
was prepared, it was stored in darkness at 4°C, and used for up to one month. 
For viability (proliferation and apoptosis) and immunocytochemical assays, 100,000 cells 
were plated per 13mm Ø collagen type-IV (Sigma, C5533)-coated borosilicate glass 
coverslips (VWR, 631-0149) that were individually placed inside the wells of a 24-well 
tissue culture-treated plate (ThermoScientific, NunclonTM, 142475).  For drug-induced 
cell-detachment assays, 300,000 cells were plated in 35mm tissue culture-treated 
polypropylene plates (Falcon®, 353001).  Cells were cultured in a humidified, 5% CO2 
incubator at 37°C (SANYO, MCO-18AIC).  After warming to 37°C in a water bath, the cell 
culture medium was replaced on day 4, day 7, day 9 and day 14 of culture. 
The cell culture protocol is based on that published by C. Brown et al., 2008. 
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Human Kidney Cell Culture 
Human kidney tissue was obtained from ethically-consented human kidneys surgically 
resected due to renal cell carcinoma (RCC) (Research Ethics Committee approval 
reference number: 07/WSE04/53).  Within 1 hour of removal, samples of macroscopically 
normal cortical tissue were dissected by a pathologist, and the specimens transported to 
the laboratory in isolation medium (RMPI 1640 medium with L-glutamine (VWR; 733-
1708) containing 5% (v/v) fetal bovine serum (FBS; GE Healthcare, UK), 2% (v/v) Pen/Strep 
(Invitrogen; 15140-122)) at 4°C.  Under sterile conditions in a laminar flow hood, roughly 
1cm3 pieces of freshly dissected cortical tissue were washed in phosphate-buffered saline 
pH 7.4 (PBS; Invitrogen, 10010-015) at 4°C.  All metallic tools used were sterilised by 
autoclaving prior to use.  Using metal tweezers and a disposable scalpel (Swann-Morton; 
0501), cortical tissue was minced into a paste in 200µl 1X PBS pH 7.4 (Invitrogen; 10010-
015) at 4°C.  The resultant tissue paste was roughly divided into quarters.  Using a sterile 
pipette tip with the top cut off, each quarter was placed in one of four 50ml 
polypropylene, conical bottom, tubes (Corning®, 430829) containing 37.5ml isolation 
medium (RMPI 1640 medium with L-glutamine (VWR; 733-1708) supplemented with 5% 
FBS (GE Healthcare, UK), 2% Pen/Strep (Invitrogen; 15140-122) and 0.67mg/ml 
collagenase type-IV (Worthington, LS004188)).  (See method of collagenase type-IV 
preparation below).  The four Falcon tubes were left at 4°C until the next day.  Gentle 
agitation of the suspension inside the tubes to prevent settling of the tissue was achieved 
during this time using a cyclic rotator (VWR; 444-0502).  Upon warming to 37°C for 15 
minutes in a water bath the next day, tissue suspensions were vigorously agitated at 200 
rotations/minute in a shaking incubator (Jencons-PLS, Orbital incubator and shaker, 5150) 
for 2 hours at 37°C to enzymatically and mechanically dissociate the cells into a single cell 
suspension.  To remove any remaining undigested tissue, the cell suspensions were 
filtered through a 40μm pore nylon strainer (BD Biosciences, UK; 352340) in to fresh 50ml 
tubes.  To remove the collagenase and end the enzymatic digestion, cells were 
centrifuged twice at 150g for 7 minutes and each time re-suspended in fresh RMPI 1640 
isolation medium (minus the collagenase).  The first time cells were re-suspended in 50ml 
RMPI 1640 isolation medium, and the second time, in 5ml RMPI 1640 isolation medium.  
Cell suspensions were then loaded on top of discontinuous Percoll (GE Healthcare, 
GZ17089102) gradients made up of 1.04 and 1.07g/ml Percoll in isolation medium and 1X 
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PBS, respectively (See Percoll Gradient method below).  Cells were then centrifuged at 
1200g for 25 minutes in a swing out rotor (Eppendorf; Germany; 5720).  A mixed 
population of proximal and distal tubule cells was aspirated from the intersection of the 
gradients and centrifuged twice at 150g for 7 minutes to remove excess Percoll.  The first 
time, cells were re-suspended in 50ml RMPI 1640 isolation medium (minus collagenase), 
and the second time, cells were re-suspended in 5ml renal epithelial growth medium 
(REGM; Lonza, CC3191) containing the REGM SingleQuot kit supplements and growth 
factors, fetal calf serum (FCS), amphotericin B, epinephrine, human epidermal growth 
factor, hydrocortisone, insulin, transferrin and triiodothyronine (Lonza; CC4127).  Rather 
than adding the gentamycin aliquot of the REGM SingleQuot kit supplements, 1% 
Penicillin (100units/ml)/Streptomycin (100µg/ml) (Invitrogen; 15140-122), was added to 
the culture medium.  Gentamycin is a regularly used antibiotic in cell culture.  However, 
it is also a nephrotoxin and it was thought that it may induce cell injury.  As such a 
combination of Penicillin/Streptomycin was used.  Once a bottle of Renal Epithelial 
Growth Medium containing the desired supplements was prepared, it was stored in 
darkness at 4°C, and used for up to one month. 
For immunocytochemical assays, 100,000 cells were plated per 13mm Ø collagen type-IV 
(Sigma, C5533)-coated borosilicate glass coverslips (VWR, 631-0149) that were 
individually placed inside the wells of a 24-well tissue culture-treated plate 
(ThermoScientific, NunclonTM, 142475).  Cells were cultured in a humidified, 5% CO2 
incubator at 37°C (SANYO, MCO-18AIC).  After warming to 37°C in a water bath, the cell 
culture medium was replaced on day 4 and day 7 (experiments performed at day 8). 
The cell culture protocol is based on that published by C. Brown et al., 2008. 
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Preparation of the Percoll Gradient for Isolating Primary Renal Cells 
The Percoll gradient stock solution and gradients were prepared fresh on day of use under 
sterile conditions in a laminar flow tissue culture hood (BIOQUELL, ABS1200CLS2-MK2).  
For two mouse kidney cortex samples (one animal) two Percoll gradients were prepared.  
For a roughly 1cm3 sample of human kidney cortex, four Percoll gradients were prepared.  
The volumes required in each case is respectively described below.  Into each 50ml 
polypropylene, conical bottom tube (Corning®, 430829), 7ml of the 1.07 density solution 
was added.  With the 50ml tube at a 45° angle, 7ml of the 1.04 density solution was then 
slowly pipetted down the inside of the tube, such that the 1.04 density solution sat on 
top of the 1.07 density solution.  In a similar manner, 5ml of the cell suspension was then 
layered on top of the 1.04 density solution. 
Percoll Stock Solution: 
10X HBSS (Invitrogen; 14065-049)  2ml  (Mouse) 4ml (Human) 
Percoll (GE Healthcare; GZ17089102) 18ml  (Mouse) 36ml (Human) 
Percoll Gradient Density 1.04: 
Percoll Stock Solution    5ml (Mouse) 10ml (Human) 
RMPI 1640 Medium (VWR; 733-1708) 12ml (Mouse) 24ml (Human) 
Percoll Gradient Density 1.07: 
Percoll Stock Solution    10ml (Mouse) 20ml (Human) 
1X PBS (Invitrogen; 10010-015)  8ml (Mouse) 16ml (Human) 
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Preparation of Collagenase Type-IV for Enzymatic Cell Isolation 
The collagenase type-IV for enzymatic cell digestion was prepared under sterile 
conditions in a laminar flow tissue culture hood (BIOQUELL, ABS1200CLS2-MK2).  25ml of 
RMPI 1640 isolation medium (Lonza, BE12-702F) was added to a 2.5g pot of collagenase 
type-IV (Worthington, LS004188) powder and repeatedly pipetted up and down to fully 
suspend to powder into a 100mg/ml stock solution.   The stock solution was filter-
sterilised though a 0.20µm pore size Minisart® syringe filter (Sartorius Stedium Biotech, 
Germany, 16534), after which 1ml aliquots were made in sterile 15ml tubes (Corning, 
430791) and stored at -20°C.  One aliquot was defrosted for use as and when required.  
To obtain the working concentration of collagenase type-IV (0.67mg/ml) needed for 
isolation of renal cells, 250µl of the 100mg/ml stock solution was added to 37.5ml RMPI 
1650 isolation medium (Lonza, BE12-702F). 
Preparation of glass coverslips for cell culture  
13mm Ø borosilicate glass coverslips (VWR, 631-0149) were stored until required in 
copious 100% ethanol (Sigma, 458600).  Under sterile conditions in a laminar flow hood 
(BIOQUELL, ABS1200CLS2-MK2), and using autoclave-sterilised metal tweezers, the 
13mm Ø borosilicate glass coverslips (VWR, 631-0149) were individually placed into the 
wells of a 24-well tissue culture-treated plate (ThermoScientific, NunclonTM, 142475).  
During this process, coverslips were balanced at an angle against the side of each well to 
enable any ethanol on the coverslips to evaporate away.  When all the ethanol had 
evaporated away (up to 1 hour later), the tissue culture plate containing the ethanol-
sterilized coverslips, was further sterilized using the UV irradiation setting on the laminar 
flow tissue culture hood (BIOQUELL UK LTD, ABS1200CLS2-MK2) for 20 minutes. 
All coverslips used for both mouse and human renal cell cultures, were then coated with 
tissue culture grade collagen type–IV (Sigma, C5533).  A 1mg/ml collagen stock solution 
was prepared from 5g of lyophilized collagen type-IV powder in 5ml of 0.5M sterile acetic 
acid (Fisher Scientific, A/0360/PB17).  The 1mg/ml stock solution was always prepared at 
least 24 hours in advance of requirement to allow for the collagen to completely dissolve, 
and was kept at 4°C.  A working concentration of 0.1mg/ml collagen type-IV was prepared 
from the 1mg/ml stock solution using tissue culture grade distilled water (Invitrogen; 
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15230-089).  200µl of 0.1mg/ml collagen type-IV solution was pipetted directly onto each 
13mm Ø borosilicate glass coverslip (VWR, 631-0149) and left for 2 hours.  After this time, 
the 0.1mg/ml collagen type-IV working concentration solution was removed, and the 
coverslips rinsed three times with sterile 1X PBS (Invitrogen, 10010-015) to remove any 
remaining traces of acetic acid.  The final 1X PBS wash was left in the wells until just before 
renal cells were ready for plating. 
Proliferation Assay 
The incorporation and immunofluorescent detection of 5-bromo-2'-deoxyuridine (BrdU), 
a thymidine analogue, into cellular DNA was used to investigate the percentage of mouse 
renal cells undergoing proliferation, at day 5, day 8, day 10 and day 15 of culture.  5-
bromo-2'-deoxyuridine (BrdU; Sigma, B5002) was added at a final concentration of 10µM 
to the culture medium 24 hours before cell fixation (i.e. on day 4, day 7, day 9 an day 14 
of culture).  Cells were removed from the incubator and transferred to lab bench where 
the culture medium was then removed.  Cells were fixed using 2% (w/v) 
paraformaldehyde (PFA; Sigma, 15,812-7) in 1X PBS pH 7.4 (10 minutes) at 4°C.  2% PFA 
stocks were pre-prepared and stored at -20°C.  Aliquots were defrosted slowly on ice as 
and when required.  Following fixation, cells were washed with 1X PBS pH 7.4 (3 X 5 
minutes) at room temperature.  Cells were permeabilised using 1X PBS pH 7.4 containing 
0.05% (v/v) Tween-20 (Sigma, P5927) pH 7.4 (PBST) (5 minutes).  Antigen retrieval was 
performed by incubating cells with 1N HCl (prepared from a 37% HCl stock solution 
(Sigma, 258148)) at 37°C (30 minutes) in a benchtop incubator (Techne hybridiser, HB-
1D).  The antigen retrieval solution was removed and cells washed with PBST (3 X 5 
minutes).  Non-specific antibody binding sites were blocked using blocking buffer (1% 
(w/v) bovine serum albumin (BSA; Sigma, A7906), 3% (v/v) SeaBlockTM (EastCoast Bio, 
PP83-K1574) in PBST) at room temperature (1 hour).  The blocking buffer was removed 
and cells incubated with an anti-BrdU primary antibody (mouse IgG; Abcam; ab8039) 
diluted 1:200 in blocking buffer (1 hour).  To remove unbound antibodies, PBST washes 
were subsequently performed (3 X 5 minutes).  Furthermore in darkness, Alexa Fluor® 
594-conjugated secondary antibody diluted 1:400 in blocking buffer (goat anti-mouse 
IgG; Invitrogen; A11032) was applied to cells (1 hour).  Again, to remove unbound 
antibodies, PBST washes performed (3 X 5 minutes).  In order to identify all cell nuclei, 
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cells were incubated with 0.1µg/ml Hoechst 33342 (Invitrogen; H1399), a nucleic acid 
stain, diluted in blocking buffer (10 minutes).  Cells underwent further PBST washes (3 X 
5 minutes) to remove excess Hoechst 33342.  Cells were briefly rinsed with distilled H20, 
before excess H20 was tapped off and coverslips mounted on slides using ProLong® Gold 
reagent (Invitrogen; P36930), a fluorescent anti-fade mounting medium.  Slides were 
allowed to air-dry in darkness.  Random snapshots of slides were captured using a BX61 
microscope (Olympus, Japan) and the percentage of proliferating cells out of the total 
number of cells was determined.  Between 200 and 600 total cells were counted at each 
time point.  Using Microsoft EXCEL, the percentage of proliferating cell nuclei out of the 
total number of cell nuclei was determined.   Results were plotted graphically using Prism 
(GraphPad Software Inc., USA).  To identify changes in proliferation over time, a one-way 
analysis of the variance (ANOVA) and a post-hoc Tukey test was performed.  Results were 
deemed statistically significant when p<0.05 (*), P<0.01 (**) and p<0.001 (***).  N=3, n=3 
for all time points assessed. 
Apoptosis Assay 
The percentage of mouse renal cells undergoing apoptotic cell death at day 5, day 8, day 
10 and day 15 of culture, was determined using the DeadEndTM Colorimetric Apoptosis 
Detection Kit (Promega, G7360).  At each time point, cells were removed from the 
incubator and transferred to lab bench where the culture medium was then removed. 
Cells were fixed using 2% (w/v) paraformaldehyde (PFA; Sigma, 15,812-7) in 1X PBS pH 
7.4 (10 minutes) at 4°C.  2% PFA stocks were pre-prepared and stored at -20°C.  Aliquots 
were defrosted slowly on ice as and when required.  Following fixation, cells were washed 
with 1X PBS pH 7.4 (3 X 5 minutes) at room temperature.  Cells were then treated with 
the kit equilibration buffer (containing 200mM Potassium cacodylate, 25mM Tris-HCl, 
0.2mM DTT, 0.25mg/ml BSA, 2.5mM cobalt chloride) at room temperature (5 minutes).  
Biotinylated nucleotides were incorporated at the 3’-OH end of fragmented, apoptotic 
DNA by recombinant terminal deoxynucleotidyl transferase (rTdT) at 37°C (1 hour).  This 
rTDT reaction mix contained 1% (v/v) kit biotinylated nucleotide mix and 1% (v/v) kit rTDT 
enzyme in equilibration buffer.  To terminate the TUNEL reaction, cells were then 
incubated with 2X saline sodium citrate (SSC) (15 minutes) at room temperature.  2X SSC 
was prepared by diluting the 20X SSC solution supplied with the kit 1:10 with deionised 
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water before use.  After cells were washed with 1X PBS pH 7.4 (3 X 5 minutes), 
endogenous peroxidases were quenched by treating cells with 0.3% (v/v) H2O2 (Fisher 
Scientific, H/1750/15) (5 minutes).  1X PBST washes were subsequently repeated (3 X 5 
minutes).  Cells were incubated with kit streptavidin-HRP diluted 1:500 in 1X PBST (30 
minutes).  Following, further 1X PBST washes (3 X 5 minutes), immunoreactive sites were 
detected using the kit 3,3'-diaminobenzidine (DAB) (1 minute).  The working 
concentration of DAB was achieved by diluting the 20X DAB Chromogen 1:20 in DAB 
substrate buffer.  Cells were rinsed with distilled H2O (3 X 5 minutes) and then 
counterstained with haematoxylin (Sigma, HHS16) (1 minute).  Cells were dehydrated 
using 70%, 95%, 100% and 100% (v/v) ethanol (Sigma, 458600) (5 minutes each) and then 
cleared in xylene (Sigma, 534056) (2 X 5 minutes).  Coverslips were allowed to air dry, and 
then mounted on glass slides using DPX mounting medium (Sigma, 44581).  Images were 
captured using a DMRB light microscope (Leica, Germany) from which a minimum of 100 
total cells at day 5 were counted, and between 200 and 600 cells were counted at days 8, 
10 and 15.  Using Microsoft EXCEL the percentage of apoptotic cell nuclei out of the total 
number of cell nuclei was determined.  Results were plotted graphically using Prism 
(GraphPad Software Inc., USA).  To identify changes in apoptosis over time, a one-way 
analysis of the variance (ANOVA) and a post-hoc Tukey multiple comparison test was 
performed.  Results were deemed statistically significant when p<0.05 (*), P<0.01 (**) 
and p<0.001 (***).  N=3, n=3 for all time point assessed. 
Concentration-Dependent, Drug-Induced Apoptosis 
To assess concentration-dependent drug-induced apoptosis in primary mouse renal cells 
following treatment with control medium (vehicle control; medium), or medium 
containing cisplatin (1, 3, 5µM), cyclosporin A (1, 3, 5µM) or BEA (3, 10, 30µM), a similar 
protocol to that described above was used.  The DeadEndTM Fluormetric Apoptosis 
Detection Kit (Promega, G3250) was used.  Following 24-hour treatment as described, 
cells at day 8 of culture were fixed using 2% (w/v) paraformaldehyde (PFA; Sigma, 15,812-
7) in 1X PBS pH 7.4 (10 minutes) at 4°C.  Following fixation, cells were washed with 1X 
PBST pH 7.4 (3 X 5 minutes) at room temperature (5 minutes).  Fluorescein-conjugated 
nucleotides were incorporated at the 3’-OH end of fragmented, apoptotic DNA by 
recombinant terminal deoxynucleotidyl transferase (rTDT) at 37°C (1 hour).  To terminate 
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the TUNEL reaction, cells were then incubated with 2X saline sodium citrate (SSC) (15 
minutes) at room temperature.  2X SSC was prepared in advance by diluting the 20X SSC 
solution supplied with the kit 1:10 with deionised water.  After, cells were washed with 
1X PBST pH 7.4 (3 X 5 minutes).  In order to identify all cell nuclei, cells were then 
incubated with 0.1µg/ml Hoechst 33342 (Invitrogen; H1399), diluted in 1X PBST (10 
minutes), and the washed with 1X PBST (3 X 5 minutes).   Cells were briefly rinsed with 
distilled H20, before excess H20 was tapped off and coverslips mounted on slides using 
ProLong® Gold reagent (Invitrogen; P36930), a fluorescent anti-fade mounting medium.  
Random snapshots were captured using a BX61 microscope (Olympus, Japan) from which 
100 to 150 total cell nuclei were counted per coverslip.  Using Microsoft EXCEL the 
percentage of apoptotic cell nuclei out of the total number of cell nuclei was determined.  
Results were plotted graphically using Prism (GraphPad Software Inc., USA).  To identify 
changes in apoptosis, a one-way analysis of the variance (ANOVA) and a post-hoc Tukey 
multiple comparison test was performed.  Results were deemed statistically significant 
when p<0.05 (*), P<0.01 (**) and p<0.001 (***).  N=3, n=3 for all treatments. 
Concentration-Dependent, Drug-Induced Loss of Cell Adhesion 
Primary mouse renal cells were cultured in individual 35mm tissue culture-treated 
polypropylene plates (Falcon®, 353001), as per the method described above.  On day 7, 
the control medium (REGM; Lonza, CC3191) was replaced with control medium (vechicle 
control; medium) or medium containing cisplatin (Calbiochem; 232120) at final 
concentrations of 1, 3 and 10µM, cyclosporin A (Sigma; 30024) at final concentrations of 
1, 3 and 10µM, or BEA (Sigma; B65705) at final concentrations of 1, 3 and 30µM.  Cells 
were then returned to the incubator for 24 hours.  On day 8 of culture, 1ml medium was 
removed from each of the conditions and placed in a 1.5ml Eppendorf, and gently mixed 
by inverting.  Using a haemocytometer number of cells floating in the control and drug-
treated cell media, was determined.  On completion, the control cells still attached to the 
cultured dish were enzymatically dissociated in 1ml of 0.05% Trypsin-EDTA (Invitrogen; 
25300-054) at 37°C for 10 minutes.  In a similar manner using the haemocytometer, the 
number of control cells that had remained attached to the tissue culture dish was 
counted.  Using Microsoft EXCEL the number of floating cells in each of the control and 
drug-treated media, was made as a percentage of the total number of control cells i.e. 
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the combined total floating plus attached.  These data were graphically plotted using 
Prism 5 (GraphPad Software; USA). To identify changes the number of floating cells 
between conditions, a one-way analysis of the variance (ANOVA) and post-hoc TUKEY test 
was performed.  Results were deemed statistically significant when p<0.05 (*), P<0.01 
(**) and p<0.001 (***).  N=3, n=3 for all treatments.   
Mouse Cell Biomarker Immunocytochemistry 
At day 8 in culture, after 24 hours in control medium (vehicle control; medium), medium 
containing 10µM cisplatin (Calbiochem; 232120), 10µM cyclosporin A (Sigma; 30024) or 
30µM BEA (Sigma; B65705), cells were fixed using 2% (w/v) paraformaldehyde (PFA; 
Sigma; 15,812-7) at 4°C.  2% PFA solutions were prepared in advance and frozen as 10ml 
aliquots in sterile 15ml tubes (Corning, 430791) at -20°C until required.  Following fixation, 
cells were washed with 1X PBS pH 7.4 (3 X 5 minutes) and then permeabilised using 1X 
PBS, 0.05% Tween-20 (Sigma, P5927) pH 7.4 (PBST) (5 minutes).  Freshly prepared 0.3% 
(v/v) H2O2 (Fisher Scientific, H/1750/15) PBST was used to quench endogenous 
peroxidase activity (5 minutes).  Cells were then washed with 1X PBST (3 X 5 minutes).  
Non-specific binding sites were blocked using freshly prepared 1% (w/v) bovine serum 
albumin (BSA; Sigma, A7906), 3% (v/v) SeaBlockTM (EastCoast Bio, PP83-K1574) PBST 
blocking buffer (1 hour).  Thereafter, cells were incubated with anti-KIM-1 (goat IgG; 
1:200; R&D Systems; AF3689), anti-OPN (rabbit IgG; 1:200; IBL Co., Ltd, Japan; IBL-18628), 
or anti-clusterin (rabbit IgG; 1:200; Novus Biologicals; USA; NBP-19637) primary 
antibodies diluted in blocking buffer (1 hour).  Unbound antibodies were removed by 
washing cells with PBST (3 X 5 minutes).  Cells were incubated for 30 minutes with anti-
rabbit (1:500; Thermo Scientific; 31462) or anti-goat (1:500; Thermo Scientific; 31402) 
horseradish peroxidise (HRP)-conjugated secondary antibodies, respectively.  PBST 
washes (3 X 5 minutes) were repeated and immunoreactive sites subsequently visualised 
using 3-3’-diaminobenzidine (DAB) chromogen substrate solution (Dako; Denmark; 
K3468).  Cells were rinsed with distilled H2O, counterstained with haematoxylin (Sigma, 
HHS16) (1 minute), dehydrated using 70%, 95%, 100% and 100% ethanol (Sigma, 458600) 
(5 minutes each) and cleared in xylene (Sigma, 534056) (20 seconds), and allowed to air 
dry.  Coverslips were mounted on glass slides using DPX mounting medium (Sigma, 44581) 
and images were captured using a DMRB light microscope (Leica, Germany).  For each 
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coverslip, 5 random fields of view (snapshots) were captured.  To determine the 
proportion of cells staining positive for each of the biomarkers out of the total cell 
number, cell counts from these images were made.  A minimum of 500 cells per coverslip 
were counted.  Using Microsoft EXCEL, the percentage of cells positive for each of the 
biomarkers out of the total number of cells was determined.  These data were graphically 
plotted and analysed using Prism 5 (GraphPad Software; USA).  To identify an increase in 
the number of cells staining positive for each of the biomarkers in control or drug-treated 
conditions, a one-way analysis of the variance (ANOVA) and a post-hoc TUKEY test was 
performed.  Results were deemed statistically significant when p<0.05 (*), P<0.01 (**) 
and p<0.001 (***). N=3, n=3 for each treatment and biomarker. 
Human Cell Biomarker Immunocytochemistry 
At day 8 in culture, following 24-hour treatment in control medium (vehicle control; 
medium) or medium containing 25µM cisplatin (Calbiochem; 232120), human renal cells 
grown on collagen-type IV (Sigma, C5533)-coated 13mm Ø borosilicate glass coverslips 
(VWR, 631-0149) were fixed using 2% (w/v) paraformaldehyde (PFA; Sigma; 15,812-7) at 
4°C.  2% PFA solutions were prepared in advance and frozen as 10ml aliquots in 15ml 
Falcon tubes at -20°C until required.  Following fixation, cells were washed with 1X PBS 
pH 7.4 (3 X 5 minutes) and then permeabilised using 1X PBS, 0.05% Tween-20 (Sigma, 
P5927) pH 7.4 (PBST) (5 minutes).  Freshly prepared 0.3% (v/v) H2O2 (Fisher Scientific, 
H/1750/15) PBST was used to quench endogenous peroxidase activity (5 minutes).  Cells 
were then washed with 1X PBST (3 X 5 minutes).  Non-specific binding sites were blocked 
using freshly prepared 1% (w/v) bovine serum albumin (BSA; Sigma, A7906), 3% (v/v) 
SeaBlockTM (EastCoast Bio, PP83-K1574) PBST blocking buffer (1 hour).  Thereafter, cells 
were incubated with anti-KIM-1 (goat IgG; 1:200; R&D Systems; AF3689), anti-OPN (rabbit 
IgG; 1:200; IBL Co., Ltd, Japan; IBL-18628), or anti-clusterin (rabbit IgG; 1:200; Novus 
Biologicals; USA; NBP-19637) primary antibodies diluted in blocking buffer (1 hour).  
Unbound antibodies were removed by washing cells with PBST (3 X 5 minutes).  Cells were 
subsequently incubated for 30 minutes with anti-rabbit (1:500; Thermo Scientific; 31462) 
or anti-goat (1:500; Thermo Scientific; 31402) horseradish peroxidise (HRP)-conjugated 
secondary antibodies, respectively.  PBST washes (3 X 5 minutes) were repeated and 
immunoreactive sites subsequently visualised using 3-3’-diaminobenzidine (DAB) 
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chromogen substrate solution (Dako; Denmark; K3468).  Cells were rinsed with distilled 
H2O, counterstained with haematoxylin (Sigma, HHS16) (1 minute), dehydrated using 
70%, 95%, 100% and 100% ethanol (Sigma, 458600) (5 minutes each) and cleared in 
xylene (Sigma, 534056) (20 seconds).  Coverslips were mounted on glass slides using DPX 
mounting medium (Sigma, 44581).  Slides were scanned using a Mirax Scanner (Zeiss, 
Germany) and images captured using Panoramic Viewer Software (3DHISTECH Kft, 
Hungary).  Five random fields of view (snapshots) per coverslip were captured.  To 
determine the proportion of cells staining positive for each of the biomarkers out of the 
total cell number, cell counts from these images were made.  A minimum of 500 cells per 
coverslip were counted.  Using Microsoft EXCEL, the percentage of cells positive for each 
of the biomarkers out of the total number of cells was determined.  These data were 
graphically plotted using Prism 5 (GraphPad Software; USA).  N=1, n=1 for each treatment 
and biomarker. 
Rat Kidney Slice Culture 
One- to 3-month-old male Han Wistar rats were killed by CO2 inhalation following UK 
Home Office approval and carried out in accordance with the Animals (Scientific 
Procedures) Act 1986.  All metallic tools used were sterilised by autoclaving prior to use. 
Using scissors and tweezers, kidneys were excised and rinsed with 1X phosphate buffered 
saline (PBS; Invitrogen, 10010-015).  Following removal of the kidney capsule and any 
surrounding fatty tissue, the kidneys were again washed in 1X PBS.  Using tweezers to 
hold the kidney still, a disposable sterile scalpel (Swann-Morton; 0501) was used to cut 
one of the kidneys in half along the transverse plane.  Either one or both halves of one of 
the kidneys were mounted directly to the centre of the jig of an Integraslice (Campden 
Instruments, UK; 7550 PSDS).  A cylindrical tube was placed around the kidney before 
1.8% UltraPureTM low melting point agarose (Invitrogen; 16520-050) in 1X PBS pH 7.4 was 
poured into the tube to fully embed the kidney portions.  Once the agarose had solidified, 
the cylindrical tube was gently removed and the jig plus agarose-embedded kidney 
portions were screwed into the Integraslice chamber.  1X PBS (Invitrogen, 10010-015) at 
4°C was poured into the chamber to the level of the top of the agarose.  200µm-thick 
slices were cut at a speed of 0.25mm/s with a left-right slicing amplitude of 1.5mm.  The 
decision to make 200µm-thick sections was made based on previously published methods 
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(Crawford et al. 2012; Peppiatt-Wildman et al. 2012; Vickers et al. 2004).  Thicker slices 
were excluded to prevent nutrient and oxygen starvation of the cells in the middle of the 
slices which could predispose them to apoptotic and/or necrotic cell death.  Cut slices 
were removed from the slicing chamber using sterile tweezers and stored in a 12-well 
culture plate in 1X PBS on ice for up to 2 hours until all slices had been cut.  Thereafter 
under sterile conditions in a laminar flow tissue culture hood (BIOQUELL, ABS1200CLS2-
MK2), kidney slices were transferred to individual wells of a 12-well-plate containing 
control medium (Renal Epithelial Growth Medium; REGM; Lonza, CC3191) to acclimatise 
in a 5% CO2 / 95% air humidified incubator at 37°C (SANYO, MCO-18AIC). 
Determination of Rat Kidney Slice Viability Using an ATP Content Assay 
Rat kidney slices were prepared as described above.  After 0, 1, 4 and 24 hours in control 
medium or control medium containing the vehicle control (control medium) or 10µM 
cisplatin (Calbiochem; US; 232120), 10µM cyclosporin A (Sigma; 30024) or 30µM BEA 
(Sigma; B65705), slices were snap frozen in liquid nitrogen and stored at -80°C until all 
samples had been collected.  One at a time, slices were removed from the -80°C freezer, 
weighed and homogenised in 120µl phenol-TE (phenol saturated with 10mM 
tris(hydroxymethyl)aminomethane (TRIS; Sigma; T1503) pH7.5 and 1mM diaminoethane 
tetra-acetic acid pH8 (EDTA).  100µl of this lysate was transferred to a 1.5ml Eppendorf 
containing 20µl chloroform (Fischer Scientific; UK; C/4960/17) and 15µl ddH20, and kept 
on ice until all slices had been processed.  When all slices were ready, they were all shaken 
vigorously by hand for 30 seconds before being centrifuged (Sigma Laboratory Centrifuge 
SK18; SciQuip; UK) at 10000g for 5 minutes at 4°C.  The supernatants were collected and 
diluted 1:10 with ddH20.  10µl of this solution was used to perform the ATP assay.  
According to the manufacturer’s protocol, the ATP content of kidney slices was 
determined using The Molecular Probes ATP Determination Kit (Invitrogen; A22066) (a 
quantitative bioluminescence assay using recombinant firefly luciferase and its substrate 
D-luciferin).  Briefly, ATP standards (10nM, 8nM, 6nM, 4nM, 2nM, 1.8nM, 1.6nM, 1.4nM, 
1.2nM, 1nM, 0.8nM, 0.6nM, 0.4nM and 0.2nM) were prepared by diluting the supplied 
5mM ATP stock solution in distilled water.  10µl of each standard or sample was then 
added to individual wells of a 96-well plate before 100µl of reaction solution (containing 
reaction buffer, firefly luciferase, D-luciferin and Dithiothreitol at the recommended 
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concentrations) was then also added.  Luminescence at 560nm was detected using a 
Flouroskan Ascent FL™ Microplate Luminometer (Thermo Scientific; UK; 5210462).  An 
ATP standard curve was created, and the ATP content of each kidney slice sample 
subsequently determined.  This method of determining the ATP content of rat and human 
ex vivo kidney slices has been used previously (Vickers et al. 2004).  To identify differences 
in the ATP content over time within each drug-treated group, one-way ANOVA and post-
hoc Tukey tests were performed at the 5% significance level.  Differences were deemed 
statistically significant when p < 0.05 (*).  To identify differences in the ATP content 
between control and drug-treated groups after 1, 4 and 24 hours, a two-way ANOVA and 
post-hoc Tukey test was performed.  Again, differences were deemed statistically 
significant when p < 0.05 *. N=3, n=3, for all time points and conditions. 
Rat Kidney Slice H&E Staining 
After 1 and 24 hours in renal epithelial growth medium (REGM; Lonza, CC3190), slices 
were removed from the humidified, 5% CO2, 37°C incubator (SANYO, MCO-18AIC), fixed 
using 2% (w/v) paraformaldehyde (PFA; Sigma, 15,1812-7) in 1X PBS pH 7.4 at 4°C (1 
hour), and then washed with 1X PBS pH 7.4 (10 minutes).  Slices were stored in 1X PBS 
until processed in to paraffin blocks by Mr Derek Scarborough, Cardiff University.  Four 
µm-thick kidney sections were cut and air-dried onto strongly adhesive slides (Leica, 
Germany).  Slice sections were deparaffinised in xylene (Sigma, 534056) (2 x 5 minutes) 
and rehydrated to water using 100% (2 x 5 minutes), 95% (1 X 5 minutes) and 70% (1 x 2 
minutes) ethanol (Sigma, 458600).  Slice sections were incubated in haematoxylin (Sigma, 
HHS16) (1 minute), washed in running water (2 minutes), dipped in 0.2% acid water and 
then washed again in running water (2 minutes).  Sections were incubated in eosin 
(Thermo Scientific, LAMB/100-D) (1 minute) and then dehydrated using 70% (1 X 5 
minutes), 95% (1 X 5 minutes) and 100% ethanol (Sigma, 458600) (2 X 5 minutes) and 
then cleared in xylene (Sigma, 534056) (2 x 5 minutes).  Coverslips were mounted on 
slides using histomount (TAAB Labs, Aldermaston, UK).  Slides were scanned using a 
ScanScope Scanner and images captured of the kidney cortex region captured using 
ImageScope software (Aperio Technologies Incorporated, Vista, USA).  Five random fields 
of view (snapshots) per kidney slice cortex were captured from which histopathological 
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assessments made.  N=1, n=1 for control rat kidney slices.   N=3, n=3 for ex vivo rat kidney 
slices after 1 hour and 24 hours in culture. 
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3.6 Results 
Characterisation of Ex Vivo Kidney Slices  
To determine the viability of ex vivo kidney slices over time, ATP content was assessed 
after 0, 1, 4 and 24 hours culture in control medium.  In addition, the effect of treatment 
with medium containing 10µM cisplatin, 10µM cyclosporin A or 30µM BEA was also 
investigated on slice viability over time.  To identify differences in the ATP content over 
time within each drug-treated group, individual one-way ANOVA and post-hoc Tukey 
tests were performed at the 5% significance level.  Differences were deemed statistically 
significant when p < 0.05 (*).  To identify differences in the ATP content between control 
and all drug-treated groups after 1, 4 and 24 hours, a two-way ANOVA and post-hoc Tukey 
test was performed.  Again, differences were deemed statistically significant when p < 
0.05 (*).  All values are expressed as nmoles ATP/mg wet weight of slice (mean ± SEM; 
N=3, n=3). 
ATP Content of Ex Vivo Control Slices over Time 
The ATP content of control kidney slices at 0 hours (immediately after slicing) was 1.04 ± 
0.07 nmoles ATP/mg wet weight.  There was no statistical difference in ATP content after 
1 hour (1.02 ± 0.05 nmoles ATP/mg wet weight) or 4 hours (0.85 ± 0.05 nmoles ATP/mg 
wet weight) compared to that at 0 hours.  However after 24 hours, the ATP content of 
slices treated with control medium had significantly decreased to 0.57 ± 0.05 nmoles 
ATP/mg wet weight (p < 0.01 **) compared to that at 0 hours.  These data are graphically 
plotted in Figure 3.2A. 
ATP Content of Ex Vivo Slices treated with Cisplatin, Cyclosporin A and BEA over Time 
The ATP content of kidney slices treated control medium containing 10µM cisplatin, 
10µM cyclosporin A or 30µM BEA for 1, 4 and 24 hours were individually compared to the 
ATP content of control kidney slices immediately after slicing (i.e. at 0 hours).  The ATP 
content of control ex vivo kidney slices at 0 hours was 1.04 ± 0.07 nmoles ATP/mg wet 
weight.  There was no statistical difference in the ATP content of ex vivo kidney slices 
following 1 hour treatment with medium containing 10µM cisplatin (0.96 ± 0.03 nmoles 
ATP/mg wet weight; p > 0.05).  However, after 4 hours (0.62 ± 0.05 nmoles ATP/mg wet 
  
 
166 
 
weight; p < 0.01 **) and 24 hours (0.46 ± 0.07 nmoles ATP/mg wet weight; p < 0.001 ***) 
the ATP content was significantly decreased compared to that at 0 hours.  These data are 
graphically plotted in Figure 3.2B.  The ATP content of control ex vivo kidney slices at 0 
hours was 1.04 ± 0.07 nmoles ATP/mg wet weight.  There was no statistical difference in 
the ATP content of ex vivo kidney slices following 1 hour (0.96 ± 0.06 nmoles ATP/mg wet 
weight; P > 0.05) or 4 hours (0.76 ± 0.07 nmoles ATP/mg wet weight; p > 0.05) treatment 
with medium containing 10µM cyclosporin.  After 24 hours (0.48 ± 0.05 nmoles ATP/mg 
wet weight; p < 0.01 **), there was a significant decrease in ATP content of ex vivo kidney 
slices treated with medium containing 10µM cyclosporin A compared to the ATP content 
of kidney slices at 0 hours.  These data are graphically plotted in Figure 3.2C.  The ATP 
content of control ex vivo kidney slices at 0 hours (immediately after slicing) was 1.04 ± 
0.07 nmoles ATP/mg wet weight.  There was no statistical difference in the ATP content 
of ex vivo kidney slices following treatment with medium containing 30µM BEA for 1 hour 
(1.05 ± 0.06 nmoles ATP/mg wet weight; P > 0.05) or 4 hours (0.87 ± 0.05 nmoles ATP/mg 
wet weight; p > 0.05).  After 24 hours (0.54 ± 0.05 nmoles ATP/mg wet weight; p < 0.01 
**), there was a significant decrease in ATP content of ex vivo kidney slices treated with 
medium containing 30µM BEA compared control slices at 0 hours.  These data are 
graphically plotted in Figure 3.2D. 
Next, a two-way ANOVA and post-hoc Tukey test was used to identify differences in ATP 
content between control and drug-treated groups after 1, 4 and 24 hours.  After 1 hour, 
no significant differences in the ATP content of control or drug treated ex vivo slices was 
identified (p > 0.05).  After 4 hours, no significant difference was identified between 
control and cyclosporin A or BEA groups (p > 0.05), but a significant difference was seen 
between the control and the cisplatin group (p < 0.05, *).  After 24 hours, there was no 
significant difference in the ATP content of the control or any of the drug groups.  Apart 
from the significant decrease in ATP content of slices treated with control medium 
containing 10µM cisplatin after 4 hours compared to the time-matched ATP content of 
slices treated with control medium, no drug-induced decreases in ATP content were 
detected, indicating that the overall decrease in ATP content over time is independent of 
drug-treatment.  
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Figure 3.2.  ATP content of ex vivo rat kidney slices under (A) control conditions, or in 
the presence of (B) 10µM cisplatin, (C) 10µM cyclosporin A or (D) 30µM BEA for 0, 1, 4 
and 24 hours.  (A) The ATP content of rat kidney slices was 1.04 ± 0.07 nmoles ATP/mg 
wet weight at the time of slicing (0 hours).  No significant difference was detected in ATP 
content of slices cultured for 1 or 4 hours (p > 0.05; ns).  However, a significant difference 
was detected 24 hours post-treatment (0.57 ± 0.05 nmoles ATP/mg wet weight; p < 0.01 
**).  (B)  Decreases in ATP content were detected following 4 (0.62 ± 0.05 nmoles ATP/mg 
wet weight; p < 0.01 **) and 24 (0.46 ± 0.07 nmoles ATP/mg wet weight; p < 0.001 ***) 
hours treatment with cisplatin compared to that at time 0.  (C) A decrease in ATP content 
was detected 24 hours exposure to medium containing cyclosporin A (0.48 ± 0.05 nmoles 
ATP/mg wet weight; p < 0.01 **) compared to that at time 0.  (D) A decrease in ATP 
content was detected following 24 hours to medium containing BEA (0.54 ± 0.05 nmoles 
ATP/mg wet weight; p < 0.01 **) exposure compared to that at time 0.  Significant 
differences were identified using a one-way ANOVA and post-hoc Tukey test.  All values 
presented are mean ± SEM.  N=3, n=3 for each condition and time point. 
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Figure 3.3.  ATP content of ex vivo rat kidney slices under (A) control conditions, or in 
the presence of (B) 10µM cisplatin, (C) 10µM cyclosporin A or (D) 30µM BEA for 1, 4 and 
24 hours.  The ATP content of control rat kidney slices after 1 hour was 1.02 ± 0.05 nmoles 
ATP/mg wet weight.  Compared to the time-matched control, no significant difference 
was detected in ATP content of slices also cultured for 1 hour in medium containing 
cisplatin (0.96 ± 0.03 nmoles ATP/mg wet weight; p > 0.05; ns), cyclosporin A (0.96 ± 0.06 
nmoles ATP/mg wet weight; P > 0.05; ns) or BEA (1.05 ± 0.06 nmoles ATP/mg wet weight; 
P > 0.05; ns).  The ATP content of control rat kidney slices after 4 hours was 0.85 ± 0.05 
nmoles ATP/mg wet weight.  Compared to the time-matched control, a significant 
difference was detected in ATP content of slices cultured for 4 hours in medium 
containing cisplatin (0.62 ± 0.05 nmoles ATP/mg wet weight; p < 0.01; **), but not 
cyclosporin A (0.76 ± 0.07 nmoles ATP/mg wet weight; p > 0.05; ns) or BEA (0.87 ± 0.05 
nmoles ATP/mg wet weight; p > 0.05; ns). The ATP content of control rat kidney slices 
after 24 hours was 0.57 ± 0.05 nmoles ATP/mg wet weight.  Compared to the time-
matched control, no significant difference was detected in ATP content of slices also 
cultured for 24 hours in medium containing cisplatin (0.46 ± 0.07 nmoles ATP/mg wet 
weight; p > 0.05; ns), cyclosporin A (0.48 ± 0.05 nmoles ATP/mg wet weight; P > 0.05; ns) 
or BEA (0.54 ± 0.05 nmoles ATP/mg wet weight; P > 0.05; ns).  Cont = control. Cis = 
cisplatin. CsA = cyclosporin A. BEA = bromoethylamine. Significant differences were 
identified using a two-way ANOVA and post-hoc Tukey test.  All values presented are 
mean ± SEM.  N=3, n=3 for each condition and time point.  
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Ex Vivo Kidney Slice Morphology 
To further assess ex vivo kidney slice viability over time, histological assessment of slice 
morphology over time was performed.  Representative haematoxylin and eosin (H&E) 
images of a formalin-fixed, paraffin-embedded control rat kidney and ex vivo rat kidney 
slices cultured under control conditions for 1 and 24 hours are shown in Figure 3.4.  In 
control rat kidney cortex, nuclei appear uniform in size and shape and proximal tubule 
cells possess brush border membranes (Figure 3.4A).  Following 1 hour in culture under 
control conditions, ex vivo rat kidney sections already show morphological features of 
injury; cell nuclei appear smaller and more condensed than control rat kidneys, with some 
cellular detachment from the tubule basement membrane (Figure 3.4B-D).  When slices 
were kept in culture for 24 hours, clear morphological features of injury are apparent in 
all of the samples; cell nuclei appear small and condensed, there is loss of proximal tubule 
brush border membranes and sloughing epithelial cells into the tubule lumen is present 
(Figure 3.4E-G). 
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Figure 3.4.  Ex vivo rat kidney cortex slice morphology following culture for 1 (middle panels) 
and 24 (bottom panels) hours in control medium post-slicing.  Representative H&E images 
showing the morphology of the cortex of (A) a control rat kidney section, (B-D) control ex vivo rat 
kidney slices cultured for 1 hour and (E-G) control ex vivo rat kidney slices cultured for 24 hours.  
(A) In control rat kidney sections nuclei appear uniform in size and shape (circled) and proximal 
tubules possess brush border membranes (arrow heads).  (B-D) Following 1 hour in culture under 
control conditions, ex vivo rat kidney slices show morphological features of injury; cell nuclei 
appear smaller and more condensed (circled) with the cells of some tubules completely detaching 
from the basement membrane (arrows).  (E-G) After 24 hours in culture, clear morphological 
features of injury are apparent in all kidney slice samples; cell nuclei appear very small and 
condensed (circled), there is loss of proximal tubule brush border membranes (arrow heads) and 
sloughing of epithelial cells into the tubular lumens is present (arrows).  All images presented are 
representative of one section per individual sample, and are representative of 5 fields of view.  
N=1, n=1 for control rat kidney cortex.  N=3, n=3 for control rat kidney ex vivo slices cultured for 
1 hour and 24 hours.  P = proximal tubule, D = distal tubule, G = glomerulus.  Bars = 100µm.  Slice 
culture and H&E performed by JG.  Image analysis performed by RW. 
  
 
171 
 
In light of the clear deterioration of slice morphology (Figure 3.4) along with the 
significant decrease in slice ATP content indicative of cell death (Figure 3.2), the decision 
was made to focus on the characterisation of the in vitro renal cell model as a tool for 
studying drug-induced nephrotoxicity.  A similar decrease in the ATP content of ex vivo 
kidney slices over time was also observed by another researcher, Mr Joao Graça, when 
slices were cultured in a similar manner.  Together these data suggest that further 
optimisation of slice preparation and culture is required in order for meaningful 
toxicology testing data to be obtained.  
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Characterisation of In Vitro Primary Mouse Renal Cells 
Proliferation and Apoptosis Assays 
Proliferation and apoptosis assays were used to determine primary mouse renal cell 
viability under control culture conditions, for up to 15 days in culture.  The incorporation 
of 5-bromo-2'-deoxyuridine (BrdU) into actively proliferating cell nuclei, and terminal 
deoxyribonucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) of apoptotic 
cell nuclei, was used to assess the overall viability of renal cells in culture over time. 
A representative immunofluorescent image of BrdU incorporation into new DNA within 
proliferating cell nuclei after 8 days in culture is shown in Figure 3.5A.  The percentage of 
BrdU-positive cell nuclei was 81.31 ± 2.42% (mean ± SD; N=3, n=3) of total cell nuclei at 
day 5.  By day 15, the percentage of BrdU-positive cell nuclei had significantly decreased 
to 26.22 ± 2.05% (mean ± SD; N=3, n=3; p < 0.001 ***) compared to that at day 5, as 
determined using a one-way ANOVA and a post-hoc Tukey test (Figure 3.5C). 
A representative light microscopy image of apoptotic cell nuclei after 8 days in culture is 
shown in Figure 3.5B.  The percentage of cells undergoing apoptosis was 4.22 ± 0.97% 
(mean ± SD; N=3, n=3) of total cells at day 5.  By day 15, the percentage of total cells 
undergoing apoptosis had significantly decreased to 1.30 ± 0.32% (mean ± SD; N=3, n=3; 
P < 0.01 **) compared to that at day 5, as determined using a one-way ANOVA and a post-
hoc Tukey test (Figure 3.5D). 
Overall, cell viability over the culture time-course was high as determined by high 
proliferation and low apoptosis.   
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Figure 3.5.  Assessment of primary mouse renal cell viability under control conditions 
over time using a BrdU-incorporation proliferation assay and a TUNEL apoptosis assay.  
(A) A representative image of proliferating cell nuclei after 8 days in culture.  All cell nuclei 
are blue (Hoechst positive) and proliferating cell nuclei are red (BrdU positive).  Bar = 
100µm.  (B) A representative image of apoptotic TUNEL cell nuclei after 8 days in culture.  
All cell nuclei are blue (haematoxylin positive) and apoptotic cell nuclei are brown (DAB 
positive).  Bar = 100µm.  (C) At day 5, 81.31 ± 2.42% (mean ± SD; N=3, n=3) of all nuclei 
were BrdU-positive.  At day 8, there was a significant decrease in BrdU-positive nuclei 
(69.91 ± 1.13%; mean ± SD; N=3, n=3; p < 0.05 *) compared to that at day 5.  Significant 
differences in BrdU-positive nuclei were also seen at day 10 (54.44 ± 6.00%; mean ± SD; 
N=3, n=3; p < 0.001 ***) and day 15 (26.22 ± 2.05; mean ± SD; N=3, n=3; p < 0.001 ***) 
compared to day 5.  Significant differences were identified using a one-way ANOVA and 
a post-hoc Tukey test.  Random snapshots were taken such that between 200 and 600 
cell nuclei in total were counted at each time point.  (D) At day 5, 4.22 ± 0.97% (mean ± 
SD; N=3, n=3) of cell nuclei were apoptotic.  At day 8, there was a significant decrease in 
apoptotic nuclei (1.79 ± 0.34%; mean ± SD; N=3, n=3; p < 0.01 **) compared to that at 
day 5.  Significant decreases in the percentage of apoptotic nuclei were also seen at day 
10 (1.34 ± 0.46%; mean ± SD; N=3, n=3; p < 0.01 **) and day 15 (1.30 ± 0.32%; mean ± 
SD; N=3, n=3; p < 0.01 **) when compared to that at day 5.  Random snapshots were 
taken such that a minimum of 100 total cell nuclei were counted at day 5, and between 
200 and 600 cell nuclei at days 8, 10 and 15.  Significant differences were identified using 
a one-way ANOVA and a post-hoc Tukey test.  
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Concentration-Dependent, Drug-Induced Apoptosis 
Concentration-dependent drug-induced apoptosis in primary mouse renal cells was 
assessed using a TUNEL assay.  Cells were grown for 7 days in control medium before 24 
hour-treatment with control medium (vehicle control; medium), or medium containing 
cisplatin (1, 3, 5µM), cyclosporin A (1, 3, 5µM) or BEA (3, 10, 30µM).  To identify 
differences in the percentage of apoptotic cells between control and drug treatments, 
individual one-way ANOVA and post-hoc Tukey tests was performed for each drug.  All 
three drugs induced a concentration-dependent increase in the percentage of apoptotic 
cells compared to the control. 
In the cisplatin group, 1.2 ± 0.4% (mean ± SD; N=3, n=3) of control cell nuclei were 
apoptotic. Compared to the control, no significant difference in the percentage of 
apoptotic nuclei was identified in cells treated with medium containing 1µM cisplatin (1.6 
± 0.5%; mean ± SD; N=3, n=3; p > 0.05 ns).  However significant differences were identified 
in cells treated with medium containing 3µM cisplatin (3.9 ± 0.6%; mean ± SD; N=3, n=3; 
p < 0.01 **) and 5µM cisplatin (7.3 ± 6.7%; mean ± SD; N=3, n=3; p < 0.001 ***).   
In the cyclosporin A group, 0.87 ± 0.57% (mean ± SD; N=3, n=3) of control cell nuclei were 
apoptotic.  Compared to the control, no significant difference in the percentage of 
apoptotic nuclei was identified in cells treated with medium containing 1µM cyclosporin 
A (1.6 ± 0.6%; mean ± SD; N=3, n=3; p > 0.05 ns).  However significant differences were 
identified in cells treated with medium containing 3µM cyclosporin A (4.1 ± 0.6%; mean 
± SD; N=3, n=3; p < 0.01; **) and 5µM cyclosporin A (7.4 ± 1.0; mean ± SD; N=3, n=3; p < 
0.001 ***). 
In the BEA group, 1.0 ± 0.4% (mean ± SD; N=3, n=3) of control cell nuclei were apoptotic.  
Compared to the control, no significant difference in the percentage of apoptotic nuclei 
was identified in cells treated with medium containing 3µM BEA (1.5 ± 0.6%; mean ± SD; 
N=3, n=3; p > 0.05 ns) or 10µM BEA (1.4 ± 0.4%; mean ± SD; N=3, n=3; p > 0.05 ns).  
However significant differences were identified in cells treated with medium containing 
30µM BEA (3.5 ± 0.3; mean ± SD; N=3, n=3; p < 0.01 **). 
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Figure 3.6. Percentage of apoptotic primary mouse renal cell nuclei following 24-hour 
treatment with medium containing (A) 0, 1, 3 and 5µM cisplatin, (B) 0, 1, 3 and 5µM 
cyclosporin A or (C) 0, 3, 10 and 30µM BEA. (A) 1.2 ± 0.4% (mean ± SD; N=3, n=3) of 
control cell nuclei were apoptotic.  Compared to the control, no significant difference in 
the percentage of apoptotic nuclei was identified in cells treated with medium containing 
1µM cisplatin (1.6 ± 0.5%; mean ± SD; N=3, n=3; p > 0.05 ns).  However significant 
differences were identified in cells treated with medium containing 3µM cisplatin (3.9 ± 
0.6%; mean ± SD; N=3, n=3; p < 0.01 **) and 5µM cisplatin (7.3 ± 6.7%; mean ± SD; N=3, 
n=3; p < 0.001 ***).  (B) 0.87 ± 0.57% (mean ± SD; N=3, n=3) of control cell nuclei were 
apoptotic.  Compared to the control, no significant difference in the percentage of 
apoptotic nuclei was identified in cells treated with medium containing 1µM cyclosporin 
A (1.6 ± 0.6%; mean ± SD; N=3, n=3; p > 0.05 ns).  However significant differences were 
identified in cells treated with medium containing 3µM cyclosporin A (4.1 ± 0.6%; mean 
± SD; N=3, n=3; p < 0.01; **) and 5µM cyclosporin A (7.4 ± 1.0; mean ± SD; N=3, n=3; p < 
0.001 ***).  (C) 1.0 ± 0.4% (mean ± SD; N=3, n=3) of control cell nuclei were apoptotic.  
Compared to the control, no significant difference in the percentage of apoptotic nuclei 
was identified in cells treated with medium containing 3µM BEA (1.5 ± 0.6%; mean ± SD; 
N=3, n=3; p > 0.05 ns) or 10µM BEA (1.4 ± 0.4%; mean ± SD; N=3, n=3; p > 0.05 ns).  
However significant differences were identified in cells treated with medium containing 
30µM BEA (3.5 ± 0.3; mean ± SD; N=3, n=3; p < 0.01 **).  Significant differences were 
identified using individual one-way ANOVA and post-hoc Tukey tests.  Random snapshots 
were taken such that a between 100 and 150 total cells were counted for each drug and 
each concentration.  Cell culture and assay performed by VP.  Cell counts performed by 
VP.  Statistical analysis performed by RW.  
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Concentration-Dependent, Drug-Induced Loss of Cell Adhesion 
A concentration-dependent drug-induced effect on cell adhesion to the tissue culture 
plate was assessed by counting the number of detached (floating) cells in the culture 
medium following treatment.  Cells were grown for 7 days in control medium before 24 
hour-treatment with control medium (vehicle control; medium), or medium containing 
cisplatin (1, 3, 10µM), cyclosporin A (1, 3, 10µM) or BEA (1, 3, 30µM).  At day 8 of culture, 
the number of floating cells in each of the treatment groups was calculated as a 
percentage of the total number of control cells (which included those floating in the 
control culture medium and those still attached to the control tissue culture plate).  To 
identify significant differences between control and drug treatments, individual one-way 
ANOVA and post hoc Tukey tests were performed for each drug. 
Figure 3.7 shows an increase in cell detachment from the tissue culture plate in response 
to treatment with medium containing cisplatin.  The percentage of detached cells floating 
in control cell medium was 5.14 ± 1.39% (mean ± SD; N=3, n=3) of the total number of 
control cells.  Treatment with medium containing 1µM cisplatin did not significantly 
increase the percentage of floating cells (12.63 ± 2.49%; mean ± SD; N=3, n=3; p > 0.05 
ns) compared to the control.  However, treatment with medium containing 3µM and 
10µM cisplatin significantly increased the percentage of floating cells to 28.48 ± 10.72% 
(mean ± SD; N=3, n=3; p < 0.05 *) and 64.43 ± 6.92% (mean ± SD; N=3, n=3; p < 0.001 
***), respectively.  Concentration-dependent increase in cell detachment from the tissue 
culture plate was visible by light microscopy (N=1, n=1); cells remaining attached to the 
tissue culture plate were visible beneath the floating cells in the medium prior to 
collection for counting cell counting. 
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Figure 3.7.  Cisplatin-induced detachment of primary mouse renal cells from the tissue culture 
plate.  (A) The percentage of detached cells floating in control medium was 5.14 ± 1.39% (mean 
± SD; N=3, n=3) of the total number of control cells.  Treatment with medium containing 1µM 
cisplatin did not significantly increase the percentage of floating cells (12.63 ± 2.49%; mean ± SD; 
N=3, n=3; p < 0.05 ns) compared to the control.  Treatment with medium containing 3µM and 
10µM cisplatin significantly increased the percentage of floating cells to 28.48 ± 10.72% (mean ± 
SD; N=3, n=3; p < 0.05 *) and 64.43 ± 6.92% (mean ± SD; N=3, n=3; p < 0.001 ***), respectively.  
Significant differences were identified using a one-way ANOVA and a post-hoc Tukey test. 
Representative light microscopy images of the tissue culture plates following exposure to medium 
containing (B) 0, (C) 1, (D) 3 and (E) 10µM cisplatin (N=1, n=1).  Cells remaining attached to the 
tissue culture plate are visible beneath the detached cells (arrow heads) floating in the culture 
medium.  Bars = 200µm.  
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Figure 3.8 shows an increase in cell detachment from the tissue culture plate in response 
to treatment with medium containing cyclosporin A.  The percentage of detached cells 
floating in control cell medium was 5.14 ± 1.39% (mean ± SD; N=3, n=3) of the total 
number of control cells.  Treatment with medium containing 1µM cyclosporin A did not 
significantly increase the percentage of floating cells (10.55 ± 2.34%; mean ± SD; N=3, 
n=3; p > 0.05 ns) compared to the control.  However, treatment with medium containing 
3µM and 10µM cyclosporin A significantly increased the percentage of floating cells to 
19.17 ± 4.68% (mean ± SD; N=3, n=3; p < 0.01 **) and 37.24 ± 5.17% (mean ± SD; N=3, 
n=3; p < 0.001 ***), respectively.  Concentration-dependent increase in cell detachment 
from the tissue culture plate was visible by light microscopy (N=1, n=1); cells remaining 
attached to the tissue culture plate were visible beneath the floating cells in the medium 
prior to collection for counting cell counting.  
  
 
179 
 
 
Figure 3.8.  Cyclosporin A-induced detachment of primary mouse renal cells from the 
tissue culture plate.  (A) The percentage of detached cells floating in control medium was 
5.14 ± 1.39% (mean ± SD; N=3, n=3) of the total number of control cells.  Treatment with 
medium containing 1µM cyclosporin A did not significantly increase the percentage of 
floating cells (10.55 ± 2.34%; mean ± SD; N=3, n=3; p < 0.05 ns) compared to the control.  
Treatment with medium containing 3µM and 10µM cyclosporin A significantly increased 
the percentage of floating cells to 19.17 ± 4.68% (mean ± SD; N=3, n=3; p < 0.01 **) and 
37.24 ± 5.17% (mean ± SD; N=3, n=3; p < 0.001 ***), respectively.  Significant differences 
were identified using a one-way ANOVA and a post-hoc Tukey test.  Representative light 
microscopy images of the tissue culture plates following exposure to medium containing 
(B) 0, (C) 1, (D) 3 and (E) 10µM cyclosporin A (N=1, n=1).  Cells remaining attached to the 
tissue culture plate are visible beneath the detached cells (arrow heads) floating in the 
culture medium.  Bars = 200µm. 
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Figure 3.9 shows an increase in cell detachment from the tissue culture plate in response 
to treatment with medium containing BEA.  The percentage of detached cells floating in 
control cell medium was 5.14 ± 1.39% (mean ± SD; N=3, n=3) of the total number of 
control cells.  Treatment with medium containing 1µM BEA did not significantly increase 
the percentage of floating cells (8.22 ± 2.60%; mean ± SD; N=3, n=3; p > 0.05 ns) compared 
to the control.  However, treatment with medium containing 3µM and 30µM BEA 
significantly increased the percentage of floating cells to 16.74 ± 3.33% (mean ± SD; N=3, 
n=3; p < 0.001 ***) and 25.35 ± 1.24% (mean ± SD; N=3, n=3; p < 0.001 ***), respectively.  
Concentration-dependent increase in cell detachment from the tissue culture plate was 
visible by light microscopy (N=1, n=1); cells remaining attached to the tissue culture plate 
were visible beneath the floating cells in the medium prior to collection for counting cell 
counting. 
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Figure 3.9. BEA-induced detachment of primary mouse renal cells from the tissue culture plate.  
(A) The percentage of detached cells floating in control medium was 5.14 ± 1.39% (mean ± SD; 
N=3, n=3) of the total number of control cells.  Treatment with medium containing 1µM BEA did 
not significantly increase the percentage of floating cells (8.22 ± 2.60%; mean ± SD; N=3, n=3; p > 
0.05 ns) compared to the control.  Treatment with medium containing 3µM and 30µM BEA 
significantly increased the percentage of floating cells to 16.74 ± 3.33% (mean ± SD; N=3, n=3; p 
< 0.001 ***) and 25.35 ± 1.24% (mean ± SD; N=3, n=3; p < 0.001 ***), respectively.  Significant 
differences were identified using a one-way ANOVA and a post-hoc Tukey test.  Representative 
light microscopy images of the tissue culture plates following exposure to medium containing (B) 
0, (C) 1, (D) 3 and (E) 30µM BEA (N=1, n=1).  Cells remaining attached to the tissue culture plate 
are visible beneath the detached cells (arrow heads) floating in the culture medium.  Bars = 
200µm.  
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KIM-1 Immunoreactivity in Mouse Cells following Nephrotoxin Treatment 
De novo expression of the kidney injury biomarker, kidney injury molecule-1 (KIM-1), was 
identified in primary mouse renal cells following 24-hour treatment with medium 
containing cisplatin, cyclosporin A and BEA (Figure 3.11 and 3.12).  Representative images 
of KIM-1 immunoreactivity in each treatment group are presented in Figure 3.11.  In all 
drug-treatment groups, KIM-1 was localised to cell membranes (arrow heads).  Following 
treatment with control medium (vehicle control; medium), a small number of cells (3.24 
± 0.05% (mean ± SD; N=3, n=3)) displayed KIM-1 immunoreactivity (Figure 3.12).  
Following treatment with medium containing 10µM cisplatin, the percentage of cells 
expressing KIM-1 increased significantly (79.21 ± 5.68%; mean ± SD; N=3, n=3; p < 0.001 
***), compared to the control.  Following treatment with medium containing 10µM 
cyclosporin A, the percentage of cells expressing KIM-1 increased significantly (44.02 ± 
5.73%; mean ± SD; N=3, n=3; p < 0.001 ***), compared to the control.  Following 
treatment with medium containing 30µM BEA, the percentage of cells expressing KIM-1 
increased significantly (48.83 ± 4.89%; mean ± SD; N=3, n=3; p < 0.001 ***), compared to 
the control.  Significant differences were identified using a one-way ANOVA and a post-
hoc Tukey test. 
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Figure 3.11.  KIM-1 immunoreactivity in primary mouse renal cells cultured for 24 hours in (A-
C) control medium or medium containing (D-F) 10µM cisplatin, (G-I) 10µM cyclosporin A and (J-
L) 30µM BEA.  (A-C) KIM-1 immunoreactivity was detected in a small number of cells cultured in 
control medium (vehicle control; medium) (arrow head).  Treatment with medium containing (D-
F) 10µM cisplatin, (G-I) 10µM cyclosporin A and (J-L) 30µM BEA increased the number of cells 
expressing KIM-1.  Clear membrane expression was identified in drug-treatment groups (arrow 
heads).  Images presented are representative of 5 fields of view per individual sample.  KIM-1 
immunoreactivity is brown, and the haematoxylin co-stain identifying nuclei is blue.  N=3, n=3 for 
all groups.  Bars = 100µm. 
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Figure 3.12.  Percentage of primary mouse renal cells expressing KIM-1 following 24 
hours treatment with control medium or medium containing 10µM cisplatin (CIS), 
10µM cyclosporin A (CsA) or 30µM BEA Following treatment with control medium 
(vehicle control; medium), a small number of cells (3.24 ± 0.05% (mean ± SD; N=3, n=3)) 
displayed KIM-1 immunoreactivity.  Following treatment with medium containing 10µM 
cisplatin, the percentage of cells expressing KIM-1 increased significantly (79.21 ± 5.68%; 
mean ± SD; N=3, n=3; p < 0.001 ***), compared to the control.  Following treatment with 
medium containing 10µM cyclosporin A, the percentage of cells expressing KIM-1 
increased significantly (44.02 ± 5.73%; mean ± SD; N=3, n=3; p < 0.001 ***), compared to 
the control.  Following treatment with medium containing 30µM BEA, the percentage of 
cells expressing KIM-1 increased significantly (48.83 ± 4.89%; mean ± SD; N=3, n=3; p < 
0.001 ***), compared to the control.  To quantify the percentage of cells expressing KIM-
1, snapshots of 5 random fields of view from each coverslip were taken, from which a 
minimum of 500 cells were assessed for biomarker expression.  Significant differences 
were identified using a one-way ANOVA and a post-hoc Tukey test. 
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Osteopontin Immunoreactivity in Mouse Cells following Nephrotoxin Treatment 
De novo expression of the kidney injury biomarker osteopontin was identified in primary 
mouse renal cells following 24-hour treatment with medium containing cisplatin, 
cyclosporin A and BEA (Figure 3.13 and 3.14).  Representative images of osteopontin 
immunoreactivity in each treatment group are presented in Figure 3.13.  In all groups, 
osteopontin was localised to cell cytoplasm (arrow heads).  Following treatment with 
control medium (vehicle control; medium), 13.82 ± 2.28% (mean ± SD; N=3, n=3) of cells 
displayed osteopontin immunoreactivity (Figure 3.14).  Following treatment with medium 
containing 10µM cisplatin, the percentage of cells expressing osteopontin increased 
significantly (71.91 ± 8.23%; mean ± SD; N=3, n=3; p < 0.001 ***), compared to the 
control.  Following treatment with medium containing 10µM cyclosporin A, the 
percentage of cells expressing osteopontin increased significantly (41.76 ± 1.92%; mean 
± SD; N=3, n=3; p < 0.001 ***), compared to the control.  Following treatment with 
medium containing 30µM BEA, the percentage of cells expressing osteopontin increased 
significantly (35.14 ± 2.47%; mean ± SD; N=3, n=3; p < 0.01 **), compared to the control.  
Significant differences were identified using a one-way ANOVA and a post-hoc Tukey test. 
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Figure 3.13.  Osteopontin immunoreactivity in primary mouse renal cells cultured for 24 hours 
in (A-C) control medium or medium containing (D-F) 10µM cisplatin, (G-I) 10µM cyclosporin A 
and (J-L) 30µM BEA.  (A-C) Osteopontin immunoreactivity was detected in a small number of cells 
cultured in control medium (vehicle control; medium) (arrow head).  Treatment with medium 
containing (D-F) 10µM cisplatin, (G-I) 10µM cyclosporin A and (J-L) 30µM BEA increased the 
number of cells expressing osteopontin.  In all groups, osteopontin immunoreactivity was 
localised to the cell cytoplasm (arrow heads).  Images presented are representative of 5 fields of 
view per individual sample.  Osteopontin immunoreactivity is brown, and the haematoxylin co-
stain identifying nuclei is blue.  N=3, n=3 for all groups.  Bars = 100µm. 
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Figure 3.14.  Percentage of primary mouse renal cells expressing osteopontin (OPN) 
following 24 hour-treatment with control medium or medium containing 10µM 
cisplatin (CIS), 10µM cyclosporin A (CsA) or 30µM BEA.  Following treatment with control 
medium (vehicle control; medium), 13.82 ± 2.28% (mean ± SD; N=3, n=3) of cells displayed 
osteopontin immunoreactivity.  Following treatment with medium containing 10µM 
cisplatin, the percentage of cells expressing osteopontin increased significantly (71.91 ± 
8.23%; mean ± SD; N=3, n=3; p < 0.001 ***), compared to the control.  Following 
treatment with medium containing 10µM cyclosporin A, the percentage of cells 
expressing osteopontin increased significantly (41.76 ± 1.92%; mean ± SD; N=3, n=3; p < 
0.001 ***), compared to the control.  Following treatment with medium containing 30µM 
BEA, the percentage of cells expressing osteopontin increased significantly (35.14 ± 
2.47%; mean ± SD; N=3, n=3; p < 0.01 **), compared to the control.  To quantify the 
percentage of cells expressing osteopontin, snapshots of 5 random fields of view from 
each coverslip were taken, from which a minimum of 500 cells were assessed for 
biomarker expression.  Significant differences were identified using a one-way ANOVA 
and a post-hoc Tukey test. 
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Clusterin Immunoreactivity in Mouse Cells following Nephrotoxin Treatment 
No expression of the kidney injury biomarker clusterin was detected in primary mouse 
renal cells following 24-hour treatment with control medium (vehicle control: medium) 
or medium containing 10µM cisplatin, 10µM cyclosporin A and 30µM BEA (Figure 3.15). 
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Figure 3.15. Clusterin immunoreactivity in primary mouse renal cells cultured for 24 hours in 
(A-C) control medium or medium containing (D-F) 10µM cisplatin, (G-I) 10µM cyclosporin A and 
(J-L) 30µM BEA.  (A-C) No clusterin immunoreactivity was detected in cells cultured in control 
medium (vehicle control; medium) (arrow head).  No clusterin immunoreactivity was detected 
following treatment with medium containing (D-F) 10µM cisplatin, (G-I) 10µM cyclosporin A and 
(J-L) 30µM BEA.  Images presented are representative of 5 fields of view per individual sample.  
The haematoxylin co-stain identifying nuclei is blue.  N=3, n=3 for all groups.  Bars = 100µm. 
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Characterisation of In Vitro Primary Human Renal Cells 
Previous studies using primary human renal cells as a tool for studying mineral ion 
homeostasis were performed using cells cultured for 8 days (see chapter 1 of this thesis).  
Cells at this time point are highly viable as determined using proliferation and apoptosis 
assays (see chapter 1 of this thesis).  As such, characterisation of in vitro primary human 
renal cells as a model for studying drug-induced toxicity in this study, was also performed 
at this time point.  Cells were grown for 7 days in control medium before 24-hour 
treatment with control medium (vehicle control; medium) or medium containing 25µM 
cisplatin.  The effect of cisplatin-treatment on the expression of the kidney injury 
biomarkers, KIM-1, osteopontin and clusterin was assessed in cells that had then been in 
culture for 8 days.  
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Effect of Cisplatin on Kidney Injury Molecule-1 Expression in Human Cells 
De novo expression of the kidney injury biomarker, kidney injury molecule-1 (KIM-1) was 
identified in primary human renal cells following treatment with the known nephrotoxin, 
cisplatin (Figure 3.16 and 3.19).  No KIM-1 immunoreactivity was identified in cells treated 
for 24 hours with control medium (vehicle control; medium) (Figure 3.16 A, C, E).  0% of 
cells expressed KIM-1 (N=1, n=1) (Figure 3.19).  However, 24-hour treatment with 
medium containing 25µM cisplatin, induced KIM-1 immunoreactivity in the cell cytoplasm 
(Figure 3.16 B, D, F).  98% of cells expressed KIM-1 (N=1, n=1) (Figure 3.19). 
 
Figure 3.16. KIM-1 immunoreactivity in primary human renal cells cultured for 24 hours 
in (A, C, E) control medium or (B, D, F) medium containing 25µM cisplatin.  No KIM-1 
immunoreactivity was detected in cells treated with control medium (vehicle control; 
medium) (A, C, E).  In cells treated with medium containing 25µM cisplatin, KIM-1 
immunoreactivity was present in the cell cytoplasm (B, D, E) (arrows heads).  KIM-1 
immunoreactivity is brown, and the haematoxylin co-stain identifying individual cell 
nuclei is blue.  Images presented are representative of 5 fields of view.  A, C, & E are 
images taken from the same coverslip, and B, D, & F are images taken from the same 
coverslip; N=1, n=1 for each condition.  Bars = 150µm. 
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Effect of Cisplatin on Osteopontin Expression in Human Cells 
De novo expression of the osteopontin was identified in primary human renal cells 
following treatment with the known nephrotoxin, cisplatin (Figure 3.17 and 3.19).  
Osteopontin immunoreactivity in cells treated for 24 hours with control medium (vehicle 
control; medium) (Figure 3.17 A, C, E).  57% of cells expressed osteopontin (N=1, n=1) 
(Figure 3.19).  However, 24-hour treatment with medium containing 25µM cisplatin, 
increased the number of cells displaying osteopontin immunoreactivity (Figure 3.17 B, D, 
F).  95% of cells expressed osteopontin (N=1, n=1) (Figure 3.19).  Osteopontin was 
localised to the cell cytoplasm. 
 
Figure 3.17. Osteopontin immunoreactivity in primary human renal cells cultured for 24 hours 
in (A, C, E) control medium or (B, D, F) medium containing 25µM cisplatin.  Osteopontin 
immunoreactivity was detected in cells treated with control medium (vehicle control; medium) 
(A, C, E).  In cells treated with medium containing 25µM cisplatin, the number of cells displaying 
osteopontin immunoreactivity increased.  In both groups, osteopontin immunoreactivity was 
localised to the cell cytoplasm (B, D, E) (arrow heads).  Osteopontin immunoreactivity is brown, 
and the haematoxylin co-stain identifying individual cell nuclei is blue.  Images presented are 
representative of 5 fields of view.  A, C, & E are images taken from the same coverslip, and B, 
D, & F are images taken from the same coverslip; N=1, n=1 for each condition.  Bars = 150µm. 
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Effect of Cisplatin on Clusterin Expression in Human Cells 
De novo expression of the kidney injury biomarker clusterin was identified in primary 
human renal cells following treatment with the known nephrotoxin, cisplatin (Figure 3.18 
and 3.19).  Clusterin immunoreactivity was detected in 4% (N=1, n=1) of cells treated for 
24 hours with control medium (vehicle control; medium) (Figure 3.18 A, C, E, and Figure 
3.19).  However, 24-hour treatment with medium containing 25µM cisplatin, increased 
the number of cells displaying clusterin immunoreactivity (Figure 3.18 B, D, F).  41% of 
cells expressed clusterin (N=1, n=1) (Figure 3.19).  Clusterin was localised to the cell 
cytoplasm with a small number of cells also displaying membrane localisation. 
 
Figure 3.18. Clusterin immunoreactivity in primary human renal cells cultured for 24 hours in (A, C, E) 
control medium or (B, D, F) medium containing 25µM cisplatin.  Clusterin immunoreactivity was detected 
in a small number of cells treated with control medium (vehicle control; medium) (A, C, E) (C insert image, 
arrow head).  In cells treated with medium containing 25µM cisplatin, the number of cells displaying 
clusterin immunoreactivity increased. Clusterin was localised to the cell cytoplasm, although additional 
membrane expression was also seen in some cells (F, inset image, arrow heads).  Clusterin 
immunoreactivity is brown, and the haematoxylin co-stain identifying individual cell nuclei is blue.  Images 
presented are representative of 5 fields of view.  A, C, & E are images taken from the same coverslip, and 
B, D, & F are images taken from the same coverslip; N=1, n=1 for each condition.  Bars = 150µm; F inset bar 
= 50µm. 
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Figure 3.19.  Percentage of primary human renal cells expressing KIM-1, osteopontin 
(OPN) and clusterin following 24-hour treatment with control medium or medium 
containing 25µM cisplatin.  Following treatment with control medium (vehicle control; 
medium), 0% (N=1, n=1) of cells displayed KIM-1 immunoreactivity.  Following treatment 
with medium containing 25µM cisplatin, the percentage of cells expressing KIM-1 
increased to 98% (N=1, n=1).  57% (N=1, n=1) and 95% (N=1, n=1) of cells displayed 
osteopontin immunoreactivity following treatment with control medium or medium 
containing 25µM cisplatin, respectively.   4% (N=1, n=1) and 41% (N=1, n=1) of cells 
displayed osteopontin immunoreactivity following treatment with control medium or 
medium containing 25µM cisplatin, respectively.  To quantify the percentage of cells 
expressing each of the biomarkers, snapshots of 5 random fields of view from each 
coverslip were taken, from which a minimum of 500 cells were assessed for biomarker 
expression. 
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3.7 Discussion 
The kidney is a major organ of drug-induced toxicity (Bonventre et al. 2010), and as such, 
kidney injury is one of the most frequent adverse events reported during drug 
development (Jang et al. 2013).  However, lack of fully characterised preclinical models 
for predicting nephrotoxicity specifically in humans means that it is often detected at late 
stages of drug development (Redfern et al. 2010).  In vitro models capable of bridging-
the-translational-gap between toxicity testing in animals and humans are required.  As 
such, the aim of this study was to perform a characterisation of ex vivo kidney slices and 
in vitro primary renal cells as potential models to meet this need.  Owing to limited access 
to human renal tissue/cells available in the present study, both models underwent initial 
characterisation using rodent tissue; rat tissue was chosen for the ex vivo tissue slice 
cultures, and mouse cells were chosen for the in vitro primary cell cultures.  
Characterisation of such models using both rodent and human tissue/cells to be used in 
parallel would improve translational drug development. 
Ex vivo kidney slices 
To begin characterisation of ex vivo rat kidney slices as a tool for studying drug-induced 
nephrotoxicity, a commercially available firefly luciferase ATP assay was used to 
determine slice viability immediately following slicing (i.e. at time 0 hours) and after 1, 4 
and 24 hours in culture under control conditions.  No significant difference was observed 
after 1 and 4 hours, but there was a significant difference in ATP content after 24 hours 
compared to immediately following slicing.  As the presence of ATP is indicative of 
metabolically active cells, the decrease in ATP content over time is suggestive of cell 
death.  This finding indicates that experiments using the slices be performed as soon as 
possible post preparation i.e. be very acute.  The assay was also used to determine if the 
ATP content of slices was affected following exposure to the known nephrotoxic drugs 
cisplatin (a proximal tubule nephrotoxin), cyclosporin A (a distal tubule nephrotoxin) and 
BEA (a collecting duct nephrotoxin) over the same time course in culture.  Such a readout 
would be useful for assessing drug-induced cell death.  However, no significant 
differences in any of the drug treatments compared to the time-matched controls were 
observed, except for that of slices treated with medium containing 10µM cisplatin for 4 
hours.  The significant decrease in the ATP content of slices treated with medium 
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containing 10µM cisplatin for 4 hours compared to time-matched control slices suggests 
that cisplatin was able to induce cell death within this time frame.  Cisplatin has been 
shown to induce cell death within a number of different cancer cell lines (HT-29, HCT-116, 
HepG2, and MCF-7) within 8 to 11 hours of treatment (Alborzinia et al. 2011), and as such 
it is possible that in the kidney, cisplatin can begin to induce cell death within a similar 
timeframe.  These data suggest that using the ATP content of slices as a tool for assessing 
slice viability in response to nephrotoxins may be useful.  However, it is also important to 
note that in this study the ATP content of control slices immediately after slicing (i.e. at 
time 0 hours) was less than half that previously reported under control conditions after 
24 hours by another group using a similar model (Vickers et al. 2004).  If this is indeed 
true, there are a number of improvements to the slicing protocol used in this study that 
could be made to improve the viability of the slices under control conditions.  Firstly, the 
kidneys used in this study came from rats killed by CO2 inhalation.  CO2 inhalation is 
thought to reduce the oxygen tension in the kidney leading to ischemia and is carried out 
over a prolonged period of time, usually about 10 minutes.  As such, it would be 
preferable for future studies to use cervical dislocation in order euthanize rodents 
immediately such that the kidneys could be removed and placed in cold buffer before 
cells have the opportunity to become ischemic.  This method of killing rats has been 
performed by others investigating ex vivo rat kidney sections (Peppiatt-Wildman et al. 
2012).  Secondly, instead of using 4°C PBS in which to prepare the slices, oxygenated, V7 
preservation solution at 10°C could be used, as this has been used by others for ex vivo 
slice preparation (Vickers et al. 2004).  Finally, rather than culturing the slices in a regular 
culture plate in a regular incubator, it would be wise to invest in a ‘rocker’ and ‘roller’ 
systems so that slices could be cultured in oxygenated medium on semi-permeable 
membranes and in metal cradles, respectively.  In the Vickers et al. paper, they used 
oxygenated, V7 preservation solution at 10°C to prepare slices and a ‘roller’ system, and 
as such, it would be useful to obtain this equipment to enhance the viability of ex vivo 
tissue slices for future work. 
In line with the decrease in ATP content over time in the current study, morphological 
changes indicative of cell death were also apparent by histological assessment.  After just 
one hour in culture, evidence of nuclear condensation, and sloughing of cells into the 
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tubular lumen was observed.  After 24 hours, there was also loss of proximal tubule brush 
border membranes in all samples assessed.  Taken together therefore, the decrease in 
ATP content and morphological changes indicative of cell death over time indicate that 
improvements to the slice preparation/culture be made in order for the utility of this 
model to be fully assessed. 
All that said, ex vivo kidney slices do still represent an exciting tool for studies of drug-
induced toxicity.  For preclinical drug safety assessment, for example, the use of ex vivo 
slices has many potential advantages.  Firstly, many slices can be prepared from one 
kidney meaning that many drugs can be trialled simultaneously, or even the same drug 
can be trialled over a range of different concentrations. The observation of nephrotoxicity 
at a certain concentration, but not at a lower concentration, could guide drug dosing 
regimens in subsequent in vivo rodent studies.  In essence, much more data could be 
generated that doing several in vivo studies, and as such, this would conform with the 
National Centre for the Replacement, Refinement and Reduction (NC3R) of animals in 
research guidelines.  Additionally, the slices are thin enough such that mechanisms of 
toxicity (involving for example changes at the subcellular organelle level) could be studied 
using live cell imaging by confocal or 2-photon microscopy. 
In vitro primary renal cells 
Traditionally, rat is a species relevant to toxicology testing, and as such, in vitro cultures 
of primary rat renal cells have already undergone initial characterisation as a tool for 
studying drug-transporter and drug-drug interactions (Chung et al. 2013).  Mouse is not a 
species traditionally associated with toxicology testing, and as such, in vitro cultures of 
primary mouse renal cells have not been characterised to the same extent.  The decision 
in the present study to use mouse cells over rat cells was based on the fact that their 
characterisation could also be useful for elucidating molecular mechanisms of drug 
toxicity using cells obtained from mice that have undergone targeted gene deletion in 
future studies.  That said, it would be useful for the same experiments carried out in the 
present study using mouse cells to be performed using rat cells, thereby building on the 
characterisation of the rat model developed by Chung et al. 2013. 
Proliferation and apoptosis assays showed high cell viability as evidenced by high 
proliferation and low apoptosis of in vitro primary mouse renal cells for up to day 15 in 
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culture.  In vivo, high renal cell proliferation occurs as a result of cell dedifferentiation and 
regeneration following ischemic or toxic insults (Bonventre 2003).  However, it is unlikely 
that the high proliferation observed in this model was result of cell dedifferentiation 
induced by injury following removal from their natural environment.  The reason for this, 
is that only a small number of mouse renal cells cultured for 8 days in control medium 
expressed (as determined by immunocytochemistry) KIM-1, a kidney biomarker 
massively upregulated in proliferating, dedifferentiated cells following injury (Ichimura et 
al. 1998; Ichimura et al. 2004).  Instead, high proliferation rates are likely due to the 
addition of growth supplements to the culture medium.  Indeed, previous studies support 
the fact that primary renal cell cultures do not undergo dedifferentiation.  Brown et al. 
(2008), show that human primary renal cells maintain expression of both phenotypic 
proteins and morphological characteristics, whilst experiments performed in the host 
laboratory identified no increase in vimentin, a marker of cell dedifferentiation, over time 
in culture (see chapter 1 of this thesis).  Strengthening the case for the use of primary 
renal cells over established cell lines such as HK2 as a tool for studying drug-induced 
toxicity, is the fact that extensive KIM-1 expression has been reported to be expressed in 
such cells (Han et al. 2002), suggesting they are already in a dedifferentiated state. 
Concentration-dependent drug-induced apoptosis in primary mouse renal cells was 
quantified using a TUNEL assay.  Compared to control cells, cells treated with medium 
containing increasing concentrations of cisplatin, cyclosporin A and BEA displayed an 
concentration-dependent apoptotic cell death.  Future studies could also focus on 
quantifying drug-induced death using a lactate dehydrogenase assay (useful for when cell 
death is either apoptotic or necrotic) or caspase activation (useful when cell death is 
apoptotic). 
In vivo, drug-induced nephrotoxicity is often associated with renal epithelial cell 
detachment from the basement membrane, and the sloughing of cells into the tubule 
lumen.  This phenomenon gives rise to acute kidney injury.  Cell sloughing well-
documented in vivo phenomenon of treatment with the known nephrotoxin, cisplatin 
(Aleksunes et al. 2008; Huang et al. 2001; Wadey et al. 2013).  As such, in vitro 
experiments using loss of cell adhesion/cell detachment from the tissue culture substrate 
(rather than the basement membrane) have previously been used as a drug-induced 
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effect by other groups (Del Bello et al. 2001; Imamdi et al. 2004; Kruidering et al. 1998; 
Mueller et al. 2003; P. Price et al. 2006; Slattery et al. 2005).  Quantification of this drug-
induced effect has previously been determined by counting the number of the floating 
versus attached cells (Kruidering et al. 1998).  In the current study, primary mouse renal 
cells were treated with medium containing increasing concentrations of the nephrotoxins 
cisplatin, cyclosporin A and BEA, before the number of detached cells floating in the 
medium relative to the total number of control cells (floating plus attached), was 
quantified.  All three nephrotoxins induced a concentration-dependent increase in cell 
detachment (i.e. loss of cell adhesion) from the tissue culture plate.  Interestingly, in vitro 
studies using LLC-PK1 cells has shown that cisplatin disrupts cell-cell adhesion (giving rise 
to detached cells floating in the medium) in a PKC-dependent manner as evidenced by 
inhibition of the loss of cell adhesion in the presence of a PKC inhibitor (Imamdi et al. 
2004).  
The next assay was to assess the ability of the cells in the model to respond to nephrotoxin 
treatment with upregulation of the known biomarkers of drug-induced renal injury, KIM-
1, osteopontin and clusterin.  KIM-1 and osteopontin upregulation are well-documented 
responses to cisplatin treatment in vivo (Ichimura et al. 2004; Nan-Ya et al. 2014; Pinches 
et al. 2012b; Vinken et al. 2012; Wadey et al. 2013), and likewise, both are upregulated 
in the kidney following cyclosporin A treatment in vivo (Pichler et al. 1995; Pérez-Rojas et 
al. 2007).  Confirming the utility of the cell model in the current study as a tool for studying 
drug-induced renal injury was the identification of the upregulation of KIM-1 and 
osteopontin following 24-hour treatment with medium containing cisplatin, cyclosporin 
A and BEA.  While BEA is traditionally thought of as a collecting duct toxin, there are 
reports that it effects regions of the kidney other than the papilla in the literature 
(Delacruz et al. 1997), and hence why it can induce expression of KIM-1 and osteopontin 
in a cell culture consisting of proximal and distal tubule cells.  The number of cells 
expressing clusterin did not increase following 24-hour treatment with medium 
containing any of the nephrotoxins.  However, clusterin expression has been detected in 
cells treated for 24 hours with medium containing cisplatin and then cultured for a further 
24 hours in control medium (Dr Valentina Peta, Cardiff University, unpublished 
observations).  This is very interesting as in other models of renal injury, clusterin 
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expression has been shown to be upregulated during regeneration (Gobé et al. 1995) 
where it is thought to play a role in preventing apoptosis and enhancing cell attachment 
(Silkensen et al. 1997). 
Future studies aim to investigate and quantify the presence of the biomarkers in the 
culture medium.  If biomarker presence in the culture medium were to correlate with 
biomarker expression in cells, it would provide additional information as to whether a 
novel injury biomarker may have potential utility as a non-invasive kidney injury urinary 
biomarker in vivo.  Such studies could be performed by Western blotting or ELIZA. 
To validate my findings in mouse renal cells, a similar experiment carried out in primary, 
human, renal cells revealed an increase the number of cells expressing the kidney injury 
biomarkers KIM-1, osteopontin and clusterin following 24-hour treatment with medium 
containing cisplatin compared to time-matched control cells.  Together, data from both 
mouse and human models indicate that in vitro primary renal cell cultures offer potential 
utility as a tool for studying drug-induced nephrotoxicity.  Future studies to confirm these 
initial findings are ongoing.  In addition, future studies aim to determine which cells are 
expressing injury biomarkers using co-stain protocol with a cell-type specific markers (for 
example, E- and N-Cadherin as markers of distal or proximal tubule cells respectively 
(Prozialeck et al. 2004)).  This information would be useful in determining whether a drug 
is toxic to proximal or distal tubule cells, or both. 
A major advantage of using in vitro primary renal cells as a tool for studying drug-induced 
nephrotoxicity during preclinical drug-safety assessment, is that several drugs, or indeed 
several concentrations of the same drug, could be screened for nephrotoxicity 
simultaneously.  In this way, characterisation and validation of such models would 
conform to the National Centre for the Replacement, Refinement and Reduction of 
animals in research guidelines.  In addition, the use of rodent and human models in 
parallel would improve translational drug safety assessment thereby reducing the rate of 
drug attrition during Phase III clinical trials and saving time, energy, investment, and risk 
to public health. 
In summary, ex vivo tissue slices and in vitro primary cultures of renal cells represent two 
potential tools for screening novel drugs for their likelihood to induce nephrotoxicity 
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using biomarker expression as a readout.  Under the conditions used in the current study, 
in vitro primary cells showed the most promising utility.  Primary mouse renal cells 
displayed high viability and responded to 24-hour treatment with the known 
nephrotoxins cisplatin, cyclosporin and BEA with concentration-dependent increase in 
apoptosis and concentration-dependent loss of cell adhesion from the tissue culture 
plate.  In addition, cells responded to 24-hour treatment with medium containing 
cisplatin, cyclosporin A and BEA with upregulation of the kidney injury biomarkers KIM-1 
and osteopontin, but not that of clusterin.  Primary human renal cells responded to 24-
hour treatment with medium containing cisplatin with upregulation of KIM-1, 
osteopontin and clusterin.  The difference in the expression of clusterin in response to 
nephrotoxin-treatment in human and mouse models not only highlights species 
differences, but reinforces the idea that use human models would not only improve 
studies of drug-induced toxicity specifically in humans, but when used alongside rodent 
models, would revolutionise preclinical, translational drug safety assessment. 
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